0001193125-16-676855.txt : 20160809 0001193125-16-676855.hdr.sgml : 20160809 20160809164505 ACCESSION NUMBER: 0001193125-16-676855 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160809 DATE AS OF CHANGE: 20160809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDICAL PROPERTIES TRUST INC CENTRAL INDEX KEY: 0001287865 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32559 FILM NUMBER: 161818587 BUSINESS ADDRESS: STREET 1: 1000 UBRAN CENTER DRIVE STREET 2: SUITE 501 CITY: BIRMINGHAM STATE: AL ZIP: 35242 BUSINESS PHONE: 205-969-3755 MAIL ADDRESS: STREET 1: 1000 URBAN CENTER DRIVE STREET 2: SUITE 501 CITY: BIRMINGHAM STATE: AL ZIP: 35242 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MPT Operating Partnership, L.P. CENTRAL INDEX KEY: 0001524607 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-177186 FILM NUMBER: 161818588 BUSINESS ADDRESS: STREET 1: MEDICAL PROPERTIES TRUST, INC. STREET 2: 1000 URBAN CENTER DRIVE, SUITE 501 CITY: BIRMINGHAM STATE: AL ZIP: 35242 BUSINESS PHONE: 205-969-3755 MAIL ADDRESS: STREET 1: MEDICAL PROPERTIES TRUST, INC. STREET 2: 1000 URBAN CENTER DRIVE, SUITE 501 CITY: BIRMINGHAM STATE: AL ZIP: 35242 10-Q 1 d188486d10q.htm 10-Q 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number 001-32559

Commission file number 333-177186

 

 

MEDICAL PROPERTIES TRUST, INC.

MPT OPERATING PARTNERSHIP, L.P.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

MARYLAND

DELAWARE

 

20-0191742

20-0242069

(State or other jurisdiction of

incorporation or organization)

 

(I. R. S. Employer

Identification No.)

1000 URBAN CENTER DRIVE, SUITE 501

BIRMINGHAM, AL

  35242
(Address of principal executive offices)   (Zip Code)

(205) 969-3755

REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE:

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  

x  (Medical Properties Trust, Inc. only)

   Accelerated filer   ¨
Non-accelerated filer  

x  (MPT Operating Partnership, L.P. only)

      (Do not check if a smaller reporting company)

   Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of August 1, 2016, Medical Properties Trust, Inc. had 243,138,873 shares of common stock, par value $0.001, outstanding.

 

 

 


Table of Contents

EXPLANATORY NOTE

This report combines the Quarterly Reports on Form 10-Q for the three and six months ended June 30, 2016, of Medical Properties Trust, Inc., a Maryland corporation, and MPT Operating Partnership, L.P., a Delaware limited partnership, through which Medical Properties Trust, Inc. conducts substantially all of its operations. Unless otherwise indicated or unless the context requires otherwise, all references in this report to “we,” “us,” “our,” “our company,” “Medical Properties,” “MPT,” or “the company” refer to Medical Properties Trust, Inc. together with its consolidated subsidiaries, including MPT Operating Partnership, L.P. Unless otherwise indicated or unless the context requires otherwise, all references to “our operating partnership” or “the operating partnership” refer to MPT Operating Partnership, L.P. together with its consolidated subsidiaries.


Table of Contents

MEDICAL PROPERTIES TRUST, INC. AND MPT OPERATING PARTNERSHIP, L.P.

AND SUBSIDIARIES

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED June 30, 2016

Table of Contents

 

     Page  

PART I — FINANCIAL INFORMATION

     3   

Item 1 Financial Statements

     3   

Medical Properties Trust, Inc. and Subsidiaries

  

Condensed Consolidated Balance Sheets at June  30, 2016 and December 31, 2015

     3   

Condensed Consolidated Statements of Net Income for the Three Months and Six Months Ended June 30, 2016 and 2015

     4   

Condensed Consolidated Statements of Comprehensive Income for the Three Months and Six Months Ended June 30, 2016 and 2015

     5   

Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2016 and 2015

     6   

MPT Operating Partnership, L.P. and Subsidiaries

  

Condensed Consolidated Balance Sheets at June  30, 2016 and December 31, 2015

     7   

Condensed Consolidated Statements of Net Income for the Three Months and Six Months Ended June 30, 2016 and 2015

     8   

Condensed Consolidated Statements of Comprehensive Income for the Three Months and Six Months Ended June 30, 2016 and 2015

     9   

Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2016 and 2015

     10   

Medical Properties Trust, Inc. and MPT Operating Partnership, L.P.

  

Notes to Condensed Consolidated Financial Statements

     11   

Item  2 Management’s Discussion and Analysis of Financial Condition and Results of Operations

     24   

Item 3 Quantitative and Qualitative Disclosures about Market Risk

     32   

Item 4 Controls and Procedures

     33   

PART II — OTHER INFORMATION

     34   

Item 1 Legal Proceedings

     34   

Item 1A Risk Factors

     34   

Item 2 Unregistered Sales of Equity Securities and Use of Proceeds

     34   

Item 3 Defaults Upon Senior Securities

     34   

Item 4 Mine Safety Disclosures

     34   

Item 5 Other Information

     34   

Item 6 Exhibits

     35   

SIGNATURE

     36   

INDEX TO EXHIBITS

     37   

 

2


Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

 

     June 30,
2016
    December 31,
2015
 
(In thousands, except per share amounts)    (Unaudited)     (Note 2)  

Assets

    

Real estate assets

    

Land, buildings and improvements, intangible lease assets, and other

   $ 3,482,199      $ 3,297,705   

Real estate held for sale

     63,074        —    

Mortgage loans

     549,337        757,581   

Net investment in direct financing leases

     528,747        626,996   
  

 

 

   

 

 

 

Gross investment in real estate assets

     4,623,357        4,682,282   

Accumulated depreciation and amortization

     (278,590     (257,928
  

 

 

   

 

 

 

Net investment in real estate assets

     4,344,767        4,424,354   

Cash and cash equivalents

     181,561        195,541   

Interest and rent receivables

     47,699        46,939   

Straight-line rent receivables

     95,988        82,155   

Other loans

     259,329        664,822   

Other assets

     188,589        195,540   
  

 

 

   

 

 

 

Total Assets

   $ 5,117,933      $ 5,609,351   
  

 

 

   

 

 

 

Liabilities and Equity

    

Liabilities

    

Debt, net

   $ 2,758,635      $ 3,322,541   

Accounts payable and accrued expenses

     148,218        137,356   

Deferred revenue

     20,997        29,358   

Lease deposits and other obligations to tenants

     22,845        12,831   
  

 

 

   

 

 

 

Total Liabilities

     2,950,695        3,502,086   

Equity

    

Preferred stock, $0.001 par value. Authorized 10,000 shares; no shares outstanding

     —         —    

Common stock, $0.001 par value. Authorized 500,000 shares; issued and outstanding — 240,341 shares at June 30, 2016 and 236,744 shares at December 31, 2015

     240        237   

Additional paid in capital

     2,642,281        2,593,827   

Distributions in excess of net income

     (414,657     (418,650

Accumulated other comprehensive loss

     (65,340     (72,884

Treasury shares, at cost

     (262     (262
  

 

 

   

 

 

 

Total Medical Properties Trust, Inc. Stockholders’ Equity

     2,162,262        2,102,268   

Non-controlling interests

     4,976        4,997   
  

 

 

   

 

 

 

Total Equity

     2,167,238        2,107,265   
  

 

 

   

 

 

 

Total Liabilities and Equity

   $ 5,117,933      $ 5,609,351   
  

 

 

   

 

 

 

See accompanying notes to condensed consolidated financial statements.

 

3


Table of Contents

MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Net Income

(Unaudited)

 

     For the Three Months
Ended June 30,
    For the Six Months
Ended June 30,
 
(In thousands, except per share amounts)    2016     2015     2016     2015  

Revenues

        

Rent billed

   $ 77,960      $ 53,893      $ 152,021      $ 106,994   

Straight-line rent

     8,551        5,252        16,768        9,980   

Income from direct financing leases

     13,552        12,808        32,503        25,363   

Interest and fee income

     26,237        27,848        60,007        53,425   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenues

     126,300        99,801        261,299        195,762   

Expenses

        

Real estate depreciation and amortization

     22,832        14,956        43,974        29,712   

Impairment charges

     7,375        —         7,375        —    

Property-related

     784        530        1,685        881   

General and administrative

     12,045        10,642        23,516        21,547   

Acquisition expenses

     4,767        25,809        3,702        32,048   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     47,803        51,937        80,252        84,188   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

     78,497        47,864        181,047        111,574   

Other income (expense)

        

Interest expense

     (41,501     (26,890     (80,874     (53,556

Gain on sale of real estate and other asset dispositions, net

     16,638        —         16,678        —    

Earnings (loss) from equity and other interests

     1,200        1,853        (3,801     1,956   

Other income (expense)

     (546     225        (217     (571

Income tax expense

     (364     (563     (683     (938
  

 

 

   

 

 

   

 

 

   

 

 

 

Net other expense

     (24,573     (25,375     (68,897     (53,109
  

 

 

   

 

 

   

 

 

   

 

 

 

Income from continuing operations

     53,924        22,489        112,150        58,465   

Loss from discontinued operations

     —         —         (1     —    
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     53,924        22,489        112,149        58,465   

Net income attributable to non-controlling interests

     (200     (82     (498     (161
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to MPT common stockholders

   $ 53,724      $ 22,407      $ 111,651      $ 58,304   
  

 

 

   

 

 

   

 

 

   

 

 

 

Earnings per common share — basic

        

Income from continuing operations attributable to MPT common stockholders

   $ 0.23      $ 0.11      $ 0.47      $ 0.28   

Loss from discontinued operations attributable to MPT common stockholders

     —         —         —         —    
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to MPT common stockholders

   $ 0.23      $ 0.11      $ 0.47      $ 0.28   
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average shares outstanding — basic

     238,082        208,071        237,796        205,515   
  

 

 

   

 

 

   

 

 

   

 

 

 

Earnings per common share — diluted

        

Income from continuing operations attributable to MPT common stockholders

   $ 0.22      $ 0.11      $ 0.47      $ 0.28   

Loss from discontinued operations attributable to MPT common stockholders

     —         —         —         —    
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to MPT common stockholders

   $ 0.22      $ 0.11      $ 0.47      $ 0.28   
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average shares outstanding — diluted

     239,008        208,640        238,413        206,127   
  

 

 

   

 

 

   

 

 

   

 

 

 

Dividends declared per common share

   $ 0.23      $ 0.22      $ 0.45      $ 0.44   
  

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes to condensed consolidated financial statements.

 

4


Table of Contents

MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)

 

     For the Three Months
Ended June 30,
    For the Six Months
Ended June 30,
 
(In thousands)    2016     2015     2016     2015  

Net income

   $ 53,924      $ 22,489      $ 112,149      $ 58,465   

Other comprehensive income:

    

Unrealized gain on interest rate swap

     825        730        1,640        1,315   

Foreign currency translation gain (loss)

     (14,683     20,307        5,904        (39,286
  

 

 

   

 

 

   

 

 

   

 

 

 

Total comprehensive income

     40,066        43,526        119,693        20,494   

Comprehensive income attributable to non-controlling interests

     (200     (82     (498     (161
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income attributable to MPT common stockholders

   $ 39,866      $ 43,444      $ 119,195      $ 20,333   
  

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes to condensed consolidated financial statements.

 

5


Table of Contents

MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

     For the Six Months
Ended June 30,
 
     2016     2015  
(In thousands)       

Operating activities

    

Net income

   $ 112,149      $ 58,465   

Adjustments to reconcile net income to net cash provided by operating activities:

    

Depreciation and amortization

     45,170        30,564   

Straight-line rent revenue

     (17,268     (9,980

Straight-line rent and other write-off

     3,063        —    

Impairment charges

     7,375        —    

Direct financing lease interest accretion

     (4,766     (3,279

Share-based compensation

     4,152        5,645   

Gain from sale of real estate and other asset dispositions, net

     (16,678     —    

Amortization and write-off of deferred financing costs and debt discount

     3,897        2,770   

Other adjustments

     (6,605     (2,383

Changes in:

    

Interest and rent receivable

     (2,743     (15,685

Accounts payable and accrued expenses

     9,544        21,327   
  

 

 

   

 

 

 

Net cash provided by operating activities

     137,290        87,444   

Investing activities

    

Cash paid for acquisitions and other related investments

     (109,991     (562,633

Net proceeds from sale of real estate

     89,165        —    

Principal received on loans receivable

     705,501        354,952   

Investment in loans receivable

     (96,504     (347,768

Construction in progress and other

     (108,065     (86,053

Investment in unsecured senior notes

     (50,000     —    

Proceeds from sale of unsecured senior notes

     50,000        —    
  

 

 

   

 

 

 

Net cash provided by (used for) investing activities

     480,106        (641,502

Financing activities

    

Revolving credit facilities, net

     (1,075,000     80,586   

Proceeds from debt

     500,000        —    

Payments of term debt

     (147     (140

Distributions paid

     (104,788     (84,487

Proceeds from sale of common shares, net of offering costs

     44,306        479,902   

Lease deposits and other obligations to tenants

     9,593        (14,453

Debt issuance costs paid and other financing activities

     (8,465     (662
  

 

 

   

 

 

 

Net cash (used for) provided by financing activities

     (634,501     460,746   
  

 

 

   

 

 

 

Increase (decrease) in cash and cash equivalents for period

     (17,105     (93,312

Effect of exchange rate changes

     3,125        (5,325

Cash and cash equivalents at beginning of period

     195,541        144,541   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 181,561      $ 45,904   
  

 

 

   

 

 

 

Interest paid

   $ 57,118      $ 52,130   

Supplemental schedule of non-cash financing activities:

    

Distributions declared, unpaid

   $ 55,272      $ 46,026   

See accompanying notes to condensed consolidated financial statements.

 

6


Table of Contents

MPT OPERATING PARTNERSHIP, L.P. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

 

     June 30,
2016
    December 31,
2015
 
(In thousands)    (Unaudited)     (Note 2)  

Assets

    

Real estate assets

    

Land, buildings and improvements, intangible lease assets, and other

   $ 3,482,199      $ 3,297,705   

Real estate held for sale

     63,074        —     

Mortgage loans

     549,337        757,581   

Net investment in direct financing leases

     528,747        626,996   
  

 

 

   

 

 

 

Gross investment in real estate assets

     4,623,357        4,682,282   

Accumulated depreciation and amortization

     (278,590     (257,928
  

 

 

   

 

 

 

Net investment in real estate assets

     4,344,767        4,424,354   

Cash and cash equivalents

     181,561        195,541   

Interest and rent receivables

     47,699        46,939   

Straight-line rent receivables

     95,988        82,155   

Other loans

     259,329        664,822   

Other assets

     188,589        195,540   
  

 

 

   

 

 

 

Total Assets

   $ 5,117,933      $ 5,609,351   
  

 

 

   

 

 

 

Liabilities and Capital

    

Liabilities

    

Debt, net

   $ 2,758,635      $ 3,322,541   

Accounts payable and accrued expenses

     92,623        84,628   

Deferred revenue

     20,997        29,358   

Lease deposits and other obligations to tenants

     22,845        12,831   

Payable due to Medical Properties Trust, Inc.

     55,205        52,338   
  

 

 

   

 

 

 

Total Liabilities

     2,950,305        3,501,696   

Capital

    

General Partner — issued and outstanding — 2,400 units at June 30, 2016 and 2,363 units at December 31, 2015

     22,299        21,773   

Limited Partners:

    

Common units — issued and outstanding — 237,941 units at June 30, 2016 and 234,381 units at December 31, 2015

     2,205,693        2,153,769   

LTIP units — issued and outstanding — 292 units at June 30, 2016 and December 31, 2015

     —         —    

Accumulated other comprehensive loss

     (65,340     (72,884
  

 

 

   

 

 

 

Total MPT Operating Partnership, L.P. Capital

     2,162,652        2,102,658   

Non-controlling interests

     4,976        4,997   
  

 

 

   

 

 

 

Total Capital

     2,167,628        2,107,655   
  

 

 

   

 

 

 

Total Liabilities and Capital

   $ 5,117,933      $ 5,609,351   
  

 

 

   

 

 

 

See accompanying notes to condensed consolidated financial statements.

 

7


Table of Contents

MPT OPERATING PARTNERSHIP, L.P. AND SUBSIDIARIES

Condensed Consolidated Statements of Net Income

(Unaudited)

 

     For the Three Months
Ended June 30,
    For the Six Months
Ended June 30,
 
(In thousands, except per unit amounts)    2016     2015     2016     2015  

Revenues

        

Rent billed

   $ 77,960      $ 53,893      $ 152,021      $ 106,994   

Straight-line rent

     8,551        5,252        16,768        9,980   

Income from direct financing leases

     13,552        12,808        32,503        25,363   

Interest and fee income

     26,237        27,848        60,007        53,425   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenues

     126,300        99,801        261,299        195,762   

Expenses

        

Real estate depreciation and amortization

     22,832        14,956        43,974        29,712   

Impairment charges

     7,375        —          7,375        —     

Property-related

     784        530        1,685        881   

General and administrative

     12,045        10,642        23,516        21,547   

Acquisition expenses

     4,767        25,809        3,702        32,048   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     47,803        51,937        80,252        84,188   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

     78,497        47,864        181,047        111,574   

Other income (expense)

        

Interest expense

     (41,501     (26,890     (80,874     (53,556

Gain on sale of real estate and other asset dispositions, net

     16,638        —          16,678        —     

Earnings (loss) from equity and other interests

     1,200        1,853        (3,801     1,956   

Other income (expense)

     (546     225        (217     (571

Income tax expense

     (364     (563     (683     (938
  

 

 

   

 

 

   

 

 

   

 

 

 

Net other expense

     (24,573     (25,375     (68,897     (53,109
  

 

 

   

 

 

   

 

 

   

 

 

 

Income from continuing operations

     53,924        22,489        112,150        58,465   

Loss from discontinued operations

     —          —          (1     —     
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     53,924        22,489        112,149        58,465   

Net income attributable to non-controlling interests

     (200     (82     (498     (161
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to MPT Operating Partnership partners

   $ 53,724      $ 22,407      $ 111,651      $ 58,304   
  

 

 

   

 

 

   

 

 

   

 

 

 

Earnings per unit — basic

        

Income from continuing operations attributable to MPT Operating Partnership partners

   $ 0.23      $ 0.11      $ 0.47      $ 0.28   

Loss from discontinued operations attributable to MPT Operating Partnership partners

     —          —          —          —     
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to MPT Operating Partnership partners

   $ 0.23      $ 0.11      $ 0.47      $ 0.28   
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average units outstanding — basic

     238,082        208,071        237,796        205,515   
  

 

 

   

 

 

   

 

 

   

 

 

 

Earnings per unit — diluted

        

Income from continuing operations attributable to MPT Operating Partnership partners

   $ 0.22      $ 0.11      $ 0.47      $ 0.28   

Loss from discontinued operations attributable to MPT Operating Partnership partners

     —          —          —          —     
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to MPT Operating Partnership partners

   $ 0.22      $ 0.11      $ 0.47      $ 0.28   
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average units outstanding — diluted

     239,008        208,640        238,413        206,127   
  

 

 

   

 

 

   

 

 

   

 

 

 

Dividends declared per unit

   $ 0.23      $ 0.22      $ 0.45      $ 0.44   
  

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes to condensed consolidated financial statements.

 

8


Table of Contents

MPT OPERATING PARTNERSHIP, L.P. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)

 

     For the Three Months
Ended June 30,
    For the Six Months
Ended June 30,
 
(In thousands)    2016     2015     2016     2015  

Net income

   $ 53,924      $ 22,489      $ 112,149      $ 58,465   

Other comprehensive income:

    

Unrealized gain on interest rate swap

     825        730        1,640        1,315   

Foreign currency translation gain (loss)

     (14,683     20,307        5,904        (39,286
  

 

 

   

 

 

   

 

 

   

 

 

 

Total comprehensive income

     40,066        43,526        119,693        20,494   

Comprehensive income attributable to non-controlling interests

     (200     (82     (498     (161
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income attributable to MPT Operating Partnership Partners

   $ 39,866      $ 43,444      $ 119,195      $ 20,333   
  

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes to condensed consolidated financial statements.

 

9


Table of Contents

MPT OPERATING PARTNERSHIP, L.P. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

     For the Six Months
Ended June 30,
 
     2016     2015  
(In thousands)       

Operating activities

    

Net income

   $ 112,149      $ 58,465   

Adjustments to reconcile net income to net cash provided by operating activities:

    

Depreciation and amortization

     45,170        30,564   

Straight-line rent revenue

     (17,268     (9,980

Straight-line rent and other write-off

     3,063        —     

Impairment charges

     7,375        —     

Direct financing lease interest accretion

     (4,766     (3,279

Unit-based compensation

     4,152        5,645   

Gain from sale of real estate and other asset dispositions, net

     (16,678     —     

Amortization and write-off of deferred financing costs and debt discount

     3,897        2,770   

Other adjustments

     (6,605     (2,383

Changes in:

    

Interest and rent receivable

     (2,743     (15,685

Accounts payable and accrued expenses

     9,544        21,327   
  

 

 

   

 

 

 

Net cash provided by operating activities

     137,290        87,444   

Investing activities

    

Cash paid for acquisitions and other related investments

     (109,991     (562,633

Net proceeds from sale of real estate

     89,165        —     

Principal received on loans receivable

     705,501        354,952   

Investment in loans receivable

     (96,504     (347,768

Construction in progress and other

     (108,065     (86,053

Investment in unsecured senior notes

     (50,000     —     

Proceeds from sale of unsecured senior notes

     50,000        —     
  

 

 

   

 

 

 

Net cash provided by (used for) investing activities

     480,106        (641,502

Financing activities

    

Revolving credit facilities, net

     (1,075,000     80,586   

Proceeds from debt

     500,000        —     

Payments of term debt

     (147     (140

Distributions paid

     (104,788     (84,487

Proceeds from sale of units, net of offering costs

     44,306        479,902   

Lease deposits and other obligations to tenants

     9,593        (14,453

Debt issuance costs paid and other financing activities

     (8,465     (662
  

 

 

   

 

 

 

Net cash (used for) provided by financing activities

     (634,501     460,746   
  

 

 

   

 

 

 

Increase (decrease) in cash and cash equivalents for period

     (17,105     (93,312

Effect of exchange rate changes

     3,125        (5,325

Cash and cash equivalents at beginning of period

     195,541        144,541   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 181,561      $ 45,904   
  

 

 

   

 

 

 

Interest paid

   $ 57,118      $ 52,130   

Supplemental schedule of non-cash financing activities:

    

Distributions declared, unpaid

   $ 55,272      $ 46,026   

See accompanying notes to condensed consolidated financial statements.

 

10


Table of Contents

MEDICAL PROPERTIES TRUST, INC., AND MPT OPERATING PARTNERSHIP, L.P.

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Organization

Medical Properties Trust, Inc., a Maryland corporation, was formed on August 27, 2003, under the Maryland General Corporation Law for the purpose of engaging in the business of investing in, owning, and leasing commercial real estate. Our operating partnership subsidiary, MPT Operating Partnership, L.P., (the “Operating Partnership”) through which we conduct all of our operations, was formed in September 2003. Through another wholly-owned subsidiary, Medical Properties Trust, LLC, we are the sole general partner of the Operating Partnership. At present, we directly own substantially all of the limited partnership interests in the Operating Partnership and have elected to report our required disclosures and that of the Operating Partnership on a combined basis except where material differences exist.

We have operated as a real estate investment trust (“REIT”) since April 6, 2004, and accordingly, elected REIT status upon the filing in September 2005 of the calendar year 2004 federal income tax return. Accordingly, we will generally not be subject to federal income tax in the United States (“U.S.”), provided that we continue to qualify as a REIT and our distributions to our stockholders equal or exceed our taxable income. Certain activities we undertake must be conducted by entities which we elected to be treated as taxable REIT subsidiaries (“TRSs”). Our TRSs are subject to both U.S. federal and state income taxes. For our properties located outside the U.S., we are subject to local taxes; however, we do not expect to incur additional taxes in the U.S. as such income will flow through our REIT.

Our primary business strategy is to acquire and develop real estate and improvements, primarily for long-term lease to providers of healthcare services such as operators of general acute care hospitals, inpatient physical rehabilitation hospitals, long-term acute care hospitals, surgery centers, centers for treatment of specific conditions such as cardiac, pulmonary, cancer, and neurological hospitals, and other healthcare-oriented facilities. We also make mortgage and other loans to operators of similar facilities. In addition, we may obtain profits or equity interests in our tenants, from time to time, in order to enhance our overall return. We manage our business as a single business segment. All of our properties are located in the U.S. and Europe.

2. Summary of Significant Accounting Policies

Unaudited Interim Condensed Consolidated Financial Statements: The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information, including rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles (“GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June 30, 2016, are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements.

For information about significant accounting policies, refer to the consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015. During the six months ended June 30, 2016, there were no material changes to these policies.

Recent Accounting Developments:

Revenue from Contracts with Customers

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. Entities may use a full retrospective approach or report the cumulative effect as of the date of adoption. On April 1, 2015, the FASB proposed deferring the effective date of this standard by one year to December 15, 2017, for annual reporting periods beginning after that date. The FASB also proposed permitting early adoption of the standard, but not before the original effective date of December 15, 2016. We are continuing to evaluate this standard; however, we do not expect it to have a significant impact on our financial results, as a substantial portion of our revenue consists of rental income from leasing arrangements, which are specifically excluded from ASU No. 2014-09.

Leases

In February 2016, the FASB issued ASU 2016-02 - Leases, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The ASU is not effective for us until January 1, 2019 with early adoption permitted. We are continuing to evaluate this standard and the impact to us from both a lessor and a lessee perspective.

Measurement of Credit Losses on Financial Instruments

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments, which is intended to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets not recorded at fair value based on historical experience, current conditions, and reasonable and supportable forecasts. The ASU will be required to be implemented through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the amendments are effective. The ASU is not effective for us until January 1, 2019. We do not expect the adoption of the ASU to have a significant impact on our consolidated financial statements.

 

11


Table of Contents

Variable Interest Entities

At June 30, 2016, we had loans to and/or equity investments in certain variable interest entities (“VIEs”), which are also tenants of our facilities, including Ernest Health, Inc. (“Ernest”). We have determined that we are not the primary beneficiary of these VIEs. The carrying value and classification of the related assets and maximum exposure to loss as a result of our involvement with these VIEs are presented below at June 30, 2016 (in thousands):

 

VIE Type

   Maximum Loss
Exposure(1)
     Asset Type
Classification
   Carrying
    Amount(2)    
 

Loans, net

   $ 295,822       Mortgage and other loans    $ 226,101   

Equity investments

   $ 37,309       Other assets    $ 328   

 

(1) Our maximum loss exposure related to loans with VIEs represents our current aggregate gross carrying value of the loan plus accrued interest and any other related assets (such as rent receivables), less any liabilities. Our maximum loss exposure related to our equity investment in VIEs represents the current carrying values of such investment plus any other related assets (such as rent receivables) less any liabilities.
(2) Carrying amount reflects the net book value of our loan or equity interest only in the VIE.

For the VIE types above, we do not consolidate the VIE because we do not have the ability to control the activities (such as the day-to-day healthcare operations of our borrower or investees) that most significantly impact the VIE’s economic performance. As of June 30, 2016, we were not required to provide any material financial support through a liquidity arrangement or otherwise to our unconsolidated VIEs, including circumstances in which it could be exposed to further losses (e.g., cash short falls).

Typically, our loans are collateralized by assets of the borrower (some assets of which are on the premises of facilities owned by us) and further supported by limited guarantees made by certain principals of the borrower.

See Note 3 and 7 for additional description of the nature, purpose and activities of our more significant VIEs and interests therein.

3. Real Estate and Lending Activities

Acquisitions

We acquired the following assets (in thousands):

 

     Six Months
Ended June 30,
 
     2016      2015  

Assets Acquired

     

Land and land improvements

   $ 9,398       $ 62,434   

Building

     37,593         390,320   

Intangible lease assets — subject to amortization (weighted average useful life 25.8 years)

     —           42,262   

Mortgage loans

     —           40,000   

Net investments in direct financing leases

     63,000         10,700   

Other loans

     —           16,917   
  

 

 

    

 

 

 

Total assets acquired

   $ 109,991       $ 562,633   

Loans repaid (1)

     —           (183,826
  

 

 

    

 

 

 

Total net assets acquired

   $ 109,991       $ 378,807   
  

 

 

    

 

 

 

 

  (1) Loans advanced to MEDIAN in 2014 and repaid in 2015 as a part of the MEDIAN transaction.

The purchase price allocations attributable to the 2016 and certain 2015 acquisitions are preliminary. When all relevant information is obtained, resulting changes, if any, to our provisional purchase price allocation will be retrospectively adjusted to reflect new information obtained about the facts and circumstances that existed as of the respective acquisition dates that, if known, would have affected the measurement of the amounts recognized as of those dates.

2016 Activity

On May 2, 2016, we acquired an acute hospital in Newark, New Jersey for an aggregate purchase price of $63 million leased to Prime Healthcare Services, Inc. (“Prime”) pursuant to a fifth master lease, which has a 15-year term with three five-year extension options, plus consumer price-indexed increases, limited to a 2% floor. Furthermore, we committed to advance an additional $30 million to Prime over a three-year period to be used solely for capital additions to the real estate; any such additions will be added to the basis upon which the lessee will pay us rents.

 

12


Table of Contents

On June 22, 2016, we closed on the final Median Kliniken S.à r.l., (“MEDIAN”) property for a purchase price of €41.6 million. See “2015 Activity” for a description of the initial MEDIAN Transaction.

From the respective acquisition dates, the properties acquired in 2016 contributed $1.1 million of revenue and income (excluding related acquisition expenses), for the three and six months ended June 30, 2016. In addition, we incurred $2.4 million of acquisition-related costs on the 2016 acquisitions for both the three and six months ended June 30, 2016.

2015 Activity

MEDIAN Transaction

On April 29, 2015, we entered into a series of definitive agreements with MEDIAN, a German provider of post-acute and acute rehabilitation services, to acquire the real estate assets of 32 hospitals owned by MEDIAN for an aggregate purchase price of approximately €688 million. Upon acquisition, each property became subject to a master lease between us and MEDIAN providing for the leaseback of the property to MEDIAN. The master lease had an initial term of 27 years and provided for an initial GAAP lease rate of 9.3%, with annual escalators at the greater of one percent or 70% of the German consumer price index.

MEDIAN is owned by an affiliate of Waterland Private Equity Fund V C.V. (“Waterland”), which acquired 94.9% of the outstanding equity interests in MEDIAN, and by a subsidiary of our operating partnership, which acquired the remaining 5.1% of the outstanding equity interests in MEDIAN, each in December 2014. In December 2014, we provided interim acquisition loans to affiliates of Waterland and MEDIAN in connection with Waterland’s acquisition of its stake in MEDIAN in an aggregate amount of approximately €425 million. In addition, we made further loans to MEDIAN during the first half of 2015 in an aggregate amount of approximately €240 million, which were used by MEDIAN to repay existing debt on properties we acquired.

Closing of the sale-leaseback transactions began in the second quarter of 2015. At each closing, the purchase price for each facility was reduced and offset against the interim loans made to affiliates of Waterland and MEDIAN as described above and against the amount of any debt assumed or repaid by us in connection with the closing. As of June 30, 2015, we had closed on 17 properties for an aggregate amount of €317 million.

Other Acquisitions

On June 16, 2015, we acquired the real estate of two facilities in Lubbock, Texas, a 60-bed inpatient rehabilitation hospital and a 37-bed long-term acute care hospital, for an aggregate purchase price of $31.5 million. We entered into a 20-year lease with Ernest for the rehabilitation hospital, which provides for three five-year extension options, and separately entered into a lease with Ernest for the long-term acute care hospital that has a final term ending December 31, 2034. In connection with the transaction, we funded an acquisition loan to Ernest of approximately $12.0 million. Ernest is operating the rehabilitation hospital in a joint venture with Covenant Health System, while the long-term acute care hospital continues to be operated by Fundamental Health under a new sublease with Ernest.

On February 27, 2015, we acquired an inpatient rehabilitation hospital in Weslaco, Texas for $10.7 million leased to Ernest pursuant to the 2012 master lease which had an original 20-year fixed term and three five-year extension options. This lease provides for consumer-priced-indexed annual rent increases, subject to a floor and a cap. In addition, we funded an acquisition loan in the amount of $5 million.

On February 13, 2015, we acquired two general acute care hospitals in the Kansas City area for $110 million. Affiliates of Prime is the tenant and operator pursuant to a new master lease that has similar terms and security enhancements as the other master lease agreements entered into in 2013. This master lease has a 10-year initial fixed term with two extension options of five years each. The lease provides for consumer-price-indexed annual rent increases, subject to a specified floor. In addition, we funded a mortgage loan in the amount of $40 million, which has a 10-year term.

From the respective acquisition dates, the properties and other assets acquired in 2015 contributed $4.2 million and $3.5 million of revenue and income (excluding related acquisition expenses), respectively, for the three months ended June 30, 2015. From the respective acquisition dates, the properties and other assets acquired in 2015 contributed $6.2 million and $4.9 million of revenue and income (excluding related acquisition expenses), respectively, for the six months ended June 30, 2015. In addition, we incurred $22.6 million and $26.7 million of acquisition-related costs on the 2015 acquisitions for the three and six months ended June 30, 2015, respectively.

 

13


Table of Contents

Pro Forma Information

The following unaudited supplemental pro forma operating data is presented for the three and six months ended June 30, 2015, as if each acquisition (including completed development projects) was completed on January 1, 2015. Supplemental pro forma earnings were adjusted to exclude acquisition-related costs on consummated deals incurred. The unaudited supplemental pro forma operating data is not necessarily indicative of what the actual results of operations would have been assuming the transactions had been completed as set forth above, nor do they purport to represent our results of operations for future periods (in thousands, except per share/unit amounts).

 

     For the Three
Months Ended
June 30, 2015
     For the Six
Months Ended
June 30, 2015
 

Total revenues

   $ 109       $ 219   

Net income

   $ 50       $ 100   

Net income per share/unit — diluted

   $ 0.21       $ 0.42   

Development Activities

During the first six months of 2016, we completed construction and began recording rental income on the following facilities:

 

    Adeptus Health, Inc. (“Adeptus Health”) – We completed seven acute care facilities for this tenant during 2016. These facilities are leased pursuant to the master leases entered into in both 2014 and 2015 and are cross-defaulted with each other and with the original master lease executed in 2013.

 

    Ernest Toledo – This inpatient rehabilitation facility located in Toledo, Ohio opened on April 1, 2016 and is being leased to Ernest pursuant to the original 2012 master lease.

See table below for a status update on our current domestic development projects (in thousands):

 

Property

  

Commitment

    

Costs

Incurred

as of

06/30/16

    

Estimated

Completion

Date

 

Adeptus Health

   $ 62,154       $ 43,763         3Q 2016   

Adeptus Health

     53,836         15,343         4Q 2016   

Adeptus Health

     5,730         206         1Q 2017   

Adeptus Health

     61,997         16,311         2Q 2017   

Adeptus Health

     71,331         —           Various   
  

 

 

    

 

 

    
   $ 255,048       $ 75,623      
  

 

 

    

 

 

    

On September 9, 2015, we acquired the real estate of a general acute care hospital under development located in Spain, for an aggregate purchase and development price to us of approximately €21.4 million. The acquisition was effected through a joint venture between us and clients of AXA Real Estate, in which we will own a 50% interest. Upon completion, the facility will be leased to a Spanish operator of acute care hospitals, pursuant to a long-term lease. We expect construction to complete on this facility in the second quarter of 2017.

Disposals

Capella Transaction

On March 21, 2016, we entered into definitive agreements with RegionalCare Hospital Partners, Inc. (“RegionalCare”), an affiliate of certain funds managed by affiliates of Apollo Global Management, LLC (together with its consolidated subsidiaries, “Apollo”), under which our investment in the operations of Capella Healthcare, Inc. (“Capella”) would be merged with RegionalCare, forming RCCH Healthcare Partners (“RCCH”).

 

14


Table of Contents

On April 29, 2016, this transaction closed and funded, effective April 30, 2016. As part of the transaction, we received net proceeds of approximately $550 million including approximately $492 million for our equity investment and loans made as part of the Capella transaction that closed on August 31, 2015. In addition, we received $210 million in prepayment of two mortgage loans for hospitals in Russellville, Arkansas, and Lawton, Oklahoma, that we made to subsidiaries of Capella in connection with the Capella transaction on August 31, 2015. We made a new $93.3 million loan for a hospital property in Olympia, Washington. Additionally, we and an Apollo affiliate invested $50 million each in unsecured senior notes issued by RegionalCare, which we sold to a large institution on June 20, 2016 at par. The proceeds from this transaction represented the recoverability of our investment in full, except for transaction costs incurred of $6.3 million.

We maintained our ownership of five Capella hospitals in Hot Springs, Arkansas; Camden, South Carolina; Hartsville, South Carolina; Muskogee, Oklahoma; and McMinnville, Oregon. Pursuant to the transaction described above, the underlying leases, one of which is a master lease covering all but one property, was amended to shorten the initial fixed lease term, increase the security deposit, and eliminate the lessees’ purchase option provisions. Due to this lease amendment, we reclassified the lease of the properties under the master lease from a direct finance lease (“DFL”) to an operating lease. This reclassification resulted in a write-off of $2.6 million in unbilled DFL rent in the 2016 second quarter.

On July 22, 2016, we acquired the Olympia, Washington property in exchange for the $93.3 million loan and an additional $7 million, which was contemplated in the original Capella transaction. The terms of the Olympia lease will be similar to the other leases with this tenant.

Post Acute Transaction

On May 23, 2016, we sold five properties (three of which were in Texas and two in Louisiana) that were leased and operated by Post Acute Medical (“Post Acute”). As part of this transaction, our outstanding loans of $4 million were paid in full, and we recovered our investment in the operations. Total proceeds from this transaction were $71 million resulting in a net gain of approximately $15 million.

Corinth Transaction

On June 17, 2016, we sold the Atrium Medical Center real estate located in Corinth, Texas, which was leased and operated by Corinth Investor Holdings. Total proceeds from the transaction were $28 million resulting in a gain on real estate of approximately $8 million. This gain on real estate was offset by approximately $9 million of non-cash charges that included the write-off of our investment in the operations of the facility, straight-line rent receivables, and a lease intangible.

HealthSouth Transaction

On May 20, 2016, we reached a firm commitment to sell three inpatient rehabilitation hospitals located in Texas and operated by HealthSouth Corporation (“HealthSouth”) for $111.5 million. At June 30, 2016, these facilities and related net assets were designated as held for sale and included the following (in thousands):

 

Real estate held for sale

   $  63,074   

Straight-line rent receivables

     2,441  

Other, net

     (625
  

 

 

 
   $  64,890   
  

 

 

 

On July 20, 2016, we completed this sale resulting in a net gain of approximately $45 million.

Summary of Operations for Disposed Assets

The properties which sold during the quarter and the assets held for sale at June 30, 2016, do not meet the definition of discontinued operations. However, the following represents the operating results (excluding gain on sale, transaction costs, and impairment or other non-cash charges) from these properties (excluding loans repaid in the Capella Transaction) for the periods presented (in thousands):

 

     For the Three Months      For the Six Months  
     Ended June 30,      Ended June 30,  
     2016      2015      2016      2015  

Revenues

   $ 3,092      $ 4,525      $ 7,607      $ 9,075  

Real estate depreciation and amortization

     (805      (949      (1,754      (1,897

Property-related expenses

     (72      (12      (113      (72

Other income (expense)

     (9      228        (68      557   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income from real estate dispositions, net

   $ 2,206      $ 3,792      $ 5,672      $ 7,663  
  

 

 

    

 

 

    

 

 

    

 

 

 

Leasing Operations

All of our leases are currently accounted for as operating leases except for the master lease of 15 Ernest facilities and six Prime facilities which are accounted for as DFLs. The components of our net investment in DFLs (which includes the Capella properties for 2015 only) consisted of the following (in thousands):

 

     As of June 30,
2016
     As of December 31,
2015
 

Minimum lease payments receivable

   $ 1,875,751       $ 2,587,912   

Estimated residual values

     292,646         393,097   

Less: Unearned income

     (1,639,650      (2,354,013
  

 

 

    

 

 

 

Net investment in direct financing leases

   $ 528,747       $ 626,996   
  

 

 

    

 

 

 

Twelve Oaks Facility

In the third quarter of 2015, we sent notice of termination of the lease to the tenant at our Twelve Oaks facility. This former tenant continues to occupy the facility. We called their letter of credit for approximately $0.5 million in the 2016 first quarter. At June 30, 2016, all past due receivables are fully reserved. Although no assurances can be made that we will not have any impairment charges in the future, we believe our real estate investment in Twelve Oaks at June 30, 2016 is fully recoverable.

Subsequent to June 30, 2016, we received approximately $2.5 million representing substantially all of amounts owed to us and agreed to general terms of a new lease, which we expect to execute during the 2016 third quarter.

 

15


Table of Contents

Loans

The following is a summary of our loans (in thousands):

 

     As of
June 30, 2016
     As of
December 31, 2015
 

Mortgage loans

   $ 549,337       $ 757,581   

Acquisition loans

     216,100         610,469   

Working capital and other loans

     43,229         54,353   
  

 

 

    

 

 

 
   $ 808,666       $ 1,422,403   
  

 

 

    

 

 

 

The decrease in our mortgage and acquisition loans are related to the Capella Transaction as discussed previously.

Our non-mortgage loans typically consist of loans to our tenants for acquisitions and working capital purposes. At June 30, 2016, acquisition loans includes our original $93.2 million loan to Ernest and the $93.3 million loan to RCCH, which was repaid in July as discussed above.

On March 1, 2012, pursuant to our convertible note agreement, we converted $1.7 million of our $5.0 million convertible note into a 9.9% equity interest in the operator of our Hoboken University Medical Center facility. At June 30, 2016, $3.3 million remains outstanding on the convertible note, and we retain the option, subject to regulatory approvals, to convert this remainder into 15.1% of equity interest in the operator.

Concentrations of Credit Risk

Our revenue concentration for the six months ended June 30, 2016 as compared to the prior year is as follows (dollars in thousands):

 

16


Table of Contents

Revenue by Operator

 

     For the Six Months Ended
June 30, 2016
    For the Six Months Ended
June 30, 2015
 

Operators

   Total
Revenue
     Percentage of
Total Revenue
    Total
Revenue
     Percentage of
Total Revenue
 

Prime

   $ 58,859         22.5   $ 49,869         25.5

MEDIAN

     47,745         18.3     32,212         16.5

Ernest

     33,322         12.8     29,695         15.2

RCCH

     32,909         12.6     —           —     

Adeptus Health

     16,205         6.2     7,425         3.8

Revenue by U.S. State and Country

 

     For the Six Months Ended
June 30, 2016
    For the Six Months Ended
June 30, 2015
 

U.S. States and Other Countries

   Total
Revenue
     Percentage of
Total Revenue
    Total
Revenue
     Percentage of
Total Revenue
 

Texas

   $ 48,256         18.5   $ 42,689         21.8

California

     33,187         12.7     33,065         16.9

All other states

     129,896         49.7     85,620         43.7
  

 

 

    

 

 

   

 

 

    

 

 

 

Total U.S.

   $ 211,339         80.9   $ 161,374         82.4

Germany

   $ 47,745         18.3   $ 32,212         16.5

United Kingdom, Italy, and Spain

     2,215         0.8     2,176         1.1
  

 

 

    

 

 

   

 

 

    

 

 

 

Total International

   $ 49,960         19.1   $ 34,388         17.6
  

 

 

    

 

 

   

 

 

    

 

 

 

Grand Total

   $ 261,299         100.0   $ 195,762         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

From an asset basis, our concentration as of June 30, 2016 as compared to December 31, 2015 is as follows (dollars in thousands):

Gross Assets by Operator

 

     As of June 30, 2016     As of December 31, 2015  

Operators

   Total
Gross Assets
     Percentage of
Total Gross Assets
    Total
Gross Assets
     Percentage of
Total Gross Assets
 
     (A)      (B)     (A)      (B)  

Prime

   $ 1,126,654         20.8   $ 1,032,353         17.1

MEDIAN

     1,054,368         19.4     1,031,039         17.1

Ernest

     584,411         10.8     579,182         9.6

Adeptus Health

     500,000         9.2     500,000         8.3

RCCH

     458,659         8.5     1,059,989         17.6

 

17


Table of Contents

Gross Assets by U.S. State and Country

 

     As of June 30, 2016     As of December 31, 2015  
U.S. States and Other Countries    Total
Gross Assets
     Percentage of
Total Gross Assets
    Total
Gross Assets
     Percentage of
Total Gross Assets
 
     (A)      (B)     (A)      (B)  

Texas

   $ 920,959         17.0   $ 1,060,990         17.6

California

     547,079         10.1     547,085         9.1

All other states

     2,530,018         46.6     3,047,204         50.5

Other domestic assets

     189,358         3.5     177,317         2.9
  

 

 

    

 

 

   

 

 

    

 

 

 

Total U.S.

   $ 4,187,414         77.2   $ 4,832,596         80.1

Germany

   $ 1,054,368         19.4   $ 1,031,039         17.1

United Kingdom, Italy, and Spain

     156,630         3.0     161,317         2.7

Other international assets

     23,983         0.4     10,970         0.1
  

 

 

    

 

 

   

 

 

    

 

 

 

Total International

   $ 1,234,981         22.8   $ 1,203,326         19.9
  

 

 

    

 

 

   

 

 

    

 

 

 

Grand Total

   $ 5,422,395         100.0   $ 6,035,922         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

 

(A) Gross Assets represents total assets plus accumulated depreciation/amortization assuming all real estate commitments as of the period end are fully funded.
(B) Includes both leased and loaned assets.

On an individual property basis, we had no investment of any single property greater than 2.3% of our total assets as of June 30, 2016.

4. Debt

The following is a summary of our debt (dollar amounts in thousands):

 

     As of June 30, 2016     As of December 31, 2015  
     Balance      Interest Rate     Balance      Interest Rate  

Revolving credit facility

   $ 25,000         Variable      $ 1,100,000         Variable   

2006 Senior Unsecured Notes

     125,000         Various        125,000         Various   

2011 Senior Unsecured Notes

     450,000         6.875     450,000         6.875

2012 Senior Unsecured Notes:

          

Principal amount

     350,000         6.375     350,000         6.375

Unamortized premium

     1,991           2,168      
  

 

 

      

 

 

    
     351,991           352,168      

2013 Senior Unsecured Notes (A)

     222,120         5.750     217,240         5.750

2014 Senior Unsecured Notes

     300,000         5.500     300,000         5.500

2015 Senior Unsecured Notes (A)

     555,300         4.000     543,100         4.000

2016 Senior Unsecured Notes

     500,000         6.375     —          —    

Term loans

     263,253         Various        263,400         Various   
  

 

 

      

 

 

    
   $ 2,792,664         $ 3,350,908      

Debt issue costs, net

     (34,029        (28,367   
  

 

 

      

 

 

    
   $ 2,758,635         $ 3,322,541      
  

 

 

      

 

 

    

 

(A) These notes are Euro-denominated and reflect the exchange rate at June 30, 2016 and December 31, 2015, respectively.

 

18


Table of Contents

As of June 30, 2016, principal payments due on our debt (which exclude the effects of any discounts, premiums, or debt issue costs recorded) are as follows (in thousands):

 

2016

   $ 125,152 (A) 

2017

     320   

2018

     37,781   

2019

     250,000   

2020

     222,120   

Thereafter

     2,155,300   
  

 

 

 

Total

   $ 2,790,673   
  

 

 

 

 

(A) $65 million of our 2006 Senior Unsecured Notes were paid in full in July 2016, while the remaining $60 million will mature in October 2016.

On February 22, 2016, we completed a $500 million senior unsecured notes offering (“2016 Senior Unsecured Notes”), proceeds of which were used to repay borrowings under our revolving credit facility. Interest on the notes will be payable on March 1 and September 1 of each year, commencing on September 1, 2016. Interest on the notes will be paid in cash at a rate of 6.375% per year. The notes mature on March 1, 2024. We may redeem some or all of the notes at any time prior to March 1, 2019 at a “make whole” redemption price. On or after March 1, 2019, we may redeem some or all of the notes at a premium that will decrease over time. In addition, at any time prior to March 1, 2019, we may redeem up to 35% of the notes at a redemption price equal to 106.375% of the aggregate principal amount thereof, plus accrued and unpaid interest thereon, using proceeds from one or more equity offerings. In the event of a change in control, each holder of the notes may require us to repurchase some or all of the notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest to the date of purchase.

During the second quarter 2010, we entered into an interest rate swap to manage our exposure to variable interest rates by fixing $65 million of our 2006 Senior Unsecured Notes, which started July 31, 2011 (date on which the interest rate turned variable) through maturity date (or July 2016), at a rate of 5.507%. We also entered into an interest rate swap to fix $60 million of our 2006 Senior Unsecured Notes which started October 31, 2011 (date on which the related interest rate turned variable) through the maturity date (or October 2016) at a rate of 5.675%. The fair value of the interest rate swaps was $1.3 million and $2.9 million as of June 30, 2016 and December 31, 2015, respectively, which is reflected in accounts payable and accrued expenses on the consolidated balance sheets.

We account for our interest rate swaps as cash flow hedges. Accordingly, the effective portion of changes in the fair value of our swaps is recorded as a component of accumulated other comprehensive income/loss on the balance sheet and reclassified into earnings in the same period, or periods, during which the hedged transactions effect earnings, while any ineffective portion is recorded through earnings immediately. We did not have any hedge ineffectiveness from inception of our interest rate swaps through June 30, 2016 and therefore, there was no income statement effect recorded during the three and six month periods ended June 30, 2016 or 2015. We do expect current losses included in accumulated other comprehensive loss to be reclassified into earnings through October 2016. At June 30, 2016 and December 31, 2015, we have posted $0.8 million and $1.7 million of collateral related to our interest rate swaps, respectively, which is reflected in other assets on our consolidated balance sheets.

Covenants

Our debt facilities impose certain restrictions on us, including restrictions on our ability to: incur debts; create or incur liens; provide guarantees in respect of obligations of any other entity; make redemptions and repurchases of our capital stock; prepay, redeem or repurchase debt; engage in mergers or consolidations; enter into affiliated transactions; dispose of real estate or other assets; and change our business. In addition, the credit agreements governing our revolving credit facility and term loan limit the amount of dividends we can pay as a percentage of normalized adjusted funds from operations (“FFO”), as defined in the agreements, on a rolling four quarter basis. At June 30, 2016, the dividend restriction was 95% of normalized adjusted FFO. The indentures governing our senior unsecured notes also limit the amount of dividends we can pay based on the sum of 95% of funds from operations, proceeds of equity issuances and certain other net cash proceeds. Finally, our senior unsecured notes require us to maintain total unencumbered assets (as defined in the related indenture) of not less than 150% of our unsecured indebtedness.

In addition to these restrictions, the revolving credit facility and term loan contain customary financial and operating covenants, including covenants relating to our total leverage ratio, fixed charge coverage ratio, secured leverage ratio, consolidated adjusted net worth, unsecured leverage ratio, and unsecured interest coverage ratio. This facility also contains customary events of default, including among others, nonpayment of principal or interest, material inaccuracy of representations and failure to comply with our covenants. If an event of default occurs and is continuing under the facility, the entire outstanding balance may become immediately due and payable. At June 30, 2016, we were in compliance with all such financial and operating covenants.

 

19


Table of Contents

At June 30, 2016, the unsecured leverage ratio covenant was 77.5%. In September 2016, the unsecured leverage ratio will reset to 65%. We are currently in compliance with the reset leverage covenant.

5. Common Stock/Partners’ Capital

Medical Properties Trust, Inc.

On March 1, 2016, we updated our at-the-market equity offering program, which gives us the ability to sell up to $227 million of stock with a commission rate of 1.25%. During the six months ended June 30, 2016, we sold approximately 3 million shares of our common stock under this program, resulting in net proceeds of approximately $45 million, after deducting approximately $0.6 million of commissions.

On January 14, 2015, we completed an underwritten public offering of 34.5 million shares (including the exercise of the underwriters’ 30-day option to purchase an additional 4.5 million shares) of our common stock, resulting in net proceeds of approximately $480 million, after deducting estimated offering expenses.

MPT Operating Partnership, L.P.

At June 30, 2016, the Company has a 99.83% ownership interest in the Operating Partnership with the remainder owned by three other partners, two of whom are employees and one of whom is a director. During the six months ended June 30, 2016 and 2015, the Operating Partnership issued 3 million units and 34.5 million units, respectively, in direct response to the common stock offerings by Medical Properties Trust, Inc.

6. Stock Awards

We adopted the 2013 Equity Incentive Plan (the “Equity Incentive Plan”) during the second quarter of 2013, which authorizes the issuance of common stock options, restricted stock, restricted stock units, deferred stock units, stock appreciation rights, performance units and awards of interests in our Operating Partnership. The Equity Incentive Plan is administered by the Compensation Committee of the Board of Directors. We have reserved 8,196,770 shares of common stock for awards under the Equity Incentive Plan for which 5,615,497 shares remain available for future stock awards as of June 30, 2016. We awarded the following stock awards during 2016 and 2015:

Time-based awards —We granted 45,528 shares to independent directors in 2016 and 217,177 shares to management, independent directors and certain employees in time-based restricted stock. These awards vest quarterly based on service, over three years, in equal amounts.

Performance-based awards —Our management team and certain employees were awarded 176,046 shares of performance based awards in 2015. No such awards have been granted in 2016. These awards vest ratably over a three-year period based on the achievement of certain total shareholder return measures, with a carry-back and carry-forward provision through December 31, 2017. Dividends on these awards are paid only upon achievement of the performance measures.

Multi-year Performance-based awards —We awarded 505,050 shares in 2015 of multi-year performance-based awards to management. No such awards have been granted in 2016. These shares are subject to three-year cumulative performance hurdles based on measures of total shareholder return. At the end of the three-year performance period, any earned shares will be subject to an additional two years of ratable time-based vesting on an annual basis. Dividends are paid on these shares only upon achievement of the performance measures.

7. Fair Value of Financial Instruments

We have various assets and liabilities that are considered financial instruments. We estimate that the carrying value of cash and cash equivalents, and accounts payable and accrued expenses approximate their fair values. Included in our accounts payable and accrued expenses are our interest rate swaps, which are recorded at fair value based on Level 2 observable market assumptions using standardized derivative pricing models. We estimate the fair value of our interest and rent receivables using Level 2 inputs such as discounting the estimated future cash flows using the current rates at which similar receivables would be made to others with similar credit ratings and for the same remaining maturities. The fair value of our mortgage loans and working capital loans are estimated by using Level 2 inputs such as discounting the estimated future cash flows using the current rates which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities. We determine the fair value of our senior unsecured notes (excluding our 2006 Senior Unsecured Notes) using Level 2 inputs such as quotes from securities dealers and market makers. We estimate the fair value of our 2006 Senior Unsecured Notes, our revolving credit facility, and term loans using Level 2 inputs based on the present value of future payments, discounted at a rate which we consider appropriate for such debt.

 

20


Table of Contents

Fair value estimates are made at a specific point in time, are subjective in nature, and involve uncertainties and matters of significant judgment. Settlement of such fair value amounts may not be possible and may not be a prudent management decision. The following table summarizes fair value estimates for our financial instruments (in thousands):

 

     June 30, 2016      December 31, 2015  

Asset (Liability)

   Book
Value
     Fair
Value
     Book
Value
     Fair
Value
 

Interest and rent receivables

   $ 47,699       $ 47,653       $ 46,939       $ 46,858   

Loans (1)

     590,037         623,399         508,851         543,859   

Debt, net

     (2,758,635      (2,863,382      (3,322,541      (3,372,773

 

(1) Excludes loans related to Ernest and Capella (2015 only) since they are recorded at fair value and discussed below.

Items Measured at Fair Value on a Recurring Basis

Our equity interest in Ernest and related loans, which were acquired in 2012, are being measured at fair value on a recurring basis as we elected to account for these investments using the fair value option method. We have elected to account for these investments at fair value due to the size of the investments and because we believe this method is more reflective of current values. We have not made a similar election for other equity interests or loans made in or prior to 2016, except for our investments in Capella that were disposed of in the 2016 second quarter.

At June 30, 2016, these amounts were as follows (in thousands):

 

Asset Type

   Fair
Value
     Cost      Asset Type
Classification
 

Mortgage loans

   $ 101,762       $ 101,762         Mortgage loans   

Acquisition and other loans

     116,867         116,867         Other loans   

Equity investments

     3,300         3,300         Other assets   
  

 

 

    

 

 

    
   $ 221,929       $ 221,929      
  

 

 

    

 

 

    

Our mortgage loans with Ernest are recorded at fair value based on Level 2 inputs by discounting the estimated cash flows using the market rates which similar loans would be made to borrowers with similar credit ratings and the same remaining maturities. Our acquisition loans and equity investments in Ernest are recorded at fair value based on Level 3 inputs, by using a discounted cash flow model, which requires significant estimates of our investee such as projected revenue and expenses and appropriate consideration of the underlying risk profile of the forecast assumptions associated with the investee. We classify these loans and equity investments as Level 3, as we use certain unobservable inputs to the valuation methodology that are significant to the fair value measurement, and the valuation requires management judgment due to the absence of quoted market prices. For these cash flow models, our observable inputs include use of a capitalization rate, discount rate (which is based on a weighted-average cost of capital), and market interest rates, and our unobservable input includes an adjustment for a marketability discount (“DLOM”) on our equity investment of 40% at June 30, 2016.

In regards to the underlying projection of revenues and expenses used in the discounted cash flow model, such projections are provided by Ernest. However, we will modify such projections (including underlying assumptions used) as needed based on our review and analysis of Ernest’s historical results, meetings with key members of management, and our understanding of trends and developments within the healthcare industry.

In arriving at the DLOM, we started with a DLOM range based on the results of studies supporting valuation discounts for other transactions or structures without a public market. To select the appropriate DLOM within the range, we then considered many qualitative factors including the percent of control, the nature of the underlying investee’s business along with our rights as an investor pursuant to the operating agreement, the size of investment, expected holding period, number of shareholders, access to capital marketplace, etc. To illustrate the effect of movements in the DLOM, we performed a sensitivity analysis below by using basis point variations (dollars in thousands):

 

21


Table of Contents

Basis Point Change in Marketability Discount

   Estimated Increase (Decrease)
In Fair Value
 

+100 basis points

   $ (54

- 100 basis points

     54   

Because the fair value of Ernest investments noted above approximate their original cost, we did not recognize any unrealized gains/losses during the first half of 2016 or 2015.

8. Earnings Per Share/Common Unit

Medical Properties Trust, Inc.

Our earnings per share were calculated based on the following (in thousands):

 

     For the Three Months
Ended June 30,
 
     2016      2015  

Numerator:

     

Income from continuing operations

   $ 53,924       $ 22,489   

Non-controlling interests’ share in continuing operations

     (200      (82

Participating securities’ share in earnings

     (132      (250
  

 

 

    

 

 

 

Income from continuing operations, less participating securities’ share in earnings

     53,592         22,157   

Income from discontinued operations attributable to MPT common stockholders

     —          —    
  

 

 

    

 

 

 

Net income, less participating securities’ share in earnings

   $ 53,592       $ 22,157   
  

 

 

    

 

 

 

Denominator:

     

Basic weighted-average common shares

     238,082         208,071   

Dilutive potential common shares

     926         569   
  

 

 

    

 

 

 

Dilutive weighted-average common shares

     239,008         208,640   
  

 

 

    

 

 

 

 

     For the Six Months
Ended June 30,
 
     2016      2015  

Numerator:

     

Income from continuing operations

   $ 112,150       $ 58,465   

Non-controlling interests’ share in continuing operations

     (498      (161

Participating securities’ share in earnings

     (276      (516
  

 

 

    

 

 

 

Income from continuing operations, less participating securities’ share in earnings

     111,376         57,788   

Loss from discontinued operations attributable to MPT common stockholders

     (1      —    
  

 

 

    

 

 

 

Net income, less participating securities’ share in earnings

   $ 111,375       $ 57,788   
  

 

 

    

 

 

 

Denominator:

     

Basic weighted-average common shares

     237,796         205,515   

Dilutive potential common shares

     617         612   
  

 

 

    

 

 

 

Dilutive weighted-average common shares

     238,413         206,127   
  

 

 

    

 

 

 

 

22


Table of Contents

MPT Operating Partnership, L.P.

Our earnings per common unit were calculated based on the following (in thousands):

 

     For the Three Months
Ended June 30,
 
     2016      2015  

Numerator:

     

Income from continuing operations

   $ 53,924       $ 22,489   

Non-controlling interests’ share in continuing operations

     (200      (82

Participating securities’ share in earnings

     (132      (250
  

 

 

    

 

 

 

Income from continuing operations, less participating securities’ share in earnings

     53,592         22,157   

Income from discontinued operations attributable to MPT Operating Partnership partners

     —           —    
  

 

 

    

 

 

 

Net income, less participating securities’ share in earnings

   $ 53,592       $ 22,157   
  

 

 

    

 

 

 

Denominator:

     

Basic weighted-average units

     238,082         208,071   

Dilutive potential units

     926         569   
  

 

 

    

 

 

 

Dilutive weighted-average units

     239,008         208,640   
  

 

 

    

 

 

 

 

     For the Six Months
Ended June 30,
 
     2016      2015  

Numerator:

     

Income from continuing operations

   $ 112,150       $ 58,465   

Non-controlling interests’ share in continuing operations

     (498      (161

Participating securities’ share in earnings

     (276      (516
  

 

 

    

 

 

 

Income from continuing operations, less participating securities’ share in earnings

     111,376         57,788   

Loss from discontinued operations attributable to MPT Operating Partnership partners

     (1      —    
  

 

 

    

 

 

 

Net income, less participating securities’ share in earnings

   $ 111,375       $ 57,788   
  

 

 

    

 

 

 

Denominator:

     

Basic weighted-average units

     237,796         205,515   

Dilutive potential units

     617         612   
  

 

 

    

 

 

 

Dilutive weighted-average units

     238,413         206,127   
  

 

 

    

 

 

 

9. Commitments and Contingencies

Contingencies

We are a party to various legal proceedings incidental to our business. In the opinion of management, after consultation with legal counsel, the ultimate liability, if any, with respect to those proceedings is not presently expected to materially affect our financial position, results of operations or cash flows.

 

23


Table of Contents

10. Subsequent Events

Stock Issuance

During the month of July, we sold 2.7 million shares of common stock under our at-the-market program generating net proceeds of $41.1 million.

Bond Issuance

On July 22, 2016, we completed a $500 million senior unsecured notes offering. Interest on the notes will be payable on February 1 and August 1 of each year, commencing on February 1, 2017. Interest on the notes will be paid in cash at a rate of 5.25% per year. The notes mature on August 1, 2026. We may redeem some or all of the notes at any time prior to August 1, 2021 at a “make whole” redemption price. On or after August 1, 2021, we may redeem some or all of the notes at a premium that will decrease over time. In addition, at any time prior to August 1, 2019, we may redeem up to 35% of the notes at a redemption price equal to 105.25% of the aggregate principal amount thereof, plus accrued and unpaid interest thereon, using proceeds from one or more equity offerings. In the event of a change in control, each holder of the notes may require us to repurchase some or all of the notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest to the date of purchase.

We used the net proceeds from this offering to redeem our $450 million 2011 bonds, which will be completed on August 12, 2016. We expect to incur a one-time charge related to the redemption of approximately $23 million.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of the consolidated financial condition and consolidated results of operations are presented on a combined basis for Medical Properties Trust and MPT Operating Partnership, L.P. as there are no material differences between these two entities.

The following discussion and analysis of the consolidated financial condition and consolidated results of operations should be read together with the condensed consolidated financial statements and notes thereto contained in this Form 10-Q and the consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2015.

Forward-Looking Statements.

This report on Form 10-Q contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results or future performance, achievements or transactions or events to be materially different from those expressed or implied by such forward-looking statements, including, but not limited to, the risks described in our Annual Report on Form 10-K and as updated in our quarterly reports on Form 10-Q for future periods, and current reports on Form 8-K as we file them with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934. Such factors include, among others, the following:

 

    U.S. (both national and local) and European (in particular Germany, the United Kingdom, Spain, and Italy) economic, business, real estate and other market conditions;

 

    the competitive environment in which we operate;

 

    the execution of our business plan;

 

    financing risks;

 

    acquisition and development risks;

 

    potential environmental contingencies and other liabilities;

 

    other factors affecting real estate industry generally or the healthcare real estate industry in particular;

 

    our ability to maintain our status as a REIT for U.S. federal and state income tax purposes;

 

    our ability to attract and retain qualified personnel;

 

    changes in foreign currency exchange rates;

 

    U.S. (both federal and state) and European (in particular Germany, the United Kingdom, Spain, and Italy) healthcare and other regulatory requirements; and

 

    U.S. national and local economic conditions, as well as conditions in Europe and any other foreign jurisdictions where we own or will own healthcare facilities, which may have a negative effect on the following, among other things:

 

    the financial condition of our tenants, our lenders, counterparties to our interest rate swaps and other hedged transactions and institutions that hold our cash balances, which may expose us to increased risks of default by these parties;

 

    our ability to obtain equity or debt financing on attractive terms or at all, which may adversely impact our ability to pursue acquisition and development opportunities, refinance existing debt and our future interest expense; and

 

24


Table of Contents
    the value of our real estate assets, which may limit our ability to dispose of assets at attractive prices or obtain or maintain debt financing secured by our properties or on an unsecured basis.

Key Factors that May Affect Our Operations

Our revenue is derived from rents we earn pursuant to the lease agreements with our tenants, from interest income from loans to our tenants and other facility owners and from profits or equity interests in certain of our tenants’ operations. Our tenants operate in the healthcare industry, generally providing medical, surgical and rehabilitative care to patients. The capacity of our tenants to pay our rents and interest is dependent upon their ability to conduct their operations at profitable levels. We believe that the business environment of the industry segments in which our tenants operate is generally positive for efficient operators. However, our tenants’ operations are subject to economic, regulatory and market conditions that may affect their profitability, which could impact our results. Accordingly, we monitor certain key factors, changes to which we believe may provide early indications of conditions that may affect the level of risk in our portfolio.

Key factors that we consider in underwriting prospective tenants and borrowers and in monitoring the performance of existing tenants and borrowers include the following:

 

    admission levels and surgery/procedure/diagnosis volumes by type;

 

    the current, historical and prospective operating margins (measured by earnings before interest, taxes, depreciation, amortization and facility rent) of each tenant or borrower and at each facility;

 

    the ratio of our tenants’ and borrowers’ operating earnings both to facility rent and to facility rent plus other fixed costs, including debt costs;

 

    trends in the source of our tenants’ or borrowers’ revenue, including the relative mix of public payors (including Medicare, Medicaid/MediCal, managed care in the U.S. and pension funds in Germany) and private payors (including commercial insurance and private pay patients);

 

    the effect of evolving healthcare regulations on our tenants’ and borrowers’ profitability; and

 

    the competition and demographics of the local and surrounding areas in which the tenants or borrowers operate.

Certain business factors, in addition to those described above that directly affect our tenants and borrowers, will likely materially influence our future results of operations. These factors include:

 

    trends in the cost and availability of capital, including market interest rates, that our prospective tenants may use for their real estate assets instead of financing their real estate assets through lease structures;

 

    changes in healthcare regulations that may limit the opportunities for physicians to participate in the ownership of healthcare providers and healthcare real estate;

 

    reductions in reimbursements from Medicare, state healthcare programs, and commercial insurance providers that may reduce our tenants’ or borrowers’ profitability and our lease rates;

 

    competition from other financing sources; and

 

    the ability of our tenants and borrowers to access funds in the credit markets.

CRITICAL ACCOUNTING POLICIES

Refer to our 2015 Annual Report on Form 10-K, for a discussion of our critical accounting policies, which include revenue recognition, investment in real estate, purchase price allocation, loans, losses from rent receivables, stock-based compensation, our fair value option election, and our accounting policy on consolidation. During the six months ended June 30, 2016, there were no material changes to these policies.

Overview

        We are a self-advised real estate investment trust (“REIT”) focused on investing in and owning net-leased healthcare facilities across the U.S. and selectively in foreign jurisdictions. We have operated as a REIT since April 6, 2004, and accordingly, elected REIT status upon the filing of our calendar year 2004 federal income tax return. Medical Properties Trust, Inc. was incorporated under Maryland law on August 27, 2004, and MPT Operating Partnership, L.P. was formed under Delaware law on September 10, 2003. We conduct substantially all of our business through MPT Operating Partnership, L.P. We acquire and develop healthcare facilities and lease the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear most of the costs associated with the property. We also make mortgage loans to healthcare operators collateralized by their real estate assets. In addition, we selectively make loans to certain of our operators through our taxable REIT subsidiaries, the proceeds of which are typically used for acquisitions and working capital. Finally, from time to time, we acquire a profits or other equity interest in our tenants that gives us a right to share in such tenant’s profits and losses.

 

25


Table of Contents

At June 30, 2016, our portfolio consisted of 209 properties leased or loaned to 27 operators, of which 14 are under development and 12 are in the form of mortgage loans.

Our investments in healthcare real estate, including mortgage and other loans, as well as any equity investments in our tenants are considered a single reportable segment. All of our investments are currently located in the U.S. and Europe. Our total assets are made up of the following (dollars in thousands):

 

     As of June 30,
2016
     % of
Total
    As of December 31,
2015
     % of
Total
 

Real estate owned (gross)

   $ 4,074,020         79.6   $ 3,924,701         70.0

Mortgage loans

     549,337         10.7     757,581         13.5

Other loans

     259,329         5.1     664,822         11.9

Other assets

     235,247         4.6     262,247         4.6
  

 

 

    

 

 

   

 

 

    

 

 

 

Total assets (1)

   $ 5,117,933         100.0   $ 5,609,351         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

 

(1) Includes $1.2 billion and $1.3 billion of healthcare real estate assets in Europe at June 30, 2016 and December 31, 2015, respectively.

The following is our revenue by operating type (dollar amounts in thousands):

Revenue by property type:

 

     For the Three
Months Ended
June 30, 2016
     % of
Total
    For the Three
Months Ended
June 30, 2015
     % of
Total
 

General Acute Care Hospitals (1)

   $ 76,468         60.5   $ 55,868         56.0

Rehabilitation Hospitals

     38,265         30.3     30,528         30.6

Long-term Acute Care Hospitals

     11,567         9.2     13,405         13.4
  

 

 

    

 

 

   

 

 

    

 

 

 

Total revenue

   $ 126,300         100.0   $ 99,801         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 
     For the Six
Months Ended
June 30, 2016
     % of
Total
    For the Six
Months Ended
June 30, 2015
     % of
Total
 

General Acute Care Hospitals (1)

   $ 159,978         61.2   $ 109,921         56.1

Rehabilitation Hospitals

     76,388         29.3     58,994         30.2

Long-term Acute Care Hospitals

     24,933         9.5     26,847         13.7
  

 

 

    

 

 

   

 

 

    

 

 

 

Total revenue

   $ 261,299         100.0   $ 195,762         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

 

(1) Includes three medical office buildings.

We have 54 employees as of August 1, 2016. We believe that any foreseeable increase in the number of our employees will have only immaterial effects on our operations and general and administrative expenses. We believe that our relations with our employees are good. None of our employees are members of any labor union.

 

26


Table of Contents

Results of Operations

Three Months Ended June 30, 2016 Compared to June 30, 2015

Net income for the three months ended June 30, 2016, was $53.7 million, compared to $22.4 million for the three months ended June 30, 2015. This increase is due primarily to additional revenue from MEDIAN and Capella, completed development projects, and gains on real estate disposals, along with a reduction in acquisition expenses. Funds from operations (“FFO”), after adjusting for certain items (as more fully described in Reconciliation of Non-GAAP Financial Measures), was $75.5 million, or $0.32 per diluted share for the 2016 second quarter as compared to $62.9 million, or $0.30 per diluted share for the 2015 second quarter. This 20% increase in FFO is primarily due to the increase in revenue from acquisitions and loan investments made since June 2015 along with the completion of development properties in 2016.

A comparison of revenues for the three month periods ended June 30, 2016 and 2015 is as follows (dollar amounts in thousands):

 

     2016      % of
Total
    2015      % of
Total
    Year over
Year
Change
 

Rent billed

   $ 77,960         61.7   $ 53,893         54.0     44.7

Straight-line rent

     8,551         6.8     5,252         5.3     62.8

Income from direct financing leases

     13,552         10.7     12,808         12.8     5.8

Interest and fee income

     26,237         20.8     27,848         27.9     (5.8 )% 
  

 

 

    

 

 

   

 

 

    

 

 

   

Total revenues

   $ 126,300         100.0   $ 99,801         100.0     26.6
  

 

 

    

 

 

   

 

 

    

 

 

   

Our total revenue for the 2016 second quarter is up $26.5 million or 26.6% over the prior year. This increase is made up of the following:

 

    Operating lease revenue (including rent billed and straight-line rent) – up $27.4 million over the prior year of which $0.1 million is from our annual escalation provisions in our leases, $24.6 million is from incremental revenue from acquisitions made after June 2015, and $5.2 million is incremental revenue from development properties that were completed and put into service in 2015 and 2016. These increases are partially offset by a $0.5 million straight-line rent write-off related to our Corinth facility in the 2016 second quarter and $1.8 million of lower revenue related to dispositions post June 30, 2015.

 

    Income from direct financing leases – up $0.7 million over the prior year of which $0.2 million is from our annual escalation provisions in our leases and $3.0 million is from incremental revenue from acquisitions made after June 2015, offset by a $2.6 million write-off of direct financing lease non-cash income related to the Capella Transaction.

 

    Interest from loans – down $1.6 million over the prior year primarily attributable to approximately $11 million of revenue in 2015 from loans that were converted to real estate in connection with the MEDIAN Transaction on or after June 30, 2015 (see Note 3 to Item 1 of this Form 10-Q for further details). This decrease in revenue was partially offset by $9.5 million of additional interest in 2016 from new loans made on or after June 30, 2015.

Real estate depreciation and amortization during the second quarter of 2016 increased to $22.8 million from $15.0 million in 2015, due to the incremental depreciation from the properties acquired since June 30, 2015 and the development properties completed in 2015 and 2016. In the 2016 second quarter, we accelerated the amortization of the lease intangible asset related to our Corinth facility resulting in $1.1 million of additional expense.

Acquisition expenses decreased from $25.8 million in 2015 to $4.8 million in 2016 primarily as a result of the MEDIAN acquisitions in 2015, including approximately $21.5 million of real estate transfer taxes.

During the three months ended June 30, 2016, we had various dispositions resulting in a net gain on sale of real estate and other asset dispositions of $16.6 million and impairment charges of $7.4 million (see Note 3 to Item 1 of this Form 10-Q for further details).

General and administrative expenses totaled $12.0 million for the 2016 second quarter, which is 9.5% of total revenues compared to 10.7% in the 2015 second quarter. The decline in general and administrative expenses as a percentage of revenue is primarily due to our business model as we can generally increase our revenue significantly without increasing our head count and related expenses at the same rate. On a dollar basis, general and administrative expenses were up $1.4 million from the prior year second quarter due to higher international administrative expenses from the growth and expansion of our company along with approximately $0.8 million of higher professional expenses that we do not expect to incur next quarter. We expect general and administrative expenses to be in the $11 million range next quarter.

Interest expense, for the quarters ended June 30, 2016 and 2015, totaled $41.5 million and $26.9 million, respectively. This increase is primarily related to higher average debt balances in the current year quarter associated with our 2015 and 2016 Senior Unsecured Notes and our expanded credit facility. Our weighted average interest rate is 4.9% for the quarter ended June 30, 2016, which is a slight increase from 4.8% in 2015 due to obtaining more permanent financing in 2016. See Note 4 to our Condensed Consolidated Financial Statements in Item 1 to this Form 10-Q for further information on our debt activities.

 

27


Table of Contents

Income tax expense typically includes U.S. federal and state income taxes on our TRS entities, as well as non-U.S. income based or withholding taxes on certain investments located in jurisdictions outside the U.S. The income tax expense for the three months ended June 30, 2016, was primarily due to our European investments. We utilize the asset and liability method of accounting for income taxes. Deferred tax assets are recorded to the extent we believe these assets will more likely than not be realized. In making such determination, all available positive and negative evidence is considered, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance. Based upon our review of all positive and negative evidence, including our three-year cumulative pre-tax book loss position in many entities, we concluded that a full valuation allowance should continue to be recorded against the majority of our U.S and foreign net deferred tax assets at June 30, 2016. In the future, if we determine that it is more likely than not that we will realize our U.S. and foreign net deferred tax assets, we will reverse the applicable portion of the valuation allowance, recognize an income tax benefit in the period in which such determination is made, and incur higher income taxes in future periods.

Six Months Ended June 30, 2016 Compared to June 30, 2015

Net income for the six months ended June 30, 2016, was $111.7 million compared to net income of $58.3 million for the six months ended June 30, 2015, primarily due to additional revenue from MEDIAN and Capella, completed development projects, and gains on real estate disposals, along with a reduction in acquisition expenses. FFO, after adjusting for certain items (as more fully described in Reconciliation of Non-GAAP Financial Measures), was $159.0 million, or $0.67 per diluted share for the first six months in 2016 as compared to $119.8 million, or $0.58 per diluted share for the first six months of 2015. This 33% increase in FFO is primarily due to the increase in revenue from acquisitions and completed development projects made since June 2015.

A comparison of revenues for the six month periods ended June 30, 2016 and 2015 is as follows (dollar amounts in thousands):

 

     2016      % of
Total
    2015      % of
Total
    Year over
Year
Change
 

Rent billed

   $ 152,021         58.2   $ 106,994         54.7     42.1

Straight-line rent

     16,768         6.4     9,980         5.1     68.0

Income from direct financing leases

     32,503         12.4     25,363         12.9     28.2

Interest and fee income

     60,007         23.0     53,425         27.3     12.3
  

 

 

    

 

 

   

 

 

    

 

 

   

Total revenues

   $ 261,299         100.0   $ 195,762         100.0     33.5
  

 

 

    

 

 

   

 

 

    

 

 

   

Our total revenue for the first six months of 2016 is up $65.5 million or 33.5% over the prior year. This increase is made up of the following:

 

    Operating lease revenue (including rent billed and straight-line rent) – up $51.8 million over the prior year of which $0.2 million is from our annual escalation provisions in our leases, $47.0 million is from incremental revenue from acquisitions made after June 2015, and $9.3 million is incremental revenue from development properties that were completed and put into service in 2015 and 2016. These increases are partially offset by a $0.5 million straight-line rent write-off related to our Corinth facility in the 2016 second quarter and $2.3 million related to dispositions.

 

    Income from direct financing leases – up $7.1 million over the prior year of which $0.4 million is from our annual escalation provisions in our leases and $9.1 million is from incremental revenue from acquisitions made after June 2015, offset by a $2.6 million write-off of direct financing lease non-cash income related to the Capella Transaction.

 

    Interest from loans – up $6.6 million over the prior year of which $26.5 million is from incremental revenue in 2016 from acquisitions (primarily from the Capella Transaction), partially offset by $20.2 million of interest revenue in 2015 from loans that were converted to real estate on or after June 30, 2015 in connection with the MEDIAN Transaction – see Note 3 to Item 1 of this Form 10-Q for further details.

Real estate depreciation and amortization during the first six months of 2016 increased to $44.0 million from $29.7 million in the same period of 2015 due to the incremental depreciation from the properties acquired and the development properties completed in 2015 and 2016. In the 2016 second quarter, we accelerated the amortization of the lease intangible asset related to our Corinth facility resulting in $1.1 million of additional expense.

Acquisition expenses decreased from $32.0 million in 2015 to $3.7 million in 2016 primarily as a result of the MEDIAN acquisitions in 2015, including $21.5 million of real estate transfer taxes.

During the six months ended June 30, 2016, we had various dispositions resulting in a net gain on sale of real estate and other asset dispositions of $16.7 million and impairment charges of $7.4 million (see Note 3 to Item 1 of this Form 10-Q for further details).

Earnings from our equity interests declined from $2.0 million of income in the first six months of 2015 to a loss of $(3.8) million in 2016. The loss in 2016 includes $5.3 million of acquisition expenses, representing our share of such expenses incurred by our Italian joint venture to acquire its eight hospital properties.

General and administrative expenses in the first six months of 2016 totaled $23.5 million, which is 9.0% of revenues down from 11.0% of revenues in the prior year. The decline in general and administrative expenses as a percentage of revenues is primarily due to our business model as we can generally increase our revenues significantly without increasing our head count and related expense at the same rate. On a dollar basis, general and administrative expenses were up $2.0 million from the prior year first six months due to higher international administrative expenses, which are up as a result of the growth and expansion of our company, and $0.8 million of non-recurring other professional fees.

 

28


Table of Contents

Interest expense for the first six months of 2016 and 2015 totaled $80.9 million and $53.6 million, respectively. This increase is related to higher average debt balances in the current year associated with our 2015 and 2016 Senior Unsecured Notes and our expanded credit facility. Our weighted average interest rate is slightly lower period over period – 4.7% for the first six months of 2016 and 5.1% for the first six months of 2015. See Note 4 to our Condensed Consolidated Financial Statements in Item 1 to this Form 10-Q for further information on our debt activities.

Reconciliation of Non-GAAP Financial Measures

Investors and analysts following the real estate industry utilize funds from operations, or FFO, as a supplemental performance measure. FFO, reflecting the assumption that real estate asset values rise or fall with market conditions, principally adjusts for the effects of GAAP depreciation and amortization of real estate assets, which assumes that the value of real estate diminishes predictably over time. We compute FFO in accordance with the definition provided by the National Association of Real Estate Investment Trusts, or NAREIT, which represents net income (loss) (computed in accordance with GAAP), excluding gains (losses) on sales of real estate and impairment charges on real estate assets, plus real estate depreciation and amortization and after adjustments for unconsolidated partnerships and joint ventures.

In addition to presenting FFO in accordance with the NAREIT definition, we also disclose normalized FFO, which adjusts FFO for items that relate to unanticipated or non-core events or activities or accounting changes that, if not noted, would make comparison to prior period results and market expectations less meaningful to investors and analysts.

We believe that the use of FFO, combined with the required GAAP presentations, improves the understanding of our operating results among investors and the use of normalized FFO makes comparisons of our operating results with prior periods and other companies more meaningful. While FFO and normalized FFO are relevant and widely used supplemental measures of operating and financial performance of REITs, they should not be viewed as a substitute measure of our operating performance since the measures do not reflect either depreciation and amortization costs or the level of capital expenditures and leasing costs necessary to maintain the operating performance of our properties, which can be significant economic costs that could materially impact our results of operations. FFO and normalized FFO should not be considered an alternative to net income (loss) (computed in accordance with GAAP) as indicators of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity.

The following table presents a reconciliation of net income attributable to MPT common stockholders to FFO for the three and six months ended June 30, 2016 and 2015 (in thousands, except per share data):

 

     For the Three Months Ended      For the Six Months Ended  
     June 30, 2016      June 30, 2015      June 30, 2016      June 30, 2015  

FFO information:

           

Net income attributable to MPT common stockholders

   $ 53,724       $ 22,407       $ 111,651       $ 58,304   

Participating securities’ share in earnings

     (132      (250      (276      (516
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income, less participating securities’ share in earnings

   $ 53,592       $ 22,157       $ 111,375       $ 57,788   

Depreciation and amortization

     23,335         14,956         44,807         29,712   

Gain on sale of real estate

     (22,613      —           (22,653      —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Funds from operations

   $ 54,314       $ 37,113       $ 133,529       $ 87,500   

Write-off of straight line rent and other

     3,063         —           3,063         —     

Transaction costs from non-real estate dispositions

     5,975         —           5,975         —     

Acquisition expenses

     4,801         25,809         9,034         32,048   

Impairment charges

     7,375         —           7,375         —     

Unutilized financing fees / debt refinancing costs

     —           —           4         238   
  

 

 

    

 

 

    

 

 

    

 

 

 

Normalized funds from operations

   $ 75,528       $ 62,922       $ 158,980       $ 119,786   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

29


Table of Contents
     For the Three Months Ended      For the Six Months Ended  
     June 30, 2016      June 30, 2015      June 30, 2016      June 30, 2015  

Per diluted share data:

           

Net income, less participating securities’ share in earnings

   $ 0.22       $ 0.11       $ 0.47       $ 0.28   

Depreciation and amortization

     0.10         0.07         0.18         0.14   

Gain on sale of real estate

     (0.09      —           (0.09      —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Funds from operations

   $ 0.23       $ 0.18       $ 0.56       $ 0.42   

Write-off of straight line rent and other

     0.01         —           0.01         —     

Transaction costs from non-real estate dispositions

     0.03         —           0.03         —     

Acquisition expenses

     0.02         0.12         0.04         0.16   

Impairment charges

     0.03         —           0.03         —     

Unutilized financing fees / debt refinancing costs

     —           —           —           —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Normalized funds from operations

   $ 0.32       $ 0.30       $ 0.67       $ 0.58   
  

 

 

    

 

 

    

 

 

    

 

 

 

LIQUIDITY AND CAPITAL RESOURCES

2016 Cash Flow Activity

During the first half of 2016, we generated $137.3 million of cash flows from operating activities, primarily consisting of rent and interest from mortgage and other loans. We used these operating cash flows along with cash on-hand to fund our dividends of $104.8 million and certain investing activities.

On February 22, 2016, we completed the 2016 Senior Unsecured Notes offering for $500 million. On April 30, 2016, we closed on the Capella Transaction (as further discussed in Note 3 to Item 1 of this Form 10-Q) resulting in net proceeds of $550 million along with an additional $50 million once we sold our investment in RegionalCare bonds in June 2016. On May 23, 2016, we sold our investment in five properties leased and operated by Post Acute for $71 million. On June 17, 2016, we sold our investment in one property leased and operated by Corinth Investor Holdings for $28 million. Finally, during June, we sold 3 million shares under our at-the-market offering program realizing net proceeds of approximately $45 million. We used these proceeds to reduce our revolving credit facility by $1.1 billion during 2016 and fund our remaining investing activities.

Subsequent to June 30, 2016, we sold an additional 2.7 million shares of common stock under our at-the-market program generating net proceeds of $41.1 million. On July 13, 2016, we completed a new $500 million senior unsecured notes offering. We used the net proceeds from this offering to redeem our $450 million 2011 Senior Unsecured Notes, which will be completed on August 12, 2016. Net proceeds from the bond offering and redemption will approximate $19 million, and we expect to incur a one-time charge related to the redemption of approximately $23 million (see Note 10 to Item 1 of this Form 10-Q for further details). Finally, on July 20, 2016, we sold three facilities leased to HealthSouth for $111.5 million.

2015 Cash Flow Activity

During the six months ended June 30, 2015, we generated $87.4 million of cash flow from operating activities, primarily consisting of rent and interest from mortgage and other loans. We used these operating cash flows along with cash on-hand to fund our dividends of $84.5 million and certain investing activities including the additional funding of our development activities.

On January 14, 2015, we completed an underwritten public offering of 34.5 million shares (including the exercise of the underwriters’ 30-day option to purchase an additional 4.5 million shares) of our common stock, resulting in net proceeds of approximately $480 million, after deducting estimated offering expenses. We used the net proceeds from this offering along with $81 million from our revolving credit facility to fund our acquisitions and new loan investments in 2015.

Short-term Liquidity Requirements: As of June 30, 2016, we have $125.2 million in debt principal payments due in 2016 — see debt maturity schedule below. At August 1, 2016, our availability under our revolving credit facility plus cash on-hand approximated $1.5 billion. We have an at-the-market equity offering program under which we may sell up to an additional $140 million in shares, which may be used for general corporate purposes as needed. We believe any excess availability in our revolving credit facility, our current monthly cash receipts from rent and loan interest, and the availability under our at-the-market equity offering program is sufficient to fund our operations, debt and interest obligations, our firm commitments (including capital expenditures, if any, and expected funding requirements on our development projects), and dividends in order to comply with REIT requirements for the next twelve months.

 

30


Table of Contents

Long-term Liquidity Requirements: Exclusive of the revolving credit facility (which we can extend for an additional year to June 2019), we have less than $150 million in debt principal payments due between now and June 2019 (see debt maturity schedule below). With our liquidity at August 1, 2016 of approximately $1.5 billion along with our current monthly cash receipts from rent and loan interest and with the availability under our at-the-market equity offering program, we believe we have the liquidity available to us to fund our operations, debt and interest obligations, dividends in order to comply with REIT requirements, and firm commitments (including capital expenditures, if any, and expected funding requirements on our development projects) currently.

However, access to capital is an integral part of our business plan. In order to fund debt maturities coming due in 2019 and later years, and as we consider strategic investment opportunities, while maintaining compliance with our debt covenants (as described in Note 4 to Item 1 of this Form 10-Q), we believe additional capital may be needed and we may access one or a combination of the following:

 

    sale of equity securities,

 

    proceeds from strategic property or other asset sales,

 

    entering into new bank term loans,

 

    issuing of new U.S. dollar or euro denominated debt securities, including senior unsecured notes,

 

    entering into joint venture arrangements, and/or

 

    amending our current credit facility.

However, there is no assurance that conditions will be favorable for such possible transactions or that our plans will be successful.

As of June 30, 2016, principal payments due on our debt (which exclude the effects of any discounts, premiums, or debt issue costs recorded) are as follows (in thousands):

 

2016

   $ 125,152 (A) 

2017

     320   

2018

     37,781   

2019

     250,000   

2020

     222,120   

Thereafter

     2,155,300   
  

 

 

 

Total

   $ 2,790,673   
  

 

 

 

 

(A) $65 million of our 2006 Senior Unsecured Notes were paid in full in July 2016, while the remaining $60 million will mature in October 2016.

Disclosure of Contractual Obligations

We presented our contractual obligations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Except for the issuance of the 2016 Senior Unsecured Notes and the subsequent pay down of our revolving credit facility from this bond issuance and asset disposals, there have been no significant changes in those obligations during the six months ended June 30, 2016. See Note 4 of Item 1 of this Form 10-Q for more detailed information.

The following table updates our contractual obligations schedule for the reduction in our revolving credit facility and for the 2016 Senior Unsecured Notes offering (in thousands):

 

Contractual Obligations

   Less Than
1 Year
     1-3 Years      3-5 Years      After
5 Years
     Total  

Revolving credit facility (1)

   $ 4,368       $ 29,222       $ —         $ —         $ 33,590   

2016 Senior Unsecured Notes

     32,583         63,750         63,750         595,625         755,708   

 

(1) As of June 30, 2016, we have a $1.3 billion revolving credit facility. However, this table assumes the balance outstanding under the revolver and rate in effect at June 30, 2016 remain in effect through maturity.

 

31


Table of Contents

Distribution Policy

The table below is a summary of our distributions declared during the two year period ended June 30, 2016:

 

Declaration Date

   Record Date    Date of Distribution    Distribution per Share  

May 19, 2016

   June 16, 2016    July 14, 2016    $ 0.23   

February 19, 2016

   March 17, 2016    April 14, 2016    $ 0.22   

November 12, 2015

   December 10, 2015    January 14, 2016    $ 0.22   

August 20, 2015

   September 17, 2015    October 15, 2015    $ 0.22   

May 14, 2015

   June 11, 2015    July 9, 2015    $ 0.22   

February 23, 2015

   March 12, 2015    April 9, 2015    $ 0.22   

November 13, 2014

   December 4, 2014    January 8, 2015    $ 0.21   

August 21, 2014

   September 18, 2014    October 15, 2014    $ 0.21   

We intend to pay to our stockholders, within the time periods prescribed by the Internal Revenue Code (“Code”), all or substantially all of our annual taxable income, including taxable gains (if any) from the sale of real estate and recognized gains on the sale of securities. It is our policy to make sufficient cash distributions to stockholders in order for us to maintain our status as a REIT under the Code and to avoid corporate income and excise taxes on undistributed income. See Note 4 to our condensed consolidated financial statements in Item 1 to this Form 10-Q for any restrictions placed on dividends by our new credit facility.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Market risk includes risks that arise from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices and other market changes that affect market sensitive instruments. We seek to mitigate the effects of fluctuations in interest rates by matching the terms of new investments with new long-term fixed rate borrowings to the extent possible. We may or may not elect to use financial derivative instruments to hedge interest rate exposure. These decisions are principally based on our policy to match our variable rate investments with comparable borrowings, but are also based on the general trend in interest rates at the applicable dates and our perception of the future volatility of interest rates.

In addition, the value of our facilities will be subject to fluctuations based on changes in local and regional economic conditions and changes in the ability of our tenants to generate profits, all of which may affect our ability to refinance our debt if necessary. The changes in the value of our facilities would be impacted also by changes in “cap” rates, which is measured by the current base rent divided by the current market value of a facility.

Our primary exposure to market risks relates to fluctuations in interest rates and foreign currency. The following analyses present the sensitivity of the market value, earnings and cash flows of our significant financial instruments to hypothetical changes in interest rates and exchange rates as if these changes had occurred. The hypothetical changes chosen for these analyses reflect our view of changes that are reasonably possible over a one-year period. These forward looking disclosures are selective in nature and only address the potential impact from these hypothetical changes. They do not include other potential effects which could impact our business as a result of changes in market conditions. In addition, they do not include measures we may take to minimize our exposure such as entering into future interest rate swaps to hedge against interest rate increases on our variable rate debt.

Interest Rate Sensitivity

For fixed rate debt, interest rate changes affect the fair market value but do not impact net income to common stockholders or cash flows. Conversely, for floating rate debt, interest rate changes generally do not affect the fair market value but do impact net income to common stockholders and cash flows, assuming other factors are held constant. At June 30, 2016, our outstanding debt totaled $2.8 billion, which consisted of fixed-rate debt of $2.5 billion (including $125 million of floating debt swapped to fixed) and variable rate debt of $0.3 billion. If market interest rates increase by 1%, the fair value of our debt at June 30, 2016 would decrease by $4.2 million. Changes in the fair value of our fixed rate debt will not have any impact on us unless we decided to repurchase the debt in the open market.

If market rates of interest on our variable rate debt increase by 1%, the increase in annual interest expense on our variable rate debt would decrease future earnings and cash flows by $0.1 million per year. If market rates of interest on our variable rate debt decrease by 1%, the decrease in interest expense on our variable rate debt would increase future earnings and cash flows by $0.1 million per year. This assumes that the average amount outstanding under our variable rate debt for a year is $0.3 billion, the balance of such variable rate debt at June 30, 2016.

 

32


Table of Contents

Foreign Currency Sensitivity

With our investments in Germany and throughout Europe, we are subject to fluctuations in the Euro and British Pound to U.S. dollar currency exchange rates. Increases or decreases in the value of the Euro to U.S. dollar and the British Pound to U.S. dollar exchange rates may impact our financial condition and/or our results of operations. Based solely on operating results to-date in 2016 and on an annualized basis, if the Euro exchange rate were to change by 5%, our FFO would change by approximately $3.0 million. Based solely on operating results to-date in 2016 and on an annualized basis, if the British Pound exchange rate were to change by 5%, our FFO would change by approximately $0.2 million.

Item 4. Controls and Procedures.

We have adopted and maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b), under the Securities Exchange Act of 1934, as amended, we have carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the quarter covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information required to be disclosed by us in the reports that we file with the SEC.

There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

33


Table of Contents

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

Our Adjusted EBITDA is dependent upon our relationship with, and success of, our largest tenants, Prime, MEDIAN, Ernest, Adeptus Health and RCCH.

As of June 30, 2016, affiliates of Prime, MEDIAN, Ernest, Adeptus Health and RCCH leased or mortgaged facilities representing 21%, 19%, 11%, 9% and 9%, respectively, of our total gross assets assuming all current real estate commitments (such as remaining commitments on ongoing development projects) are fully funded.

Our relationship with these operators and their financial performance and resulting ability to satisfy their lease and loan obligations to us are material to our financial results and our ability to service our debt. We are dependent upon the ability of these operators to make rent and loan payments to us, and any failure or delay to meet these obligations could have a material adverse effect on our financial condition and results of operations.

In addition, the healthcare industry is highly regulated by federal, state, and local laws, and is directly affected by federal conditions of participation, state licensing requirements, facility inspections, state and federal reimbursement policies, regulations concerning capital and other expenditures, certification requirements and other such laws, regulations, and rules. We are aware of various federal and state inquiries, investigations, and other proceedings currently affecting several of our tenants and would expect such governmental compliance and enforcement activities to be ongoing at any given time with respect to one or more of our tenants, either on a confidential or public basis. During the second quarter of 2016, the Department of Justice joined a lawsuit against Prime alleging irregular admission practices intended to increase the number of inpatient care admissions of Medicare patients, including unnecessarily classifying some patients as “inpatient” rather than “observation”. Other large acute hospital operators have also recently defended such allegations, sometimes resulting in financial settlements and agreements with regulators to modify admission policies, resulting in lower reimbursements for those patients.

An adverse result to Prime or one of our other largest tenants in one or more such governmental proceedings may have a material adverse effect on the relevant tenant’s operations and financial condition and on its ability to make required lease and mortgage payments to us. In instances where we have an equity investment in our tenants’ operations, in addition to the effect on these tenants’ ability to meet their financial obligation to us, our ownership and investment interests may also be negatively impacted.

The United Kingdom’s anticipated exit from the European Union could adversely affect us.

On June 23, 2016, the United Kingdom held a referendum in which a majority of voters voted to exit the European Union, known as Brexit. Negotiations are expected to commence to determine the future terms of the United Kingdom’s relationship with the European Union, including, among other things, the terms of trade between the United Kingdom and the European Union. The effects of Brexit will depend on any agreements the United Kingdom makes to retain access to European Union markets either during a transitional period or more permanently. Brexit could adversely affect European and global economic or market conditions and could contribute to instability in global financial markets. In addition, Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the United Kingdom determines which European Union laws to replace or replicate. Any of these effects of Brexit, and others we cannot anticipate, may adversely affect us.

We currently hold, and may acquire additional, interests in healthcare facilities located in the United Kingdom and Europe, as well as other investments that are denominated in British Pounds and Euros. In addition, our operating partnership has issued, and may issue in the future, senior unsecured notes denominated in Euros. Any of the effects of Brexit described above, and others we cannot anticipate, could have a material adverse effect on our business, the value of our real estate and other investments, and our potential growth in Europe, and could amplify the currency risks faced by us.

There have been no material changes to the Risk Factors as presented in our Annual Report on Form 10-K for the year ended December 31, 2015 other than what is noted above.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

(a) None.

 

(b) Not applicable.

 

(c) None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

 

(a) None.

 

(b) None.

 

34


Table of Contents

Item 6. Exhibits.

 

Exhibit
Number
  

Description

31.1    Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. (Medical Properties Trust, Inc.)
31.2    Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. (Medical Properties Trust, Inc.)
31.3    Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. (MPT Operating Partnership, L.P.)
31.4    Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. (MPT Operating Partnership, L.P.)
32.1    Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (Medical Properties Trust, Inc.)
32.2    Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (MPT Operating Partnership, L.P.)
Exhibit 101.INS    XBRL Instance Document
Exhibit 101.SCH    XBRL Taxonomy Extension Schema Document
Exhibit 101.CAL    XBRL Taxonomy Extension Calculation Linkbase Document
Exhibit 101.DEF    XBRL Taxonomy Extension Definition Linkbase Document
Exhibit 101.LAB    XBRL Taxonomy Extension Label Linkbase Document
Exhibit 101.PRE    XBRL Taxonomy Extension Presentation Linkbase Document

 

35


Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

MEDICAL PROPERTIES TRUST, INC.
By:  

/s/ J. Kevin Hanna

  J. Kevin Hanna
 

Vice President, Controller, Assistant Treasurer, and Chief Accounting Officer

(Principal Accounting Officer)

MPT OPERATING PARTNERSHIP, L.P.
By:  

/s/ J. Kevin Hanna

  J. Kevin Hanna
 

Vice President, Controller, Assistant

Treasurer, and Chief Accounting Officer

of the sole member of the general partner

of MPT Operating Partnership, L.P.

(Principal Accounting Officer)

Date: August 9, 2016

 

36


Table of Contents

INDEX TO EXHIBITS

 

Exhibit
Number
  

Description

31.1    Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. (Medical Properties Trust, Inc.)
31.2    Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. (Medical Properties Trust, Inc.)
31.3    Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. (MPT Operating Partnership, L.P.)
31.4    Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. (MPT Operating Partnership, L.P.)
32.1    Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (Medical Properties Trust, Inc.)
32.2    Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (MPT Operating Partnership, L.P.)
Exhibit 101.INS    XBRL Instance Document
Exhibit 101.SCH    XBRL Taxonomy Extension Schema Document
Exhibit 101.CAL    XBRL Taxonomy Extension Calculation Linkbase Document
Exhibit 101.DEF    XBRL Taxonomy Extension Definition Linkbase Document
Exhibit 101.LAB    XBRL Taxonomy Extension Label Linkbase Document
Exhibit 101.PRE    XBRL Taxonomy Extension Presentation Linkbase Document

 

37

EX-31.1 2 d188486dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, Edward K. Aldag, Jr., certify that:

 

1) I have reviewed this quarterly report on Form 10-Q of Medical Properties Trust, Inc.;

 

2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 9, 2016      

/s/ Edward K. Aldag, Jr.

      Edward K. Aldag, Jr.
      Chairman, President and Chief Executive Officer of Medical Properties Trust, Inc.
EX-31.2 3 d188486dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, R. Steven Hamner, certify that:

 

1) I have reviewed this quarterly report on Form 10-Q of Medical Properties Trust, Inc.;

 

2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 9, 2016      

/s/ R. Steven Hamner

      R. Steven Hamner
      Executive Vice President and Chief Financial Officer of Medical Properties Trust, Inc.
EX-31.3 4 d188486dex313.htm EX-31.3 EX-31.3

Exhibit 31.3

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, Edward K. Aldag, Jr., certify that:

 

1) I have reviewed this quarterly report on Form 10-Q of MPT Operating Partnership, L.P.;

 

2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 9, 2016      

/s/ Edward K. Aldag, Jr.

      Edward K. Aldag, Jr.
      Chairman, President and Chief Executive Officer of the sole member of the general partner of MPT Operating Partnership, L.P.
EX-31.4 5 d188486dex314.htm EX-31.4 EX-31.4

Exhibit 31.4

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, R. Steven Hamner, certify that:

 

1) I have reviewed this quarterly report on Form 10-Q of MPT Operating Partnership, L.P.;

 

2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 9, 2016      

/s/ R. Steven Hamner

      R. Steven Hamner
      Executive Vice President and Chief Financial Officer of the sole member of the general partner of MPT Operating Partnership, L.P.
EX-32.1 6 d188486dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(b) UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this quarterly report on Form 10-Q of Medical Properties Trust, Inc. (the “Company”) for the quarter ended June 30, 2016 (the “Report”), each of the undersigned, Edward K. Aldag, Jr. and R. Steven Hamner, certifies, pursuant to Section 18 U.S.C. Section 1350, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 9, 2016      

/s/ Edward K. Aldag, Jr.

      Edward K. Aldag, Jr.
      Chairman, President and Chief Executive Officer of Medical Properties Trust, Inc.
     

/s/ R. Steven Hamner

      R. Steven Hamner
      Executive Vice President and Chief Financial Officer of Medical Properties Trust, Inc.
EX-32.2 7 d188486dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(b) UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this quarterly report on Form 10-Q of MPT Operating Partnership, L.P. (the “Company”) for the quarter ended June 30, 2016 (the “Report”), each of the undersigned, Edward K. Aldag, Jr. and R. Steven Hamner, certifies, pursuant to Section 18 U.S.C. Section 1350, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 9, 2016      

/s/ Edward K. Aldag, Jr.

      Edward K. Aldag, Jr.
      Chairman, President and Chief Executive Officer of the sole member of the general partner of MPT Operating Partnership, L.P.
     

/s/ R. Steven Hamner

      R. Steven Hamner
      Executive Vice President and Chief Financial Officer of the sole member of the general partner of MPT Operating Partnership, L.P.
EX-101.INS 8 mpw-20160630.xml XBRL INSTANCE DOCUMENT 60000000 110000000 0.06375 500000000 50000000 30000000 65000000 2700000 243138873 2500000 60000000 5000000 0.093 227000000 12000000 41600000 0.0525 500000000 23000000 450000000 93300000 7000000 65000000 0.05507 46026000 45904000 378807000 562633000 183826000 317000000 240000000 16917000 46026000 45904000 40000000 390320000 62434000 10700000 42262000 0.50 500000 0 500000000 240341000 0.001 240341000 10000000 0.001 -414657000 222120000 2863382000 2950695000 5117933000 1639650000 -65340000 2162262000 20997000 2758635000 240000 2642281000 320000 125152000 2167238000 4976000 250000000 37781000 2790673000 55272000 148218000 528747000 188589000 181561000 221929000 623399000 549337000 109991000 1875751000 221929000 47653000 5117933000 109991000 808666000 63074000 262000 95988000 22845000 590037000 4344767000 2155300000 278590000 3300000 47699000 259329000 4623357000 292646000 255048000 3482199000 43229000 216100000 116867000 116867000 8196770 5615497 25000000 0.775 263253000 125000000 1300000 0.05750 222120000 0.06875 450000000 2792664000 0.04000 555300000 0.06375 1991000 351991000 350000000 0.06375 500000000 0.05500 300000000 2400000 2400000 22299000 292000 292000 7 64890000 625000 63074000 2441000 295822000 328000 3300000 3300000 101762000 101762000 0.9983 2950305000 5117933000 -65340000 2162652000 20997000 2758635000 2167628000 4976000 55272000 92623000 528747000 188589000 181561000 549337000 5117933000 63074000 95988000 22845000 4344767000 278590000 47699000 259329000 4623357000 55205000 3482199000 237941000 237941000 2205693000 547079000 1054368000 920959000 4187414000 2530018000 1234981000 156630000 189358000 23983000 226101000 800000 549337000 0.023 0 5422395000 584411000 500000000 1054368000 1126654000 458659000 3000000 37309000 93200000 62154000 53836000 5730000 61997000 71331000 93300000 37593000 9398000 63000000 0.65 144541000 0.051 425000000 0.949 144541000 34500000 0 500000000 236744000 0.001 236744000 10000000 0.001 -418650000 3372773000 3502086000 5609351000 2354013000 -72884000 2102268000 29358000 3322541000 237000 2593827000 2107265000 4997000 137356000 626996000 195540000 195541000 543859000 757581000 2587912000 46858000 5609351000 1422403000 262000 82155000 12831000 508851000 4424354000 257928000 46939000 664822000 4682282000 393097000 3297705000 54353000 610469000 1100000000 263400000 125000000 2900000 0.05750 217240000 0.06875 450000000 3350908000 0.04000 543100000 0.06375 2168000 352168000 350000000 0.05500 300000000 2363000 2363000 21773000 292000 292000 3501696000 5609351000 -72884000 2102658000 29358000 3322541000 2107655000 4997000 84628000 626996000 195540000 195541000 757581000 5609351000 82155000 12831000 4424354000 257928000 46939000 664822000 4682282000 52338000 3297705000 234381000 234381000 2153769000 547085000 1031039000 1060990000 4832596000 3047204000 1203326000 161317000 177317000 10970000 1700000 757581000 6035922000 579182000 500000000 1031039000 1032353000 1059989000 2 P10Y 40000000 P5Y P10Y 2 5000000 10700000 P5Y P17Y 3 2016-09-01 Interest on the notes will be payable on March 1 and September 1 of each year We may redeem some or all of the notes at any time prior to March 1, 2019 at a “make whole” redemption price. On or after March 1, 2019, we may redeem some or all of the notes at a premium that will decrease over time. In addition, at any time prior to March 1, 2019, we may redeem up to 35% of the notes at a redemption price equal to 106.375% of the aggregate principal amount thereof, plus accrued and unpaid interest thereon, using proceeds from one or more equity offerings. In the event of a change in control, each holder of the notes may require us to repurchase some or all of the notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest to the date of purchase. 2024-03-01 1.06375 2019-03-01 1.01 0.35 550000000 6300000 210000000 93300000 492000000 63000000 0.02 P15Y 3 P3Y 111500000 3 15000000 4000000 71000000 5 2 3 1700000 0.099 688000000 32 0.70 P27Y 0.0125 37 60 31500000 P5Y 2 P20Y 3 8000000 28000000 9000000 45000000 0.35 2026-08-01 1.0525 1.01 2017-02-01 2016-08-12 Interest on the notes will be payable on February 1 and August 1 of each year We may redeem some or all of the notes at a premium that will decrease over time. In addition, at any time prior to August 1, 2019, we may redeem up to 35% of the notes at a redemption price equal to 105.25% of the aggregate principal amount thereof, plus accrued and unpaid interest thereon, using proceeds from one or more equity offerings. In the event of a change in control, each holder of the notes may require us to repurchase some or all of the notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest to the date of purchase. 2021-08-01 17 21400000 480000000 4500000 0.28 0.28 0 206127000 205515000 0.28 0 0.42 0.44 0.28 612000 87444000 195762000 347768000 -39286000 53425000 9075000 7663000 9980000 84487000 111574000 58304000 52130000 20494000 20333000 25363000 140000 58465000 58465000 100000 562633000 -571000 2383000 1315000 -53109000 219000 30564000 161000 938000 53556000 479902000 5645000 32048000 29712000 881000 -641502000 -662000 2770000 84188000 -5325000 21547000 161000 354952000 80586000 -93312000 161000 1897000 21327000 460746000 57788000 14453000 15685000 57788000 557000 106994000 86053000 516000 3279000 1956000 72000 9980000 176046 505050 217177 6200000 4900000 26700000 0.28 0.28 0 206127000 205515000 0.28 0 0.44 0.28 612000 87444000 34500000 195762000 347768000 -39286000 53425000 9980000 84487000 111574000 58304000 52130000 20494000 20333000 25363000 140000 58465000 58465000 562633000 -571000 2383000 1315000 -53109000 30564000 161000 938000 53556000 479902000 5645000 32048000 29712000 881000 -641502000 -662000 2770000 84188000 -5325000 21547000 161000 354952000 80586000 -93312000 161000 21327000 460746000 57788000 14453000 15685000 57788000 106994000 86053000 516000 3279000 1956000 9980000 0.169 33065000 0.165 32212000 0.218 42689000 0.824 161374000 0.437 85620000 0.176 34388000 0.011 2176000 0 1.000 195762000 0.152 29695000 0.038 7425000 0.165 32212000 0.255 49869000 P25Y9M18D <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>9. Commitments and Contingencies</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Contingencies</i></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> We are a party to various legal proceedings incidental to our business. In the opinion of management, after consultation with legal counsel, the ultimate liability, if any, with respect to those proceedings is not presently expected to materially affect our financial position, results of operations or cash flows.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>6. Stock Awards</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> We adopted the 2013 Equity Incentive Plan (the &#x201C;Equity Incentive Plan&#x201D;) during the second quarter of 2013, which authorizes the issuance of common stock options, restricted stock, restricted stock units, deferred stock units, stock appreciation rights, performance units and awards of interests in our Operating Partnership. The Equity Incentive Plan is administered by the Compensation Committee of the Board of Directors. We have reserved 8,196,770 shares of common stock for awards under the Equity Incentive Plan for which 5,615,497 shares remain available for future stock awards as of June&#xA0;30, 2016. We awarded the following stock awards during 2016 and 2015:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Time-based awards&#xA0;</i>&#x2014;We granted 45,528 shares to independent directors in 2016 and 217,177 shares to management, independent directors and certain employees in time-based restricted stock. These awards vest quarterly based on service, over three years, in equal amounts.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Performance-based awards</i>&#xA0;&#x2014;Our management team and certain employees were awarded 176,046 shares of performance based awards in 2015. No such awards have been granted in 2016. These awards vest ratably over a three-year period based on the achievement of certain total shareholder return measures, with a carry-back and carry-forward provision through December&#xA0;31, 2017. Dividends on these awards are paid only upon achievement of the performance measures.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Multi-year Performance-based awards</i>&#xA0;&#x2014;We awarded 505,050 shares in 2015 of multi-year performance-based awards to management. No such awards have been granted in 2016. These shares are subject to three-year cumulative performance hurdles based on measures of total shareholder return. At the end of the three-year performance period, any earned shares will be subject to an additional two years of ratable time-based vesting on an annual basis. Dividends are paid on these shares only upon achievement of the performance measures.</p> </div> Q2 2016 10-Q 0.47 0001287865 0.40 0.47 0 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Recent Accounting Developments:</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 151px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Revenue from Contracts with Customers</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In May 2014, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued Accounting Standards Update (&#x201C;ASU&#x201D;) No. 2014-09,&#xA0;<i>Revenue from Contracts with Customers</i>. Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. Entities may use a full retrospective approach or report the cumulative effect as of the date of adoption. On April 1, 2015, the FASB proposed deferring the effective date of this standard by one year to December 15, 2017, for annual reporting periods beginning after that date. The FASB also proposed permitting early adoption of the standard, but not before the original effective date of December 15, 2016. We are continuing to evaluate this standard; however, we do not expect it to have a significant impact on our financial results, as a substantial portion of our revenue consists of rental income from leasing arrangements, which are specifically excluded from ASU No. 2014-09.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; break-before: page"> </p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 151px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Leases</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In February 2016, the FASB issued ASU&#xA0;2016-02&#xA0;-&#xA0;<i>Leases</i>, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors).&#xA0;The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee.&#xA0;This classification will determine&#xA0;whether lease expense is recognized&#xA0;based on an effective interest method&#xA0;or&#xA0;on a straight line basis over the term of the lease.&#xA0;A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification.&#xA0;Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The ASU is not effective for us until January&#xA0;1, 2019 with early adoption permitted. We are continuing to evaluate this standard and the impact to us from both a lessor and a lessee perspective.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 151px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Measurement of Credit Losses on Financial Instruments</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In June 2016, the FASB issued ASU 2016-13,&#xA0;<i>Measurement of Credit Losses on Financial Instruments</i>, which is intended to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations.&#xA0;The ASU requires the measurement of all expected credit losses for financial assets not recorded at fair value based on historical experience, current conditions, and reasonable and supportable forecasts.&#xA0;The ASU will be required to be implemented through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the amendments are effective.&#xA0;The ASU is not effective for us until January 1, 2019. We do not expect the adoption of the ASU to have a significant impact on our consolidated financial statements.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>5. Common Stock/Partners&#x2019; Capital</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Medical Properties Trust, Inc.</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> On March&#xA0;1, 2016, we updated our at-the-market equity offering program, which gives us the ability to sell up to $227 million of stock with a commission rate of 1.25%. During the six months ended June&#xA0;30, 2016, we sold approximately 3&#xA0;million shares of our common stock under this program, resulting in net proceeds of approximately $45 million, after deducting approximately $0.6 million of commissions.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> On January&#xA0;14, 2015, we completed an underwritten public offering of 34.5&#xA0;million shares (including the exercise of the underwriters&#x2019; 30-day option to purchase an additional 4.5&#xA0;million shares) of our common stock, resulting in net proceeds of approximately $480 million, after deducting estimated offering expenses.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>MPT Operating Partnership, L.P.</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> At June&#xA0;30, 2016, the Company has a 99.83% ownership interest in the Operating Partnership with the remainder owned by three other partners, two of whom are employees and one of whom is a director. During the six months ended June&#xA0;30, 2016 and 2015, the&#xA0;Operating Partnership issued 3 million units and 34.5&#xA0;million units, respectively, in direct response to the common stock offerings by Medical Properties Trust, Inc.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> We acquired the following assets (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Six&#xA0;Months</b><br /> <b>Ended&#xA0;June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Assets Acquired</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Land and land improvements</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,398</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">62,434</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Building</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">37,593</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">390,320</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Intangible lease assets &#x2014; subject to amortization (weighted average useful life 25.8&#xA0;years)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">42,262</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Mortgage loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">40,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net investments in direct financing leases</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">63,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,700</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,917</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total assets acquired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">109,991</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">562,633</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Loans repaid (1)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(183,826</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total net assets acquired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">109,991</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">378,807</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%">&#xA0;</td> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Loans advanced to MEDIAN in 2014 and repaid in 2015 as a part of the MEDIAN transaction.</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-TOP: 12pt"> At June&#xA0;30, 2016, these amounts were as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <br class="Apple-interchange-newline" /> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 37.55pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>Asset Type</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair<br /> Value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Cost</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Asset&#xA0;Type<br /> Classification</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Mortgage loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">101,762</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">101,762</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Mortgage&#xA0;loans</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Acquisition and other loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">116,867</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">116,867</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Other loans</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Equity investments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,300</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,300</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Other assets</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">221,929</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">221,929</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">&#xA0;&#xA0;</td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">&#xA0;&#xA0;</td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">&#xA0;&#xA0;</td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td> </tr> </table> </div> <div> The carrying value and classification of the related assets and maximum exposure to loss as a result of our involvement with these VIEs are presented below at June&#xA0;30, 2016 (in thousands): <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="48%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 33.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>VIE Type</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Maximum&#xA0;Loss</b><br /> <b>Exposure(1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>Asset&#xA0;Type</b><br /> <b>Classification</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Carrying</b><br /> <b>&#xA0;&#xA0;&#xA0;&#xA0;Amount(2)&#xA0;&#xA0;&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Loans, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">295,822</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center"> Mortgage&#xA0;and&#xA0;other&#xA0;loans</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">226,101</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Equity investments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,309</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">Other assets</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">328</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Our maximum loss exposure related to loans with VIEs represents our current aggregate gross carrying value of the loan plus accrued interest and any other related assets (such as rent receivables), less any liabilities. Our maximum loss exposure related to our equity investment in VIEs represents the current carrying values of such investment plus any other related assets (such as rent receivables) less any liabilities.</td> </tr> </table> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(2)</td> <td valign="top" align="left">Carrying amount reflects the net book value of our loan or equity interest only in the VIE.</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>2. Summary of Significant Accounting Policies</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> <i>Unaudited Interim Condensed Consolidated Financial Statements</i>: The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information, including rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles (&#x201C;GAAP&#x201D;) for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June&#xA0;30, 2016, are not necessarily indicative of the results that may be expected for the year ending December&#xA0;31, 2016. The condensed consolidated balance sheet at December&#xA0;31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> For information about significant accounting policies, refer to the consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December&#xA0;31, 2015. During the six months ended June&#xA0;30, 2016, there were no material changes to these policies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Recent Accounting Developments:</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> <i>Revenue from Contracts with Customers</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In May 2014, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued Accounting Standards Update (&#x201C;ASU&#x201D;) No. 2014-09, <i>Revenue from Contracts with Customers</i>. Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. Entities may use a full retrospective approach or report the cumulative effect as of the date of adoption. On April 1, 2015, the FASB proposed deferring the effective date of this standard by one year to December 15, 2017, for annual reporting periods beginning after that date. The FASB also proposed permitting early adoption of the standard, but not before the original effective date of December 15, 2016. We are continuing to evaluate this standard; however, we do not expect it to have a significant impact on our financial results, as a substantial portion of our revenue consists of rental income from leasing arrangements, which are specifically excluded from ASU No. 2014-09.</p> <p style="MARGIN-BOTTOM: 0pt; PAGE-BREAK-BEFORE: always; MARGIN-TOP: 0pt"> </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 18pt"> <i>Leases</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In February 2016, the FASB issued ASU&#xA0;2016-02&#xA0;-&#xA0;<i>Leases</i>, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors).&#xA0;The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee.&#xA0;This classification will determine&#xA0;whether lease expense is recognized&#xA0;based on an effective interest method&#xA0;or&#xA0;on a straight line basis over the term of the lease.&#xA0;A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification.&#xA0;Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The ASU is not effective for us until January&#xA0;1, 2019 with early adoption permitted. We are continuing to evaluate this standard and the impact to us from both a lessor and a lessee perspective.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 18pt"> <i>Measurement of Credit Losses on Financial Instruments</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In June 2016, the FASB issued ASU 2016-13, <i>Measurement of Credit Losses on Financial Instruments</i>, which is intended to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations.&#xA0;The ASU requires the measurement of all expected credit losses for financial assets not recorded at fair value based on historical experience, current conditions, and reasonable and supportable forecasts.&#xA0;The ASU will be required to be implemented through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the amendments are effective.&#xA0;The ASU is not effective for us until January 1, 2019. We do not expect the adoption of the ASU to have a significant impact on our consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <i>Variable Interest Entities</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> At June&#xA0;30, 2016, we had loans to and/or equity investments in certain variable interest entities (&#x201C;VIEs&#x201D;), which are also tenants of our facilities, including Ernest Health, Inc. (&#x201C;Ernest&#x201D;). We have determined that we are not the primary beneficiary of these VIEs. The carrying value and classification of the related assets and maximum exposure to loss as a result of our involvement with these VIEs are presented below at June&#xA0;30, 2016 (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="48%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 33.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>VIE Type</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Maximum&#xA0;Loss</b><br /> <b>Exposure(1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>Asset&#xA0;Type</b><br /> <b>Classification</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Carrying</b><br /> <b>&#xA0;&#xA0;&#xA0;&#xA0;Amount(2)&#xA0;&#xA0;&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Loans, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">295,822</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center"> Mortgage&#xA0;and&#xA0;other&#xA0;loans</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">226,101</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Equity investments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,309</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">Other assets</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">328</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Our maximum loss exposure related to loans with VIEs represents our current aggregate gross carrying value of the loan plus accrued interest and any other related assets (such as rent receivables), less any liabilities. Our maximum loss exposure related to our equity investment in VIEs represents the current carrying values of such investment plus any other related assets (such as rent receivables) less any liabilities.</td> </tr> </table> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(2)</td> <td valign="top" align="left">Carrying amount reflects the net book value of our loan or equity interest only in the VIE.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> For the VIE types above, we do not consolidate the VIE because we do not have the ability to control the activities (such as the day-to-day healthcare operations of our borrower or investees) that most significantly impact the VIE&#x2019;s economic performance. As of June&#xA0;30, 2016, we were not required to provide any material financial support through a liquidity arrangement or otherwise to our unconsolidated VIEs, including circumstances in which it could be exposed to further losses (e.g., cash short falls).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> Typically, our loans are collateralized by assets of the borrower (some assets of which are on the premises of facilities owned by us) and further supported by limited guarantees made by certain principals of the borrower.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> See Note 3 and 7 for additional description of the nature, purpose and activities of our more significant VIEs and interests therein.</p> </div> MPW 238413000 237796000 false <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> <i>Unaudited Interim Condensed Consolidated Financial Statements</i>: The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information, including rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles (&#x201C;GAAP&#x201D;) for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June&#xA0;30, 2016, are not necessarily indicative of the results that may be expected for the year ending December&#xA0;31, 2016. The condensed consolidated balance sheet at December&#xA0;31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> For information about significant accounting policies, refer to the consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December&#xA0;31, 2015. During the six months ended June&#xA0;30, 2016, there were no material changes to these policies.</p> </div> 0.47 0 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Gross Assets by U.S. State and Country</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="50%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of June&#xA0;30, 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"><b>U.S. States and Other Countries</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b><br /> <b>Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of</b><br /> <b>Total&#xA0;Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b><br /> <b>Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of</b><br /> <b>Total&#xA0;Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(A)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(B)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(A)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(B)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Texas</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">920,959</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,060,990</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> California</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">547,079</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">547,085</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> All other states</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,530,018</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">46.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,047,204</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">50.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other domestic assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">189,358</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">177,317</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total U.S.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,187,414</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">77.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,832,596</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">80.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Germany</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,054,368</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,031,039</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> United Kingdom, Italy, and Spain</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">156,630</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">161,317</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other international assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">23,983</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,970</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total International</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,234,981</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,203,326</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Grand Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,422,395</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,035,922</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 2pt; WIDTH: 156px; WHITE-SPACE: normal; WORD-SPACING: 0px; BORDER-BOTTOM: rgb(0,0,0) 1px solid; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: medium/8pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(A)</td> <td valign="top" align="left">Gross Assets represents total assets plus accumulated depreciation/amortization assuming all real estate commitments as of the period end are fully funded.</td> </tr> </table> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(B)</td> <td valign="top" align="left">Includes both leased and loaned assets.</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>1. Organization</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Medical Properties Trust, Inc., a Maryland corporation, was formed on August&#xA0;27, 2003, under the Maryland General Corporation Law for the purpose of engaging in the business of investing in, owning, and leasing commercial real estate. Our operating partnership subsidiary, MPT Operating Partnership, L.P., (the &#x201C;Operating Partnership&#x201D;) through which we conduct all of our operations, was formed in September 2003. Through another wholly-owned subsidiary, Medical Properties Trust, LLC, we are the sole general partner of the Operating Partnership. At present, we directly own substantially all of the limited partnership interests in the Operating Partnership and have elected to report our required disclosures and that of the Operating Partnership on a combined basis except where material differences exist.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> We have operated as a real estate investment trust (&#x201C;REIT&#x201D;) since April&#xA0;6, 2004, and accordingly, elected REIT status upon the filing in September 2005 of the calendar year 2004 federal income tax return. Accordingly, we will generally not be subject to federal income tax in the United States (&#x201C;U.S.&#x201D;), provided that we continue to qualify as a REIT and our distributions to our stockholders equal or exceed our taxable income. Certain activities we undertake must be conducted by entities which we elected to be treated as taxable REIT subsidiaries (&#x201C;TRSs&#x201D;). Our TRSs are subject to both U.S. federal and state income taxes. For our properties located outside the U.S., we are subject to local taxes; however, we do not expect to incur additional taxes in the U.S. as such income will flow through our REIT.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Our primary business strategy is to acquire and develop real estate and improvements, primarily for long-term lease to providers of healthcare services such as operators of general acute care hospitals, inpatient physical rehabilitation hospitals, long-term acute care hospitals, surgery centers, centers for treatment of specific conditions such as cardiac, pulmonary, cancer, and neurological hospitals, and other healthcare-oriented facilities. We also make mortgage and other loans to operators of similar facilities. In addition, we may obtain profits or equity interests in our tenants, from time to time, in order to enhance our overall return. We manage our business as a single business segment. All of our properties are located in the U.S. and Europe.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Revenue by U.S. State and Country</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Six&#xA0;Months&#xA0;Ended<br /> June 30, 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Six&#xA0;Months&#xA0;Ended<br /> June 30, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 109.7pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>U.S. States and Other Countries</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> Revenue</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of<br /> Total&#xA0;Revenue</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> Revenue</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of<br /> Total&#xA0;Revenue</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Texas</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,256</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">42,689</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">21.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> California</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">33,187</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">33,065</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> All other states</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">129,896</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">49.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">85,620</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">43.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total U.S.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">211,339</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">80.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">161,374</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">82.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Germany</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,745</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">32,212</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> United Kingdom, Italy, and Spain</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,215</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,176</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total International</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,960</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,388</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Grand Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">261,299</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">195,762</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following is a summary of our debt (dollar amounts in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As&#xA0;of&#xA0;June 30, 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As&#xA0;of&#xA0;December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Balance</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Interest&#xA0;Rate</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Balance</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Interest&#xA0;Rate</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Revolving credit facility</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Variable</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,100,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Variable</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2006 Senior Unsecured Notes</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">125,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Various</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">125,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Various</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2011 Senior Unsecured Notes</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">450,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.875</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">450,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.875</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2012 Senior Unsecured Notes:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Principal amount</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">350,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.375</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">350,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.375</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Unamortized premium</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,991</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,168</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">351,991</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">352,168</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2013 Senior Unsecured Notes (A)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">222,120</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.750</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">217,240</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.750</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2014 Senior Unsecured Notes</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">300,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.500</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">300,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.500</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2015 Senior Unsecured Notes (A)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">555,300</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.000</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">543,100</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.000</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2016 Senior Unsecured Notes</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">500,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.375</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Term loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">263,253</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Various</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">263,400</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Various</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,792,664</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,350,908</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Debt issue costs, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(34,029</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(28,367</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,758,635</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,322,541</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(A)</td> <td valign="top" align="left">These notes are Euro-denominated and reflect the exchange rate at June&#xA0;30, 2016 and December&#xA0;31, 2015, respectively.</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Medical Properties Trust, Inc.</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Our earnings per share were calculated based on the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Three&#xA0;Months<br /> Ended&#xA0;June 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Numerator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,924</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,489</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Non-controlling interests&#x2019; share in continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(200</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(82</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(132</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(250</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">53,592</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22,157</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from discontinued operations attributable to MPT common stockholders</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,592</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,157</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Denominator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic weighted-average common shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">238,082</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">208,071</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive potential common shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">926</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">569</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive weighted-average common shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">239,008</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">208,640</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Six&#xA0;Months<br /> Ended&#xA0;June 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Numerator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">112,150</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,465</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Non-controlling interests&#x2019; share in continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(498</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(161</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(276</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(516</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">111,376</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">57,788</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Loss from discontinued operations attributable to MPT common stockholders</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">111,375</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">57,788</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Denominator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic weighted-average common shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">237,796</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">205,515</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive potential common shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">617</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">612</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive weighted-average common shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">238,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">206,127</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>MPT Operating Partnership, L.P.</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Our earnings per common unit were calculated based on the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Three&#xA0;Months</b><br /> <b>Ended&#xA0;June 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Numerator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,924</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,489</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Non-controlling interests&#x2019; share in continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(200</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(82</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(132</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(250</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">53,592</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22,157</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from discontinued operations attributable to MPT Operating Partnership partners</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,592</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,157</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Denominator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic weighted-average units</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">238,082</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">208,071</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive potential units</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">926</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">569</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive weighted-average units</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">239,008</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">208,640</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>For&#xA0;the&#xA0;Six Months</b><br /> <b>Ended&#xA0;June 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Numerator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">112,150</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,465</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Non-controlling interests&#x2019; share in continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(498</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(161</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(276</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(516</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">111,376</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">57,788</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Loss from discontinued operations attributable to MPT Operating Partnership partners</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">111,375</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">57,788</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Denominator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic weighted-average units</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">237,796</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">205,515</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive potential units</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">617</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">612</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive weighted-average units</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">238,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">206,127</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 0.45 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> As of June&#xA0;30, 2016, principal payments due on our debt (which exclude the effects of any discounts, premiums, or debt issue costs recorded) are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="86%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">125,152</td> <td valign="bottom" nowrap="nowrap">(A)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">320</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">37,781</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">250,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2020</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">222,120</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Thereafter</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,155,300</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,790,673</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 2pt; WIDTH: 156px; WHITE-SPACE: normal; WORD-SPACING: 0px; BORDER-BOTTOM: rgb(0,0,0) 1px solid; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: medium/8pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(A)</td> <td valign="top" align="left">$65 million of our 2006 Senior Unsecured Notes were paid in full on in July 2016, while the remaining $60 million will mature in and October 2016.</td> </tr> </table> </div> --12-31 2016-06-30 0.47 Large Accelerated Filer 617000 137290000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following unaudited supplemental pro forma operating data is presented for the three and six months ended June&#xA0;30, 2015, as if each acquisition (including completed development projects) was completed on January&#xA0;1, 2015. Supplemental pro forma earnings were adjusted to exclude acquisition-related costs on consummated deals incurred. The unaudited supplemental pro forma operating data is not necessarily indicative of what the actual results of operations would have been assuming the transactions had been completed as set forth above, nor do they purport to represent our results of operations for future periods (in thousands, except per share/unit amounts).</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>For&#xA0;the&#xA0;Three<br /> Months&#xA0;Ended<br /> June 30, 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>For&#xA0;the&#xA0;Six<br /> Months&#xA0;Ended<br /> June 30, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">109</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">219</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income per share/unit &#x2014; diluted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.21</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.42</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <i>Variable Interest Entities</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> At June&#xA0;30, 2016, we had loans to and/or equity investments in certain variable interest entities (&#x201C;VIEs&#x201D;), which are also tenants of our facilities, including Ernest Health, Inc. (&#x201C;Ernest&#x201D;). We have determined that we are not the primary beneficiary of these VIEs. The carrying value and classification of the related assets and maximum exposure to loss as a result of our involvement with these VIEs are presented below at June&#xA0;30, 2016 (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="48%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 33.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>VIE Type</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Maximum&#xA0;Loss</b><br /> <b>Exposure(1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>Asset&#xA0;Type</b><br /> <b>Classification</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Carrying</b><br /> <b>&#xA0;&#xA0;&#xA0;&#xA0;Amount(2)&#xA0;&#xA0;&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Loans, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">295,822</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center"> Mortgage&#xA0;and&#xA0;other&#xA0;loans</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">226,101</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Equity investments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,309</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">Other assets</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">328</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Our maximum loss exposure related to loans with VIEs represents our current aggregate gross carrying value of the loan plus accrued interest and any other related assets (such as rent receivables), less any liabilities. Our maximum loss exposure related to our equity investment in VIEs represents the current carrying values of such investment plus any other related assets (such as rent receivables) less any liabilities.</td> </tr> </table> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(2)</td> <td valign="top" align="left">Carrying amount reflects the net book value of our loan or equity interest only in the VIE.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> For the VIE types above, we do not consolidate the VIE because we do not have the ability to control the activities (such as the day-to-day healthcare operations of our borrower or investees) that most significantly impact the VIE&#x2019;s economic performance. As of June&#xA0;30, 2016, we were not required to provide any material financial support through a liquidity arrangement or otherwise to our unconsolidated VIEs, including circumstances in which it could be exposed to further losses (e.g., cash short falls).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> Typically, our loans are collateralized by assets of the borrower (some assets of which are on the premises of facilities owned by us) and further supported by limited guarantees made by certain principals of the borrower.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> See Note 3 and 7 for additional description of the nature, purpose and activities of our more significant VIEs and interests therein.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On May 20, 2016, we reached a firm commitment to sell three inpatient rehabilitation hospitals located in Texas and operated by HealthSouth for $111.5 million. At June 30, 2016, these facilities and related net assets were designated as held for sale and included the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Real estate held for sale</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">&#xA0;63,074</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Straight-line rent receivables</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,441</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(625</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">&#xA0;64,890</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>8. Earnings Per Share/Common Unit</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Medical Properties Trust, Inc.</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Our earnings per share were calculated based on the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Three&#xA0;Months<br /> Ended&#xA0;June 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Numerator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,924</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,489</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Non-controlling interests&#x2019; share in continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(200</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(82</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(132</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(250</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">53,592</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22,157</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from discontinued operations attributable to MPT common stockholders</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,592</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,157</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Denominator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic weighted-average common shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">238,082</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">208,071</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive potential common shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">926</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">569</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive weighted-average common shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">239,008</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">208,640</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Six&#xA0;Months<br /> Ended&#xA0;June 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Numerator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">112,150</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,465</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Non-controlling interests&#x2019; share in continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(498</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(161</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(276</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(516</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">111,376</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">57,788</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Loss from discontinued operations attributable to MPT common stockholders</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">111,375</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">57,788</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Denominator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic weighted-average common shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">237,796</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">205,515</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive potential common shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">617</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">612</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive weighted-average common shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">238,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">206,127</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>MPT Operating Partnership, L.P.</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Our earnings per common unit were calculated based on the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Three&#xA0;Months</b><br /> <b>Ended&#xA0;June 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Numerator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,924</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,489</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Non-controlling interests&#x2019; share in continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(200</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(82</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(132</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(250</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">53,592</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22,157</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from discontinued operations attributable to MPT Operating Partnership partners</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,592</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,157</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Denominator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic weighted-average units</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">238,082</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">208,071</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive potential units</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">926</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">569</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive weighted-average units</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">239,008</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">208,640</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>For&#xA0;the&#xA0;Six Months</b><br /> <b>Ended&#xA0;June 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Numerator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">112,150</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,465</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Non-controlling interests&#x2019; share in continuing operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(498</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(161</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(276</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(516</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from continuing operations, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">111,376</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">57,788</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Loss from discontinued operations attributable to MPT Operating Partnership partners</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income, less participating securities&#x2019; share in earnings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">111,375</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">57,788</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Denominator:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic weighted-average units</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">237,796</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">205,515</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive potential units</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">617</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">612</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dilutive weighted-average units</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">238,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">206,127</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> MEDICAL PROPERTIES TRUST INC <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following table summarizes fair value estimates for our financial instruments (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>June&#xA0;30, 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 54.75pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>Asset (Liability)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Book<br /> Value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair<br /> Value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Book<br /> Value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair<br /> Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Interest and rent receivables</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,699</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,653</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">46,939</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">46,858</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Loans (1)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">590,037</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">623,399</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">508,851</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">543,859</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Debt, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,758,635</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,863,382</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3,322,541</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3,372,773</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Excludes loans related to Ernest and Capella (2015 only) since they are recorded at fair value and discussed below.</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>7. Fair Value of Financial Instruments</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> We have various assets and liabilities that are considered financial instruments. We estimate that the carrying value of cash and cash equivalents, and accounts payable and accrued expenses approximate their fair values. Included in our accounts payable and accrued expenses are our interest rate swaps, which are recorded at fair value based on Level 2 observable market assumptions using standardized derivative pricing models. We estimate the fair value of our interest and rent receivables using Level 2 inputs such as discounting the estimated future cash flows using the current rates at which similar receivables would be made to others with similar credit ratings and for the same remaining maturities. The fair value of our mortgage loans and working capital loans are estimated by using Level 2 inputs such as discounting the estimated future cash flows using the current rates which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities. We determine the fair value of our senior unsecured notes (excluding our 2006 Senior Unsecured Notes) using Level 2 inputs such as quotes from securities dealers and market makers. We estimate the fair value of our 2006 Senior Unsecured Notes, our revolving credit facility, and term loans using Level 2 inputs based on the present value of future payments, discounted at a rate which we consider appropriate for such debt.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Fair value estimates are made at a specific point in time, are subjective in nature, and involve uncertainties and matters of significant judgment. Settlement of such fair value amounts may not be possible and may not be a prudent management decision. The following table summarizes fair value estimates for our financial instruments (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>June&#xA0;30, 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 54.75pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>Asset (Liability)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Book<br /> Value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair<br /> Value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Book<br /> Value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair<br /> Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Interest and rent receivables</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,699</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,653</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">46,939</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">46,858</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Loans (1)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">590,037</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">623,399</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">508,851</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">543,859</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Debt, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,758,635</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,863,382</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3,322,541</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3,372,773</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Excludes loans related to Ernest and Capella (2015 only) since they are recorded at fair value and discussed below.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Items Measured at Fair Value on a Recurring Basis</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Our equity interest in Ernest and related loans, which were acquired in 2012, are being measured at fair value on a recurring basis as we elected to account for these investments using the fair value option method. We have elected to account for these investments at fair value due to the size of the investments and because we believe this method is more reflective of current values. We have not made a similar election for other equity interests or loans made in or prior to 2016, except for our investments in Capella that were disposed of in the 2016 second quarter.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> At June&#xA0;30, 2016, these amounts were as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 37.55pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>Asset Type</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair<br /> Value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Cost</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Asset&#xA0;Type<br /> Classification</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Mortgage loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">101,762</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">101,762</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Mortgage&#xA0;loans</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Acquisition and other loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">116,867</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">116,867</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Other loans</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Equity investments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,300</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,300</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Other assets</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">221,929</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">221,929</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Our mortgage loans with Ernest are recorded at fair value based on Level 2 inputs by discounting the estimated cash flows using the market rates which similar loans would be made to borrowers with similar credit ratings and the same remaining maturities. Our acquisition loans and equity investments in Ernest are recorded at fair value based on Level 3 inputs, by using a discounted cash flow model, which requires significant estimates of our investee such as projected revenue and expenses and appropriate consideration of the underlying risk profile of the forecast assumptions associated with the investee. We classify these loans and equity investments as Level 3, as we use certain unobservable inputs to the valuation methodology that are significant to the fair value measurement, and the valuation requires management judgment due to the absence of quoted market prices. For these cash flow models, our observable inputs include use of a capitalization rate, discount rate (which is based on a weighted-average cost of capital), and market interest rates, and our unobservable input includes an adjustment for a marketability discount (&#x201C;DLOM&#x201D;) on our equity investment of 40% at June&#xA0;30, 2016.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In regards to the underlying projection of revenues and expenses used in the discounted cash flow model, such projections are provided by Ernest. However, we will modify such projections (including underlying assumptions used) as needed based on our review and analysis of Ernest&#x2019;s historical results, meetings with key members of management, and our understanding of trends and developments within the healthcare industry.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In arriving at the DLOM, we started with a DLOM range based on the results of studies supporting valuation discounts for other transactions or structures without a public market. To select the appropriate DLOM within the range, we then considered many qualitative factors including the percent of control, the nature of the underlying investee&#x2019;s business along with our rights as an investor pursuant to the operating agreement, the size of investment, expected holding period, number of shareholders, access to capital marketplace, etc. To illustrate the effect of movements in the DLOM, we performed a sensitivity analysis below by using basis point variations (dollars in thousands):</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="28%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 156.5pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>Basis&#xA0;Point Change&#xA0;in Marketability&#xA0;Discount</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"> <b>Estimated&#xA0;Increase&#xA0;(Decrease)<br /> In Fair Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> +100&#xA0;basis&#xA0;points</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(54</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> - 100&#xA0;basis&#xA0;points</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">54</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Because the fair value of Ernest investments noted above approximate their original cost, we did not recognize any unrealized gains/losses during the first half of 2016 or 2015.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>4. Debt</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The following is a summary of our debt (dollar amounts in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As&#xA0;of&#xA0;June 30, 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As&#xA0;of&#xA0;December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Balance</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Interest&#xA0;Rate</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Balance</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Interest&#xA0;Rate</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Revolving credit facility</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Variable</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,100,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Variable</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2006 Senior Unsecured Notes</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">125,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Various</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">125,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Various</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2011 Senior Unsecured Notes</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">450,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.875</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">450,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.875</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2012 Senior Unsecured Notes:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Principal amount</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">350,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.375</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">350,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.375</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Unamortized premium</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,991</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,168</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">351,991</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">352,168</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2013 Senior Unsecured Notes (A)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">222,120</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.750</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">217,240</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.750</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2014 Senior Unsecured Notes</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">300,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.500</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">300,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.500</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2015 Senior Unsecured Notes (A)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">555,300</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.000</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">543,100</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.000</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2016 Senior Unsecured Notes</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">500,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.375</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Term loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">263,253</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Various</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">263,400</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Various</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,792,664</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,350,908</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Debt issue costs, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(34,029</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(28,367</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,758,635</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,322,541</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(A)</td> <td valign="top" align="left">These notes are Euro-denominated and reflect the exchange rate at June&#xA0;30, 2016 and December&#xA0;31, 2015, respectively.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> As of June&#xA0;30, 2016, principal payments due on our debt (which exclude the effects of any discounts, premiums, or debt issue costs recorded) are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="86%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">125,152</td> <td valign="bottom" nowrap="nowrap">(A)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">320</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">37,781</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">250,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2020</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">222,120</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Thereafter</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,155,300</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,790,673</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 2pt; WIDTH: 10%; BORDER-BOTTOM: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt; LINE-HEIGHT: 8pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(A)</td> <td valign="top" align="left">$65 million of our 2006 Senior Unsecured Notes were paid in full in July 2016, while the remaining $60 million will mature in October 2016.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On February&#xA0;22, 2016, we completed a $500 million senior unsecured notes offering (&#x201C;2016 Senior Unsecured Notes&#x201D;), proceeds of which were used to repay borrowings under our revolving credit facility. Interest on the notes will be payable on March&#xA0;1 and September&#xA0;1 of each year, commencing on September&#xA0;1, 2016. Interest on the notes will be paid in cash at a rate of 6.375%&#xA0;per year. The notes mature on March&#xA0;1, 2024. We may redeem some or all of the notes at any time prior to March&#xA0;1, 2019 at a &#x201C;make whole&#x201D; redemption price. On or after March&#xA0;1, 2019, we may redeem some or all of the notes at a premium that will decrease over time. In addition, at any time prior to March&#xA0;1, 2019, we may redeem up to 35% of the notes at a redemption price equal to 106.375% of the aggregate principal amount thereof, plus accrued and unpaid interest thereon, using proceeds from one or more equity offerings. In the event of a change in control, each holder of the notes may require us to repurchase some or all of the notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest to the date of purchase.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> During the second quarter 2010, we entered into an interest rate swap to manage our exposure to variable interest rates by fixing $65 million of our 2006 Senior Unsecured Notes, which started July&#xA0;31, 2011 (date on which the interest rate turned variable) through maturity date (or July 2016), at a rate of 5.507%. We also entered into an interest rate swap to fix $60 million of our 2006 Senior Unsecured Notes which started October&#xA0;31, 2011 (date on which the related interest rate turned variable) through the maturity date (or October 2016) at a rate of 5.675%. The fair value of the interest rate swaps was $1.3 million and $2.9 million as of June&#xA0;30, 2016 and December&#xA0;31, 2015, respectively, which is reflected in accounts payable and accrued expenses on the consolidated balance sheets.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> We account for our interest rate swaps as cash flow hedges. Accordingly, the effective portion of changes in the fair value of our swaps is recorded as a component of accumulated other comprehensive income/loss on the balance sheet and reclassified into earnings in the same period, or periods, during which the hedged transactions effect earnings, while any ineffective portion is recorded through earnings immediately. We did not have any hedge ineffectiveness from inception of our interest rate swaps through June&#xA0;30, 2016 and therefore, there was no income statement effect recorded during the three and six month periods ended June&#xA0;30, 2016 or 2015. We do expect current losses included in accumulated other comprehensive loss to be reclassified into earnings through October 2016. At June&#xA0;30, 2016 and December&#xA0;31, 2015, we have posted $0.8 million and $1.7 million of collateral related to our interest rate swaps, respectively, which is reflected in other assets on our consolidated balance sheets.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Covenants</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Our debt facilities impose certain restrictions on us, including restrictions on our ability to: incur debts; create or incur liens; provide guarantees in respect of obligations of any other entity; make redemptions and repurchases of our capital stock; prepay, redeem or repurchase debt; engage in mergers or consolidations; enter into affiliated transactions; dispose of real estate or other assets; and change our business. In addition, the credit agreements governing our revolving credit facility and term loan limit the amount of dividends we can pay as a percentage of normalized adjusted funds from operations (&#x201C;FFO&#x201D;), as defined in the agreements, on a rolling four quarter basis. At June&#xA0;30, 2016, the dividend restriction was 95% of normalized adjusted FFO. The indentures governing our senior unsecured notes also limit the amount of dividends we can pay based on the sum of 95% of funds from operations, proceeds of equity issuances and certain other net cash proceeds. Finally, our senior unsecured notes require us to maintain total unencumbered assets (as defined in the related indenture) of not less than 150% of our unsecured indebtedness.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In addition to these restrictions, the revolving credit facility and term loan contain customary financial and operating covenants, including covenants relating to our total leverage ratio, fixed charge coverage ratio, secured leverage ratio, consolidated adjusted net worth, unsecured leverage ratio, and unsecured interest coverage ratio. This facility also contains customary events of default, including among others, nonpayment of principal or interest, material inaccuracy of representations and failure to comply with our covenants. If an event of default occurs and is continuing under the facility, the entire outstanding balance may become immediately due and payable. At June&#xA0;30, 2016, we were in compliance with all such financial and operating covenants.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> At June&#xA0;30, 2016, the unsecured leverage ratio covenant was 77.5%. In September 2016, the unsecured leverage ratio will reset to 65%. We are currently in compliance with the reset leverage covenant.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The properties which sold during the quarter and the assets held for sale at June 30, 2016, do not meet the definition of discontinued operations. However, the following represents the operating results (excluding gain on sale, transaction costs, and impairment or other non-cash charges) from these properties for the periods presented (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Three&#xA0;Months</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Six&#xA0;Months</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Ended&#xA0;June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Ended&#xA0;June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,092</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,607</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,075</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Real estate depreciation and amortization</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(805</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(949</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,754</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,897</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Property-related expenses</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(72</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(12</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(113</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(72</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other income (expense)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">228</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(68</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">557</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from real estate dispositions, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,206</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,792</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,672</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,663</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>10. Subsequent Events</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Stock Issuance</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> During the month of July, we sold 2.7 million shares of common stock under our at-the-market program generating net proceeds of $41.1 million.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Bond Issuance</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> On July 22, 2016, we completed a $500 million senior unsecured notes offering. Interest on the notes will be payable on February 1 and August 1 of each year, commencing on February 1, 2017. Interest on the notes will be paid in cash at a rate of 5.25% per year. The notes mature on August 1, 2026. We may redeem some or all of the notes at any time prior to August 1, 2021 at a &#x201C;make whole&#x201D; redemption price. On or after August 1, 2021, we may redeem some or all of the notes at a premium that will decrease over time. In addition, at any time prior to August 1, 2019, we may redeem up to 35% of the notes at a redemption price equal to 105.25% of the aggregate principal amount thereof, plus accrued and unpaid interest thereon, using proceeds from one or more equity offerings. In the event of a change in control, each holder of the notes may require us to repurchase some or all of the notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest to the date of purchase.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> We used the net proceeds from this offering to redeem our $450 million 2011 bonds, which will be completed on August 12, 2016. We expect to incur a one-time charge related to the redemption of approximately $23 million.</p> </div> 261299000 96504000 5904000 60007000 7607000 5672000 17268000 50000000 104788000 181047000 111651000 57118000 -1000 16678000 119693000 119195000 32503000 147000 112149000 -1000 112150000 16678000 109991000 -217000 6605000 1640000 -68897000 45170000 498000 683000 80874000 44306000 4152000 7375000 3702000 43974000 1685000 3063000 480106000 -8465000 3897000 80252000 3125000 23516000 498000 705501000 -1075000000 -17105000 498000 75623000 1754000 9544000 -634501000 500000000 50000000 89165000 0.151 111376000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The components of our net investment in DFLs (which includes the Capella properties for 2015 only) consisted of the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>As&#xA0;of&#xA0;June&#xA0;30,<br /> 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"> <b>As&#xA0;of&#xA0;December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Minimum lease payments receivable</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,875,751</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,587,912</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Estimated residual values</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">292,646</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">393,097</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Less: Unearned income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,639,650</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,354,013</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net investment in direct financing leases</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">528,747</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">626,996</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> -9593000 1.50 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> To illustrate the effect of movements in the DLOM, we performed a sensitivity analysis below by using basis point variations (dollars in thousands):</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="28%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 156.5pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>Basis&#xA0;Point Change&#xA0;in Marketability&#xA0;Discount</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"> <b>Estimated&#xA0;Increase&#xA0;(Decrease)<br /> In Fair Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> +100&#xA0;basis&#xA0;points</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(54</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> - 100&#xA0;basis&#xA0;points</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">54</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> See table below for a status update on our current domestic development projects (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <br class="Apple-interchange-newline" /> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 30.65pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>Property</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 45.25pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt" align="center"><b>Commitment</b></p> </td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; MARGIN-TOP: 0pt" align="center"><b>Costs</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; MARGIN-TOP: 0pt" align="center"><b>Incurred</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; MARGIN-TOP: 0pt" align="center"><b>as of</b></p> <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 30.65pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt" align="center"><b>06/30/16</b></p> </td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; MARGIN-TOP: 0pt" align="center"><b>Estimated</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; MARGIN-TOP: 0pt" align="center"><b>Completion</b></p> <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 39.95pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt" align="center"><b>Date</b></p> </td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Adeptus Health</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">62,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">43,763</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3Q&#xA0;2016</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Adeptus Health</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">53,836</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,343</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4Q 2016</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Adeptus Health</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,730</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">206</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1Q 2017</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Adeptus Health</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">61,997</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,311</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2Q 2017</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Adeptus Health</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">71,331</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Various</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><b>$</b></td> <td valign="bottom" align="right"><b>255,048</b></td> <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><b>$</b></td> <td valign="bottom" align="right"><b>75,623</b></td> <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">&#xA0;&#xA0;</td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">&#xA0;&#xA0;</td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">&#xA0;&#xA0;</td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td> </tr> </table> </div> 0.95 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>3. Real Estate and Lending Activities</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <i>Acquisitions</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> We acquired the following assets (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Six&#xA0;Months</b><br /> <b>Ended&#xA0;June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Assets Acquired</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Land and land improvements</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,398</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">62,434</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Building</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">37,593</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">390,320</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Intangible lease assets &#x2014; subject to amortization (weighted average useful life 25.8&#xA0;years)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">42,262</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Mortgage loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">40,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net investments in direct financing leases</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">63,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,700</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,917</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total assets acquired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">109,991</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">562,633</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Loans repaid (1)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(183,826</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total net assets acquired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">109,991</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">378,807</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%">&#xA0;</td> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Loans advanced to MEDIAN in 2014 and repaid in 2015 as a part of the MEDIAN transaction.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> The purchase price allocations attributable to the 2016 and certain 2015 acquisitions are preliminary. When all relevant information is obtained, resulting changes, if any, to our provisional purchase price allocation will be retrospectively adjusted to reflect new information obtained about the facts and circumstances that existed as of the respective acquisition dates that, if known, would have affected the measurement of the amounts recognized as of those dates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>2016 Activity</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On May&#xA0;2, 2016, we acquired an acute hospital in Newark, New Jersey for an aggregate purchase price of $63 million leased to Prime Healthcare Services, Inc. (&#x201C;Prime&#x201D;) pursuant to a fifth master lease, which has a 15-year term with three five-year extension options, plus consumer price-indexed increases, limited to a 2% floor.&#xA0;Furthermore, we committed to advance an additional $30 million to Prime over a three-year period to be used solely for capital additions to the real estate; any such additions will be added to the basis upon which the lessee will pay us rents.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> On June&#xA0;22, 2016, we closed on the final Median Kliniken S.&#xE0; r.l., (&#x201C;MEDIAN&#x201D;) property for a purchase price of &#x20AC;41.6&#xA0;million. See &#x201C;2015 Activity&#x201D; for a description of the initial MEDIAN Transaction.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> From the respective acquisition dates, the properties acquired in 2016 contributed $1.1 million of revenue and income (excluding related acquisition expenses), for the three and six months ended June 30, 2016. In addition, we incurred $2.4 million of acquisition-related costs on the 2016 acquisitions for both the three and six months ended June 30, 2016.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>2015 Activity</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>MEDIAN Transaction</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On April&#xA0;29, 2015, we entered into a series of definitive agreements with MEDIAN, a German provider of post-acute and acute rehabilitation services, to acquire the real estate assets of 32 hospitals owned by MEDIAN for an aggregate purchase price of approximately &#x20AC;688 million. Upon acquisition, each property became subject to a master lease between us and MEDIAN providing for the leaseback of the property to MEDIAN. The master lease had an initial term of 27 years and provided for an initial GAAP lease rate of 9.3%, with annual escalators at the greater of one percent or 70% of the German consumer price index.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> MEDIAN is owned by an affiliate of Waterland Private Equity Fund V C.V. (&#x201C;Waterland&#x201D;), which acquired 94.9% of the outstanding equity interests in MEDIAN, and by a subsidiary of our operating partnership, which acquired the remaining 5.1% of the outstanding equity interests in MEDIAN, each in December 2014. In December 2014, we provided interim acquisition loans to affiliates of Waterland and MEDIAN in connection with Waterland&#x2019;s acquisition of its stake in MEDIAN in an aggregate amount of approximately &#x20AC;425 million. In addition, we made further loans to MEDIAN during the first half of 2015 in an aggregate amount of approximately &#x20AC;240&#xA0;million, which were used by MEDIAN to repay existing debt on properties we acquired.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Closing of the sale-leaseback transactions began in the second quarter of 2015. At each closing, the purchase price for each facility was reduced and offset against the interim loans made to affiliates of Waterland and MEDIAN as described above and against the amount of any debt assumed or repaid by us in connection with the closing. As of June&#xA0;30, 2015, we had closed on 17 properties for an aggregate amount of &#x20AC;317&#xA0;million.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <i>Other Acquisitions</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On June&#xA0;16, 2015, we acquired the real estate of two facilities in Lubbock, Texas, a 60-bed inpatient rehabilitation hospital and a 37-bed long-term acute care hospital, for an aggregate purchase price of $31.5 million. We entered into a 20-year lease with Ernest for the rehabilitation hospital, which provides for three five-year extension options, and separately entered into a lease with Ernest for the long-term acute care hospital that has a final term ending December&#xA0;31, 2034. In connection with the transaction, we funded an acquisition loan to Ernest of approximately $12.0 million. Ernest is operating the rehabilitation hospital in a joint venture with Covenant Health System, while the long-term acute care hospital continues to be operated by Fundamental Health under a new sublease with Ernest.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On February&#xA0;27, 2015, we acquired an inpatient rehabilitation hospital in Weslaco, Texas for $10.7 million leased to Ernest pursuant to the 2012 master lease which had an original 20-year fixed term and three five-year extension options. This lease provides for consumer-priced-indexed annual rent increases, subject to a floor and a cap. In addition, we funded an acquisition loan in the amount of $5 million.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On February&#xA0;13, 2015, we acquired two general acute care hospitals in the Kansas City area for $110 million. Affiliates of Prime is the tenant and operator pursuant to a new master lease that has similar terms and security enhancements as the other master lease agreements entered into in 2013. This master lease has a 10-year initial fixed term with two extension options of five years each. The lease provides for consumer-price-indexed annual rent increases, subject to a specified floor. In addition, we funded a mortgage loan in the amount of $40 million, which has a 10-year term.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> From the respective acquisition dates, the properties and other assets acquired in 2015 contributed $4.2 million and $3.5&#xA0;million of revenue and income (excluding related acquisition expenses), respectively, for the three months ended June&#xA0;30, 2015. From the respective acquisition dates, the properties and other assets acquired in 2015 contributed $6.2 million and $4.9 million of revenue and income (excluding related acquisition expenses), respectively, for the six months ended June&#xA0;30, 2015. In addition, we incurred $22.6 million and $26.7 million of acquisition-related costs on the 2015 acquisitions for the three and six months ended June&#xA0;30, 2015, respectively.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <i>Pro Forma Information</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The following unaudited supplemental pro forma operating data is presented for the three and six months ended June&#xA0;30, 2015, as if each acquisition (including completed development projects) was completed on January&#xA0;1, 2015. Supplemental pro forma earnings were adjusted to exclude acquisition-related costs on consummated deals incurred. The unaudited supplemental pro forma operating data is not necessarily indicative of what the actual results of operations would have been assuming the transactions had been completed as set forth above, nor do they purport to represent our results of operations for future periods (in thousands, except per share/unit amounts).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>For&#xA0;the&#xA0;Three<br /> Months&#xA0;Ended<br /> June 30, 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>For&#xA0;the&#xA0;Six<br /> Months&#xA0;Ended<br /> June 30, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">109</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">219</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income per share/unit &#x2014; diluted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.21</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.42</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Development Activities</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> During the first six months of 2016, we completed construction and began recording rental income on the following facilities:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Adeptus Health, Inc. (&#x201C;Adeptus Health&#x201D;) &#x2013; We completed seven acute care facilities for this tenant during 2016. These facilities are leased pursuant to the master leases entered into in both 2014 and 2015 and are cross-defaulted with each other and with the original master lease executed in 2013.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Ernest Toledo &#x2013; This inpatient rehabilitation facility located in Toledo, Ohio opened on April&#xA0;1, 2016 and is being leased to Ernest pursuant to the original 2012 master lease.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> See table below for a status update on our current domestic development projects (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 30.65pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>Property</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 45.25pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt" align="center"><b>Commitment</b></p> </td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>Costs</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>Incurred</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>as of</b></p> <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 30.65pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt" align="center"><b>06/30/16</b></p> </td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>Estimated</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>Completion</b></p> <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 39.95pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt" align="center"><b>Date</b></p> </td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Adeptus Health</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">62,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">43,763</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3Q&#xA0;2016</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Adeptus Health</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">53,836</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,343</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4Q 2016</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Adeptus Health</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,730</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">206</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1Q 2017</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Adeptus Health</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">61,997</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,311</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2Q 2017</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Adeptus Health</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">71,331</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Various</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><b>$</b></td> <td valign="bottom" align="right"><b>255,048</b></td> <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><b>$</b></td> <td valign="bottom" align="right"><b>75,623</b></td> <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> On September&#xA0;9, 2015, we acquired the real estate of a general acute care hospital under development located in Spain, for an aggregate purchase and development price to us of approximately &#x20AC;21.4 million. The acquisition was effected through a joint venture between us and clients of AXA Real Estate, in which we will own a 50% interest. Upon completion, the facility will be leased to a Spanish operator of acute care hospitals, pursuant to a long-term lease. We expect construction to complete on this facility in the second quarter of 2017.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Disposals</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <u>Capella Transaction</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On March&#xA0;21, 2016, we entered into definitive agreements with RegionalCare Hospital Partners, Inc. (&#x201C;RegionalCare&#x201D;), an affiliate of certain funds managed by affiliates of Apollo Global Management, LLC (together with its consolidated subsidiaries, &#x201C;Apollo&#x201D;), under which our investment in the operations of Capella Healthcare, Inc. (&#x201C;Capella&#x201D;) would be merged with RegionalCare, forming RCCH Healthcare Partners (&#x201C;RCCH&#x201D;).</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> On April&#xA0;29, 2016, this transaction closed and funded, effective April&#xA0;30, 2016.&#xA0;As part of the transaction, we received net proceeds of approximately $550 million including approximately $492 million for our equity investment and loans made as part of the Capella transaction that closed on August&#xA0;31, 2015. In addition, we received $210 million in prepayment of two mortgage loans for hospitals in Russellville, Arkansas, and Lawton, Oklahoma, that we made to subsidiaries of Capella in connection with the Capella transaction on August&#xA0;31, 2015. We made a new $93.3 million loan for a hospital property in Olympia, Washington. Additionally, we and an Apollo affiliate invested $50 million each in unsecured senior notes issued by RegionalCare, which we sold to a large institution on June 20, 2016 at par.&#xA0;The proceeds from this transaction represented the recoverability of our investment in full, except for transaction costs incurred of $6.3 million.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> We maintained our ownership of five Capella hospitals in Hot Springs, Arkansas; Camden, South Carolina; Hartsville, South Carolina; Muskogee, Oklahoma; and McMinnville, Oregon.&#xA0;Pursuant to the transaction described above, the underlying leases, one of which is a master lease covering all but one property, was amended to shorten the initial fixed lease term, increase the security deposit, and eliminate the lessees&#x2019; purchase option provisions. Due to this lease amendment, we reclassified the lease of the properties under the master lease from a direct finance lease (&#x201C;DFL&#x201D;) to an operating lease. This reclassification resulted in a write-off of $2.6 million in unbilled DFL rent in the 2016 second quarter.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On July 22, 2016, we acquired the Olympia, Washington property in exchange for the $93.3 million loan and an additional $7 million, which was contemplated in the original Capella transaction. The terms of the Olympia lease will be similar to the other leases with this tenant.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>Post Acute Transaction</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On May&#xA0;23, 2016, we sold five properties (three of which were in Texas and two in Louisiana) that were leased and operated by Post Acute Medical (&#x201C;Post Acute&#x201D;). As part of this transaction, our outstanding loans of $4 million were paid in full, and we recovered our investment in the operations. Total proceeds from this transaction were $71 million resulting in a net gain of approximately $15&#xA0;million.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>Corinth Transaction</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On June&#xA0;17, 2016, we sold the Atrium Medical Center real estate located in Corinth, Texas, which was leased and operated by Corinth Investor Holdings. Total proceeds from the transaction were $28 million resulting in a gain on real estate of approximately $8&#xA0;million. This gain on real estate was offset by approximately $9 million of non-cash charges that included the write-off of our investment in the operations of the facility, straight-line rent receivables, and a lease intangible.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>HealthSouth Transaction</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On May 20, 2016, we reached a firm commitment to sell three inpatient rehabilitation hospitals located in Texas and operated by HealthSouth Corporation (&#x201C;HealthSouth&#x201D;) for $111.5 million. At June 30, 2016, these facilities and related net assets were designated as held for sale and included the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Real estate held for sale</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">&#xA0;63,074</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Straight-line rent receivables</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,441</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(625</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">&#xA0;64,890</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On July 20, 2016, we completed this sale resulting in a net gain of approximately $45 million.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>Summary of Operations for Disposed Assets</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The properties which sold during the quarter and the assets held for sale at June 30, 2016, do not meet the definition of discontinued operations. However, the following represents the operating results (excluding gain on sale, transaction costs, and impairment or other non-cash charges) from these properties (excluding loans repaid in the Capella Transaction) for the periods presented (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Three&#xA0;Months</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Six&#xA0;Months</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Ended&#xA0;June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Ended&#xA0;June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,092</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,607</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,075</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Real estate depreciation and amortization</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(805</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(949</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,754</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,897</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Property-related expenses</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(72</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(12</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(113</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(72</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other income (expense)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">228</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(68</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">557</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from real estate dispositions, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,206</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,792</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,672</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,663</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Leasing Operations</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> All of our leases are currently accounted for as operating leases except for the master lease of 15 Ernest facilities and six Prime facilities which are accounted for as DFLs. The components of our net investment in DFLs (which includes the Capella properties for 2015 only) consisted of the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>As&#xA0;of&#xA0;June&#xA0;30,<br /> 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"> <b>As&#xA0;of&#xA0;December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Minimum lease payments receivable</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,875,751</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,587,912</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Estimated residual values</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">292,646</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">393,097</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Less: Unearned income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,639,650</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,354,013</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net investment in direct financing leases</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">528,747</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">626,996</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>Twelve Oaks Facility</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In the third quarter of 2015, we sent notice of termination of the lease to the tenant at our Twelve Oaks facility. This former tenant continues to occupy the facility. We called their letter of credit for approximately $0.5 million in the 2016 first quarter. At June&#xA0;30, 2016, all past due receivables are fully reserved. Although no assurances can be made that we will not have any impairment charges in the future, we believe our real estate investment in Twelve Oaks at June&#xA0;30, 2016 is fully recoverable.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Subsequent to June 30, 2016, we received approximately $2.5 million representing substantially all of amounts owed to us and agreed to general terms of a new lease, which we expect to execute during the 2016 third quarter.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <i>Loans</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The following is a summary of our loans (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>As&#xA0;of</b><br /> <b>June&#xA0;30,&#xA0;2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>As&#xA0;of</b><br /> <b>December&#xA0;31,&#xA0;2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Mortgage loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">549,337</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">757,581</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Acquisition loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">216,100</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">610,469</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Working capital and other loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">43,229</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">54,353</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">808,666</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,422,403</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The decrease in our mortgage and acquisition loans are related to the Capella Transaction as discussed previously.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Our non-mortgage loans typically consist of loans to our tenants for acquisitions and working capital purposes. At June&#xA0;30, 2016, acquisition loans includes our original $93.2 million loan to Ernest and the $93.3 million loan to RCCH, which was repaid in July as discussed above.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On March&#xA0;1, 2012, pursuant to our convertible note agreement, we converted $1.7&#xA0;million of our $5.0&#xA0;million convertible note into a 9.9% equity interest in the operator of our Hoboken University Medical Center facility. At June&#xA0;30, 2016, $3.3&#xA0;million remains outstanding on the convertible note, and we retain the option, subject to regulatory approvals, to convert this remainder into 15.1% of equity interest in the operator.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Concentrations of Credit Risk</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Our revenue concentration for the six months ended June&#xA0;30, 2016 as compared to the prior year is as follows (dollars in thousands):</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <b><i>Revenue by Operator</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Six&#xA0;Months&#xA0;Ended<br /> June 30, 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Six&#xA0;Months&#xA0;Ended<br /> June 30, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 35.05pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>Operators</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> Revenue</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of<br /> Total&#xA0;Revenue</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> Revenue</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of<br /> Total&#xA0;Revenue</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Prime</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,859</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,869</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">25.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> MEDIAN</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">47,745</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,212</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Ernest</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">33,322</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,695</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> RCCH</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,909</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Adeptus Health</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,205</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7,425</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Revenue by U.S. State and Country</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Six&#xA0;Months&#xA0;Ended<br /> June 30, 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Six&#xA0;Months&#xA0;Ended<br /> June 30, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 109.7pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>U.S. States and Other Countries</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> Revenue</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of<br /> Total&#xA0;Revenue</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> Revenue</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of<br /> Total&#xA0;Revenue</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Texas</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,256</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">42,689</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">21.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> California</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">33,187</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">33,065</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> All other states</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">129,896</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">49.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">85,620</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">43.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total U.S.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">211,339</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">80.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">161,374</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">82.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Germany</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,745</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">32,212</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> United Kingdom, Italy, and Spain</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,215</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,176</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total International</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,960</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,388</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Grand Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">261,299</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">195,762</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> From an asset basis, our concentration as of June&#xA0;30, 2016 as compared to December&#xA0;31, 2015 is as follows (dollars in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Gross Assets by Operator</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="48%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of June&#xA0;30, 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 35.05pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>Operators</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of<br /> Total&#xA0;Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of<br /> Total&#xA0;Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(A)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(B)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(A)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(B)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Prime</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,126,654</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,032,353</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> MEDIAN</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,054,368</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,031,039</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Ernest</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">584,411</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">579,182</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Adeptus Health</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">500,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">500,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> RCCH</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">458,659</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,059,989</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <b><i>Gross Assets by U.S. State and Country</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="50%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of June&#xA0;30, 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"><b>U.S. States and Other Countries</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b><br /> <b>Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of</b><br /> <b>Total&#xA0;Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b><br /> <b>Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of</b><br /> <b>Total&#xA0;Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(A)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(B)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(A)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(B)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Texas</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">920,959</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,060,990</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> California</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">547,079</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">547,085</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> All other states</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,530,018</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">46.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,047,204</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">50.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other domestic assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">189,358</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">177,317</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total U.S.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,187,414</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">77.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,832,596</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">80.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Germany</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,054,368</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,031,039</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> United Kingdom, Italy, and Spain</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">156,630</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">161,317</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other international assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">23,983</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,970</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total International</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,234,981</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,203,326</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Grand Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,422,395</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,035,922</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 2pt; WIDTH: 10%; BORDER-BOTTOM: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt; LINE-HEIGHT: 8pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(A)</td> <td valign="top" align="left">Gross Assets represents total assets plus accumulated depreciation/amortization assuming all real estate commitments as of the period end are fully funded.</td> </tr> </table> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(B)</td> <td valign="top" align="left">Includes both leased and loaned assets.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On an individual property basis, we had no investment of any single property greater than 2.3% of our total assets as of June&#xA0;30, 2016.</p> </div> 34029000 2743000 111375000 -68000 152021000 108065000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following is a summary of our loans (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>As&#xA0;of</b><br /> <b>June&#xA0;30,&#xA0;2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>As&#xA0;of</b><br /> <b>December&#xA0;31,&#xA0;2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Mortgage loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">549,337</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">757,581</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Acquisition loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">216,100</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">610,469</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Working capital and other loans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">43,229</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">54,353</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">808,666</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,422,403</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> 0.95 276000 4766000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Gross Assets by Operator</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="48%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of June&#xA0;30, 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 35.05pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>Operators</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of<br /> Total&#xA0;Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of<br /> Total&#xA0;Gross&#xA0;Assets</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(A)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(B)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(A)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>(B)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Prime</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,126,654</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,032,353</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> MEDIAN</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,054,368</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,031,039</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Ernest</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">584,411</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">579,182</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Adeptus Health</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">500,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">500,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> RCCH</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">458,659</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,059,989</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 42px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Revenue by Operator</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Six&#xA0;Months&#xA0;Ended<br /> June 30, 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>For&#xA0;the&#xA0;Six&#xA0;Months&#xA0;Ended<br /> June 30, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 35.05pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>Operators</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> Revenue</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of<br /> Total&#xA0;Revenue</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> Revenue</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Percentage&#xA0;of<br /> Total&#xA0;Revenue</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Prime</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,859</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,869</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">25.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> MEDIAN</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">47,745</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,212</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Ernest</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">33,322</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,695</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> RCCH</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,909</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Adeptus Health</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,205</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7,425</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> -3801000 113000 16768000 P3Y 0 P3Y 0 P3Y 45528 Variable Various Various 2016-10 2016-07 6 15 1100000 2400000 5 Q2 2016 10-Q 0.47 0001524607 0.47 0 238413000 237796000 false 0.47 0 0.45 --12-31 2016-06-30 0.47 Non-accelerated Filer 617000 137290000 3000000 MPT OPERATING PARTNERSHIP, L.P. 261299000 96504000 5904000 60007000 17268000 50000000 104788000 181047000 111651000 57118000 -1000 16678000 119693000 119195000 32503000 147000 112149000 -1000 112150000 16678000 109991000 -217000 6605000 1640000 -68897000 45170000 498000 683000 80874000 44306000 4152000 7375000 3702000 43974000 1685000 3063000 480106000 -8465000 3897000 80252000 3125000 23516000 498000 705501000 -1075000000 -17105000 498000 9544000 -634501000 500000000 50000000 89165000 111376000 3 -9593000 2743000 111375000 152021000 108065000 276000 4766000 -3801000 16768000 0.101 0.127 33187000 0.194 0.183 47745000 0.170 0.185 48256000 0.772 0.809 211339000 0.466 0.497 129896000 0.228 0.191 49960000 0.030 0.008 2215000 0.035 0.004 1 2 0 -54000 54000 1.000 0.108 0.092 0.194 0.208 0.085 1.000 261299000 0.128 33322000 0.062 16205000 0.183 47745000 0.225 58859000 0.126 32909000 45000000 600000 43763000 3Q 2016 15343000 4Q 2016 206000 1Q 2017 16311000 2Q 2017 Various 0.05675 41100000 28367000 Variable Various Various 0.091 0.171 0.176 0.801 0.505 0.199 0.027 0.029 0.001 1.000 0.096 0.083 0.171 0.171 0.176 0.11 0.11 0 208640000 208071000 0.11 0 0.21 0.22 0.11 569000 99801000 20307000 27848000 4525000 3792000 47864000 22407000 43526000 43444000 12808000 22489000 22489000 50000 225000 730000 -25375000 109000 82000 563000 26890000 25809000 14956000 530000 51937000 10642000 82000 82000 949000 22157000 22157000 228000 53893000 250000 1853000 12000 5252000 4200000 3500000 22600000 0.11 0.11 0 208640000 208071000 0.11 0 0.22 0.11 569000 99801000 20307000 27848000 47864000 22407000 43526000 43444000 12808000 22489000 22489000 225000 730000 -25375000 82000 563000 26890000 25809000 14956000 530000 51937000 10642000 82000 82000 22157000 22157000 53893000 250000 1853000 5252000 0 0.22 0.22 0 239008000 238082000 0.23 0 0.23 0.23 926000 126300000 -14683000 26237000 3092000 2206000 78497000 53724000 16638000 40066000 39866000 13552000 53924000 53924000 -546000 825000 -24573000 200000 364000 41501000 7375000 4767000 22832000 784000 47803000 12045000 200000 200000 805000 53592000 53592000 -9000 77960000 132000 1200000 72000 8551000 1100000 2400000 2600000 0.22 0.22 0 239008000 238082000 0.23 0 0.23 0.23 926000 126300000 -14683000 26237000 78497000 53724000 16638000 40066000 39866000 13552000 53924000 53924000 -546000 825000 -24573000 200000 364000 41501000 7375000 4767000 22832000 784000 47803000 12045000 200000 200000 53592000 53592000 77960000 132000 1200000 8551000 0 0001287865 us-gaap:InterestRateSwapMember 2016-04-01 2016-06-30 0001287865 mpw:MptOperatingPartnershipLPMember 2016-04-01 2016-06-30 0001287865 mpw:CapellaHealthcareIncMember 2016-04-01 2016-06-30 0001287865 mpw:BusinessAcquisitionsMember mpw:TwoThousandSixteenMember 2016-04-01 2016-06-30 0001287865 2016-04-01 2016-06-30 0001287865 us-gaap:InterestRateSwapMember 2015-04-01 2015-06-30 0001287865 mpw:MptOperatingPartnershipLPMember 2015-04-01 2015-06-30 0001287865 mpw:BusinessAcquisitionsMember mpw:TwoThousandFifteenMember 2015-04-01 2015-06-30 0001287865 2015-04-01 2015-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:RCCHHealthcarePartnersMember 2015-01-01 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:PrimeHealthCareServicesMember 2015-01-01 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:MedianMember 2015-01-01 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:AdeptusHealthMember 2015-01-01 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:ErnestHealthIncMember 2015-01-01 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember 2015-01-01 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:OtherInternationalStatesMember 2015-01-01 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:OtherDomesticMember 2015-01-01 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:ItalySpainAndUnitedKingdomMember 2015-01-01 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:InternationalMember 2015-01-01 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:OtherUnitedStatesMember 2015-01-01 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember country:US 2015-01-01 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember stpr:TX 2015-01-01 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember country:DE 2015-01-01 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember stpr:CA 2015-01-01 2015-12-31 0001287865 mpw:TwoThousandSixSeniorUnsecuredNotesMember 2015-01-01 2015-12-31 0001287865 mpw:TermLoansMember 2015-01-01 2015-12-31 0001287865 us-gaap:RevolvingCreditFacilityMember 2015-01-01 2015-12-31 0001287865 2015-01-01 2015-12-31 0001287865 mpw:MarketEquityOfferingProgramMember us-gaap:SubsequentEventMember 2016-07-01 2016-07-31 0001287865 mpw:TwoThousandSixSeniorUnsecuredNotesMember mpw:InterestRateContractTwoMember 2011-10-01 2011-10-31 0001287865 mpw:AdeptusHealthFiveMember 2016-01-01 2016-06-30 0001287865 mpw:AdeptusHealthFourMember 2016-01-01 2016-06-30 0001287865 mpw:AdeptusHealthThreeMember 2016-01-01 2016-06-30 0001287865 mpw:AdeptusHealthTwoMember 2016-01-01 2016-06-30 0001287865 mpw:AdeptusHealthOneMember 2016-01-01 2016-06-30 0001287865 mpw:MarketEquityOfferingProgramMember 2016-01-01 2016-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:RCCHHealthcarePartnersMember 2016-01-01 2016-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:PrimeHealthCareServicesMember 2016-01-01 2016-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:MedianMember 2016-01-01 2016-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:AdeptusHealthMember 2016-01-01 2016-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:ErnestHealthIncMember 2016-01-01 2016-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:RCCHHealthcarePartnersMember 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:PrimeHealthCareServicesMember 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:MedianMember 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:AdeptusHealthMember 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:ErnestHealthIncMember 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember 2016-01-01 2016-06-30 0001287865 mpw:MinusHundredBasisPointsMember 2016-01-01 2016-06-30 0001287865 mpw:PlusHundredBasisPointsMember 2016-01-01 2016-06-30 0001287865 us-gaap:InterestRateSwapMember 2016-01-01 2016-06-30 0001287865 mpw:EmployeeMember 2016-01-01 2016-06-30 0001287865 us-gaap:DirectorMember 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:OtherInternationalStatesMember 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:OtherDomesticMember 2016-01-01 2016-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:ItalySpainAndUnitedKingdomMember 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:ItalySpainAndUnitedKingdomMember 2016-01-01 2016-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:InternationalMember 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:InternationalMember 2016-01-01 2016-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:OtherUnitedStatesMember 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:OtherUnitedStatesMember 2016-01-01 2016-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember country:US 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember country:US 2016-01-01 2016-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember stpr:TX 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember stpr:TX 2016-01-01 2016-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember country:DE 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember country:DE 2016-01-01 2016-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember stpr:CA 2016-01-01 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember stpr:CA 2016-01-01 2016-06-30 0001287865 mpw:MptOperatingPartnershipLPMember 2016-01-01 2016-06-30 0001287865 mpw:CapellaHealthcareIncMember 2016-01-01 2016-06-30 0001287865 mpw:BusinessAcquisitionsMember mpw:TwoThousandSixteenMember 2016-01-01 2016-06-30 0001287865 mpw:ErnestHealthIncMember mpw:LeasingOperationsMember 2016-01-01 2016-06-30 0001287865 mpw:PrimeFacilitiesMember mpw:LeasingOperationsMember 2016-01-01 2016-06-30 0001287865 mpw:TwoThousandSixSeniorUnsecuredNotesMember mpw:InterestRateContractOneMember 2016-01-01 2016-06-30 0001287865 mpw:TwoThousandSixSeniorUnsecuredNotesMember mpw:InterestRateContractTwoMember 2016-01-01 2016-06-30 0001287865 mpw:TwoThousandSixSeniorUnsecuredNotesMember 2016-01-01 2016-06-30 0001287865 mpw:TermLoansMember 2016-01-01 2016-06-30 0001287865 us-gaap:RevolvingCreditFacilityMember 2016-01-01 2016-06-30 0001287865 mpw:TimeBasedAwardsMember 2016-01-01 2016-06-30 0001287865 mpw:MultiYearPerformanceBasedAwardsMember 2016-01-01 2016-06-30 0001287865 us-gaap:PerformanceSharesMember 2016-01-01 2016-06-30 0001287865 2016-01-01 2016-06-30 0001287865 mpw:IntangibleLeaseAssetsMember 2015-01-01 2015-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:PrimeHealthCareServicesMember 2015-01-01 2015-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:MedianMember 2015-01-01 2015-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:AdeptusHealthMember 2015-01-01 2015-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:ErnestHealthIncMember 2015-01-01 2015-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember 2015-01-01 2015-06-30 0001287865 us-gaap:InterestRateSwapMember 2015-01-01 2015-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:ItalySpainAndUnitedKingdomMember 2015-01-01 2015-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:InternationalMember 2015-01-01 2015-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember mpw:OtherUnitedStatesMember 2015-01-01 2015-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember country:US 2015-01-01 2015-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember stpr:TX 2015-01-01 2015-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember country:DE 2015-01-01 2015-06-30 0001287865 mpw:RevenueMember us-gaap:CreditConcentrationRiskMember stpr:CA 2015-01-01 2015-06-30 0001287865 mpw:MptOperatingPartnershipLPMember 2015-01-01 2015-06-30 0001287865 mpw:BusinessAcquisitionsMember mpw:TwoThousandFifteenMember 2015-01-01 2015-06-30 0001287865 mpw:TimeBasedAwardsMember 2015-01-01 2015-06-30 0001287865 mpw:MultiYearPerformanceBasedAwardsMember 2015-01-01 2015-06-30 0001287865 us-gaap:PerformanceSharesMember 2015-01-01 2015-06-30 0001287865 2015-01-01 2015-06-30 0001287865 mpw:PublicOfferingMember 2015-01-14 2015-01-14 0001287865 mpw:AxaRealEstateMember mpw:AcuteCareHospitalMember mpw:TwoThousandFifteenMember country:ES 2015-09-09 2015-09-09 0001287865 mpw:TwoThousandFifteenMember mpw:MedianMember 2015-06-30 2015-06-30 0001287865 mpw:TwoThousandTwentySixSeniorUnsecuredNotesMember us-gaap:SubsequentEventMember 2016-07-22 2016-07-22 0001287865 mpw:TwoThousandSixteenSeniorUnsecuredNotesMember us-gaap:SubsequentEventMember 2016-07-22 2016-07-22 0001287865 mpw:TwoThousandSixteenSeniorUnsecuredNotesMember us-gaap:MaximumMember us-gaap:SubsequentEventMember 2016-07-22 2016-07-22 0001287865 mpw:HealthSouthMember us-gaap:SubsequentEventMember 2016-07-20 2016-07-20 0001287865 mpw:PostAcuteMember stpr:TX 2016-06-17 2016-06-17 0001287865 mpw:PostAcuteMember 2016-06-17 2016-06-17 0001287865 mpw:ErnestHealthIncMember mpw:TwoThousandFifteenMember 2015-06-16 2015-06-16 0001287865 mpw:ErnestHealthIncMember mpw:RehabilitationHospitalMember mpw:TwoThousandFifteenMember 2015-06-16 2015-06-16 0001287865 mpw:ErnestHealthIncMember mpw:AcuteCareHospitalMember mpw:TwoThousandFifteenMember 2015-06-16 2015-06-16 0001287865 mpw:MarketEquityOfferingProgramMember 2016-03-01 2016-03-01 0001287865 mpw:TwoThousandFifteenMember mpw:MedianMember 2015-04-29 2015-04-29 0001287865 2012-03-01 2012-03-01 0001287865 mpw:PostAcuteMember stpr:TX 2016-05-23 2016-05-23 0001287865 mpw:PostAcuteMember stpr:LA 2016-05-23 2016-05-23 0001287865 mpw:PostAcuteMember 2016-05-23 2016-05-23 0001287865 mpw:HealthSouthMember stpr:TX 2016-05-20 2016-05-20 0001287865 mpw:HealthSouthMember 2016-05-20 2016-05-20 0001287865 mpw:AcuteCareHospitalMember stpr:NJ 2016-05-02 2016-05-02 0001287865 mpw:CapellaHealthcareIncMember 2016-04-30 2016-04-30 0001287865 us-gaap:RevolvingCreditFacilityMember mpw:TwoThousandSixteenSeniorUnsecuredNotesMember us-gaap:MaximumMember 2016-02-22 2016-02-22 0001287865 us-gaap:RevolvingCreditFacilityMember mpw:TwoThousandSixteenSeniorUnsecuredNotesMember 2016-02-22 2016-02-22 0001287865 mpw:ErnestHealthIncMember mpw:InpatientRehabilitationHospitalMember mpw:TwoThousandFifteenMember mpw:WeslacoTexasMember 2015-02-27 2015-02-27 0001287865 mpw:AcuteCareHospitalMember mpw:TwoThousandFifteenMember stpr:KS 2015-02-13 2015-02-13 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:RCCHHealthcarePartnersMember 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:PrimeHealthCareServicesMember 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:MedianMember 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:AdeptusHealthMember 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:ErnestHealthIncMember 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember 2015-12-31 0001287865 us-gaap:MortgagesMember 2015-12-31 0001287865 us-gaap:InterestRateSwapMember 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:OtherInternationalStatesMember 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:OtherDomesticMember 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:ItalySpainAndUnitedKingdomMember 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:InternationalMember 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:OtherUnitedStatesMember 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember country:US 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember stpr:TX 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember country:DE 2015-12-31 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember stpr:CA 2015-12-31 0001287865 mpw:MptOperatingPartnershipLPMember us-gaap:CommonStockMember 2015-12-31 0001287865 mpw:MptOperatingPartnershipLPMember 2015-12-31 0001287865 mpw:MptOperatingPartnershipLPMember mpw:LtipUnitsMember 2015-12-31 0001287865 mpw:MptOperatingPartnershipLPMember us-gaap:GeneralPartnerMember 2015-12-31 0001287865 mpw:TwoThousandFourteenSeniorUnsecuredNotesMember 2015-12-31 0001287865 mpw:TwoThousandTwelveSeniorUnsecuredNotesMember 2015-12-31 0001287865 mpw:TwoThousandFifteenSeniorUnsecuredNotesMember 2015-12-31 0001287865 mpw:SeniorUnsecuredDebtMember 2015-12-31 0001287865 mpw:TwoThousandElevenSeniorUnsecuredNotesMember 2015-12-31 0001287865 mpw:TwoThousandThirteenSeniorUnsecuredNotesMember 2015-12-31 0001287865 mpw:TwoThousandSixSeniorUnsecuredNotesMember us-gaap:InterestRateContractMember 2015-12-31 0001287865 mpw:TwoThousandSixSeniorUnsecuredNotesMember 2015-12-31 0001287865 mpw:TermLoansMember 2015-12-31 0001287865 us-gaap:RevolvingCreditFacilityMember 2015-12-31 0001287865 mpw:AcquisitionLoanMember 2015-12-31 0001287865 mpw:WorkingCapitalLoansMember 2015-12-31 0001287865 2015-12-31 0001287865 mpw:PublicOfferingMember 2015-01-14 0001287865 mpw:MptOperatingPartnershipLPMember 2014-12-31 0001287865 mpw:WaterlandPrivateEquityFundMember mpw:TwoThousandFifteenMember mpw:MedianMember 2014-12-31 0001287865 mpw:TwoThousandFifteenMember mpw:MedianMember 2014-12-31 0001287865 2014-12-31 0001287865 us-gaap:RevolvingCreditFacilityMember us-gaap:ScenarioForecastMember 2016-09-30 0001287865 mpw:NetInvestmentInDirectFinancingLeasesMember 2016-06-30 0001287865 us-gaap:LandAndLandImprovementsMember 2016-06-30 0001287865 us-gaap:BuildingMember 2016-06-30 0001287865 mpw:RCCHHealthcarePartnersMember 2016-06-30 0001287865 mpw:AdeptusHealthFiveMember 2016-06-30 0001287865 mpw:AdeptusHealthFourMember 2016-06-30 0001287865 mpw:AdeptusHealthThreeMember 2016-06-30 0001287865 mpw:AdeptusHealthTwoMember 2016-06-30 0001287865 mpw:AdeptusHealthOneMember 2016-06-30 0001287865 mpw:ErnestHealthIncAndOtherAcquisitionsMember 2016-06-30 0001287865 us-gaap:EquityMethodInvestmentsMember 2016-06-30 0001287865 mpw:MarketEquityOfferingProgramMember 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:RCCHHealthcarePartnersMember 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:PrimeHealthCareServicesMember 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:MedianMember 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:AdeptusHealthMember 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:ErnestHealthIncMember 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CustomerConcentrationRiskMember 2016-06-30 0001287865 us-gaap:MortgagesMember 2016-06-30 0001287865 us-gaap:InterestRateSwapMember 2016-06-30 0001287865 mpw:MortgageAndOtherLoansMember 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:OtherInternationalStatesMember 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:OtherDomesticMember 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:ItalySpainAndUnitedKingdomMember 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:InternationalMember 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember mpw:OtherUnitedStatesMember 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember country:US 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember stpr:TX 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember country:DE 2016-06-30 0001287865 us-gaap:AssetsTotalMember us-gaap:CreditConcentrationRiskMember stpr:CA 2016-06-30 0001287865 mpw:MptOperatingPartnershipLPMember us-gaap:CommonStockMember 2016-06-30 0001287865 mpw:MptOperatingPartnershipLPMember 2016-06-30 0001287865 mpw:MortgageLoansMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgagesMember 2016-06-30 0001287865 us-gaap:OtherAssetsMember us-gaap:EquityMethodInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0001287865 us-gaap:OtherAssetsMember 2016-06-30 0001287865 us-gaap:LoansMember 2016-06-30 0001287865 mpw:HealthSouthMember stpr:TX 2016-06-30 0001287865 mpw:AcuteCareFacilitiesMember mpw:DevelopmentActivitiesMember 2016-06-30 0001287865 mpw:MptOperatingPartnershipLPMember mpw:LtipUnitsMember 2016-06-30 0001287865 mpw:MptOperatingPartnershipLPMember us-gaap:GeneralPartnerMember 2016-06-30 0001287865 mpw:TwoThousandFourteenSeniorUnsecuredNotesMember 2016-06-30 0001287865 mpw:TwoThousandSixteenSeniorUnsecuredNotesMember 2016-06-30 0001287865 mpw:TwoThousandTwelveSeniorUnsecuredNotesMember 2016-06-30 0001287865 mpw:TwoThousandFifteenSeniorUnsecuredNotesMember 2016-06-30 0001287865 mpw:SeniorUnsecuredDebtMember 2016-06-30 0001287865 mpw:TwoThousandElevenSeniorUnsecuredNotesMember 2016-06-30 0001287865 mpw:TwoThousandThirteenSeniorUnsecuredNotesMember 2016-06-30 0001287865 mpw:TwoThousandSixSeniorUnsecuredNotesMember us-gaap:InterestRateContractMember 2016-06-30 0001287865 mpw:TwoThousandSixSeniorUnsecuredNotesMember 2016-06-30 0001287865 mpw:TermLoansMember 2016-06-30 0001287865 us-gaap:RevolvingCreditFacilityMember 2016-06-30 0001287865 mpw:EquityIncentivePlanMember 2016-06-30 0001287865 mpw:AcquisitionAndOtherLoanMember mpw:OtherLoansMember us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0001287865 mpw:AcquisitionLoanMember 2016-06-30 0001287865 mpw:WorkingCapitalLoansMember 2016-06-30 0001287865 2016-06-30 0001287865 mpw:TwelveOaksFacilityMember 2016-03-31 0001287865 mpw:AxaRealEstateMember mpw:TwoThousandFifteenMember 2015-09-09 0001287865 mpw:IntangibleLeaseAssetsMember 2015-06-30 0001287865 mpw:NetInvestmentInDirectFinancingLeasesMember 2015-06-30 0001287865 us-gaap:LandAndLandImprovementsMember 2015-06-30 0001287865 us-gaap:BuildingMember 2015-06-30 0001287865 us-gaap:MortgagesMember 2015-06-30 0001287865 mpw:MptOperatingPartnershipLPMember 2015-06-30 0001287865 mpw:OtherLoansMember 2015-06-30 0001287865 mpw:TwoThousandFifteenMember mpw:MedianMember 2015-06-30 0001287865 2015-06-30 0001287865 mpw:TwoThousandSixSeniorUnsecuredNotesMember mpw:InterestRateContractOneMember 2010-06-30 0001287865 mpw:TwoThousandSixSeniorUnsecuredNotesMember us-gaap:InterestRateSwapMember 2010-06-30 0001287865 mpw:CapellaHealthcareIncMember us-gaap:SubsequentEventMember 2016-07-22 0001287865 mpw:TwoThousandElevenSeniorNotesMember us-gaap:SubsequentEventMember 2016-07-22 0001287865 mpw:TwoThousandTwentySixSeniorUnsecuredNotesMember us-gaap:SubsequentEventMember 2016-07-22 0001287865 mpw:TwoThousandSixteenSeniorUnsecuredNotesMember us-gaap:SubsequentEventMember 2016-07-22 0001287865 mpw:MedianMember 2016-06-22 0001287865 mpw:ErnestHealthIncMember mpw:TwoThousandFifteenMember 2015-06-16 0001287865 mpw:MarketEquityOfferingProgramMember us-gaap:MaximumMember 2016-03-01 0001287865 mpw:TwoThousandFifteenMember mpw:MedianMember 2015-04-29 0001287865 2012-03-01 0001287865 mpw:TwoThousandSixSeniorUnsecuredNotesMember us-gaap:ScenarioForecastMember 2016-10-31 0001287865 mpw:TwelveOaksFacilityMember us-gaap:SubsequentEventMember 2016-08-08 0001287865 2016-08-01 0001287865 mpw:MarketEquityOfferingProgramMember us-gaap:SubsequentEventMember 2016-07-31 0001287865 mpw:TwoThousandSixSeniorUnsecuredNotesMember us-gaap:SubsequentEventMember 2016-07-31 0001287865 mpw:AcuteCareHospitalMember stpr:NJ 2016-05-02 0001287865 mpw:CapellaHealthcareIncMember 2016-04-30 0001287865 us-gaap:RevolvingCreditFacilityMember mpw:TwoThousandSixteenSeniorUnsecuredNotesMember 2016-02-22 0001287865 mpw:AcuteCareHospitalMember mpw:TwoThousandFifteenMember stpr:KS 2015-02-13 0001287865 mpw:TwoThousandSixSeniorUnsecuredNotesMember mpw:InterestRateContractTwoMember 2011-10-31 iso4217:USD pure shares iso4217:EUR iso4217:USD shares mpw:Facility mpw:Investment mpw:RenewalOptions mpw:Hospital mpw:Property mpw:Bed mpw:Leases mpw:Partner mpw:Director mpw:Employee EX-101.SCH 9 mpw-20160630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Net Income (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Organization link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Real Estate and Lending Activities link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Debt link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Common Stock/Partners' Capital link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Stock Awards link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Fair Value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Earnings Per Share/Common Unit link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Real Estate and Lending Activities (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Fair Value of Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Earnings Per Share/Common Unit (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Summary of Significant Accounting Policies - Carrying Value and Classification of Related Assets and Maximum Exposure to Loss (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Real Estate and Lending Activities - Assets Acquired (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Real Estate and Lending Activities - Assets Acquired (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Real Estate and Lending Activities - 2016 Activity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Real Estate and Lending Activities - 2015 Activity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Real Estate and Lending Activities - Schedule of Unaudited Supplemental Pro Forma Operating Data (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Real Estate and Lending Activities - Development Activities - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Real Estate and Lending Activities - Summary of Status Update on Current Development Projects (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Real Estate and Lending Activities - Disposals - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Real Estate and Lending Activities - Summary of Facilities and Related Net Assets Designated as Held for Sale (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Real Estate and Lending Activities - Summary of Operations for Disposed Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Real Estate and Lending Activities - Leasing Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Real Estate and Lending Activities - Components of Net Investment in Direct Financing Leases (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Real Estate and Lending Activities - Twelve Oaks Facility - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Real Estate and Lending Activities - Summary of Loans (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Real Estate and Loans Receivable - Loans - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Real Estate and Lending Activities - Schedule of Revenue by Operator (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Real Estate and Lending Activities - Schedule of Revenue from External Customers by Geographic Areas (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Real Estate and Lending Activities - Schedule of Gross Assets by Operator (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Real Estate and Lending Activities - Schedule of Gross Assets by Geographic Areas (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Real Estate and Lending Activities - Concentrations of Credit Risk - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Debt - Summary of Debt (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Debt - Principal Payments Due for Debt (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Debt - Principal Payments Due for Debt (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Debt - Interest Rate Swap - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - Debt - Covenants - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 151 - Disclosure - Common Stock/Partners' Capital - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 152 - Disclosure - Stock Awards - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 153 - Disclosure - Fair Value of Financial Instruments - Summary of Fair Value Information of Financial Instruments (Detail) link:calculationLink link:presentationLink link:definitionLink 154 - Disclosure - Fair Value of Financial Instruments - Equity Interest in Related Party and Related Loans Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 155 - Disclosure - Fair Value of Financial Instruments - Additional information (Detail) link:calculationLink link:presentationLink link:definitionLink 156 - Disclosure - Fair Value of Financial Instruments - Summary Showing Sensitivity Analysis by Using Basis Point Variations (Detail) link:calculationLink link:presentationLink link:definitionLink 157 - Disclosure - Earnings Per Share/Common Unit - Calculation of Earnings Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 158 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 10 mpw-20160630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 mpw-20160630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 mpw-20160630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 13 mpw-20160630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2016
Aug. 01, 2016
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q2  
Trading Symbol MPW  
Entity Registrant Name MEDICAL PROPERTIES TRUST INC  
Entity Central Index Key 0001287865  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   243,138,873
MPT Operating Partnership, L.P. [Member]    
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q2  
Entity Registrant Name MPT OPERATING PARTNERSHIP, L.P.  
Entity Central Index Key 0001524607  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Real estate assets    
Land, buildings and improvements, intangible lease assets, and other $ 3,482,199 $ 3,297,705
Real estate held for sale 63,074  
Mortgage loans 549,337 757,581
Net investment in direct financing leases 528,747 626,996
Gross investment in real estate assets 4,623,357 4,682,282
Accumulated depreciation and amortization (278,590) (257,928)
Net investment in real estate assets 4,344,767 4,424,354
Cash and cash equivalents 181,561 195,541
Interest and rent receivables 47,699 46,939
Straight-line rent receivables 95,988 82,155
Other loans 259,329 664,822
Other assets 188,589 195,540
Total Assets 5,117,933 5,609,351
Liabilities    
Debt, net 2,758,635 3,322,541
Accounts payable and accrued expenses 148,218 137,356
Deferred revenue 20,997 29,358
Lease deposits and other obligations to tenants 22,845 12,831
Total Liabilities 2,950,695 3,502,086
Equity / Capital    
Preferred stock, $0.001 par value. Authorized 10,000 shares; no shares outstanding
Common stock, $0.001 par value. Authorized 500,000 shares; issued and outstanding - 240,341 shares at June 30, 2016 and 236,744 shares at December 31, 2015 240 237
Limited Partners:    
Additional paid in capital 2,642,281 2,593,827
Distributions in excess of net income (414,657) (418,650)
Accumulated other comprehensive loss (65,340) (72,884)
Treasury shares, at cost (262) (262)
Total Medical Properties Trust, Inc. Stockholders' Equity 2,162,262 2,102,268
Non-controlling interests 4,976 4,997
Total Equity / Capital 2,167,238 2,107,265
Total Liabilities and Equity / Capital 5,117,933 5,609,351
MPT Operating Partnership, L.P. [Member]    
Real estate assets    
Land, buildings and improvements, intangible lease assets, and other 3,482,199 3,297,705
Real estate held for sale 63,074  
Mortgage loans 549,337 757,581
Net investment in direct financing leases 528,747 626,996
Gross investment in real estate assets 4,623,357 4,682,282
Accumulated depreciation and amortization (278,590) (257,928)
Net investment in real estate assets 4,344,767 4,424,354
Cash and cash equivalents 181,561 195,541
Interest and rent receivables 47,699 46,939
Straight-line rent receivables 95,988 82,155
Other loans 259,329 664,822
Other assets 188,589 195,540
Total Assets 5,117,933 5,609,351
Liabilities    
Debt, net 2,758,635 3,322,541
Accounts payable and accrued expenses 92,623 84,628
Deferred revenue 20,997 29,358
Lease deposits and other obligations to tenants 22,845 12,831
Payable due to Medical Properties Trust, Inc. 55,205 52,338
Total Liabilities 2,950,305 3,501,696
Limited Partners:    
Accumulated other comprehensive loss (65,340) (72,884)
Total Medical Properties Trust, Inc. Stockholders' Equity 2,162,652 2,102,658
Non-controlling interests 4,976 4,997
Total Equity / Capital 2,167,628 2,107,655
Total Liabilities and Equity / Capital 5,117,933 5,609,351
MPT Operating Partnership, L.P. [Member] | General Partner [Member]    
Equity / Capital    
General Partner - issued and outstanding - 2,400 units at June 30, 2016 and 2,363 units at December 31, 2015 22,299 21,773
MPT Operating Partnership, L.P. [Member] | Common Units [Member]    
Limited Partners:    
Limited Partners Capital $ 2,205,693 $ 2,153,769
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2016
Dec. 31, 2015
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 240,341,000 236,744,000
Common stock, shares outstanding 240,341,000 236,744,000
MPT Operating Partnership, L.P. [Member] | Common Units [Member]    
Limited Partners, units issued 237,941,000 234,381,000
Limited Partners, units outstanding 237,941,000 234,381,000
General Partner [Member] | MPT Operating Partnership, L.P. [Member]    
General partner, units issued 2,400,000 2,363,000
General partner, units outstanding 2,400,000 2,363,000
LTIP Units [Member] | MPT Operating Partnership, L.P. [Member]    
LTIP Units, shares issued 292,000 292,000
LTIP Units, shares outstanding 292,000 292,000
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Net Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Revenues        
Rent billed $ 77,960 $ 53,893 $ 152,021 $ 106,994
Straight-line rent 8,551 5,252 16,768 9,980
Income from direct financing leases 13,552 12,808 32,503 25,363
Interest and fee income 26,237 27,848 60,007 53,425
Total revenues 126,300 99,801 261,299 195,762
Expenses        
Real estate depreciation and amortization 22,832 14,956 43,974 29,712
Impairment charges 7,375   7,375  
Property-related 784 530 1,685 881
General and administrative 12,045 10,642 23,516 21,547
Acquisition expenses 4,767 25,809 3,702 32,048
Total operating expenses 47,803 51,937 80,252 84,188
Operating income 78,497 47,864 181,047 111,574
Other income (expense)        
Interest expense (41,501) (26,890) (80,874) (53,556)
Gain on sale of real estate and other asset dispositions, net 16,638   16,678  
Earnings (loss) from equity and other interests 1,200 1,853 (3,801) 1,956
Other income (expense) (546) 225 (217) (571)
Income tax expense (364) (563) (683) (938)
Net other expense (24,573) (25,375) (68,897) (53,109)
Income from continuing operations 53,924 22,489 112,150 58,465
Loss from discontinued operations     (1)  
Net income 53,924 22,489 112,149 58,465
Net income attributable to non-controlling interests (200) (82) (498) (161)
Net income attributable to MPT common stockholders $ 53,724 $ 22,407 $ 111,651 $ 58,304
Earnings per common share - basic        
Income from continuing operations attributable to MPT common stockholders $ 0.23 $ 0.11 $ 0.47 $ 0.28
Loss from discontinued operations attributable to MPT common stockholders 0 0 0 0
Net income attributable to MPT common stockholders $ 0.23 $ 0.11 $ 0.47 $ 0.28
Weighted average shares outstanding - basic 238,082 208,071 237,796 205,515
Earnings per common share - diluted        
Income from continuing operations attributable to MPT common stockholders $ 0.22 $ 0.11 $ 0.47 $ 0.28
Loss from discontinued operations attributable to MPT common stockholders 0 0 0 0
Net income attributable to MPT common stockholders $ 0.22 $ 0.11 $ 0.47 $ 0.28
Weighted average shares outstanding - diluted 239,008 208,640 238,413 206,127
Dividends declared per common share $ 0.23 $ 0.22 $ 0.45 $ 0.44
MPT Operating Partnership, L.P. [Member]        
Revenues        
Rent billed $ 77,960 $ 53,893 $ 152,021 $ 106,994
Straight-line rent 8,551 5,252 16,768 9,980
Income from direct financing leases 13,552 12,808 32,503 25,363
Interest and fee income 26,237 27,848 60,007 53,425
Total revenues 126,300 99,801 261,299 195,762
Expenses        
Real estate depreciation and amortization 22,832 14,956 43,974 29,712
Impairment charges 7,375   7,375  
Property-related 784 530 1,685 881
General and administrative 12,045 10,642 23,516 21,547
Acquisition expenses 4,767 25,809 3,702 32,048
Total operating expenses 47,803 51,937 80,252 84,188
Operating income 78,497 47,864 181,047 111,574
Other income (expense)        
Interest expense (41,501) (26,890) (80,874) (53,556)
Gain on sale of real estate and other asset dispositions, net 16,638   16,678  
Earnings (loss) from equity and other interests 1,200 1,853 (3,801) 1,956
Other income (expense) (546) 225 (217) (571)
Income tax expense (364) (563) (683) (938)
Net other expense (24,573) (25,375) (68,897) (53,109)
Income from continuing operations 53,924 22,489 112,150 58,465
Loss from discontinued operations     (1)  
Net income 53,924 22,489 112,149 58,465
Net income attributable to non-controlling interests (200) (82) (498) (161)
Net income attributable to MPT common stockholders $ 53,724 $ 22,407 $ 111,651 $ 58,304
Earnings per common share - basic        
Income from continuing operations attributable to MPT common stockholders $ 0.23 $ 0.11 $ 0.47 $ 0.28
Loss from discontinued operations attributable to MPT common stockholders 0 0 0 0
Net income attributable to MPT common stockholders $ 0.23 $ 0.11 $ 0.47 $ 0.28
Weighted average shares outstanding - basic 238,082 208,071 237,796 205,515
Earnings per common share - diluted        
Income from continuing operations attributable to MPT common stockholders $ 0.22 $ 0.11 $ 0.47 $ 0.28
Loss from discontinued operations attributable to MPT common stockholders 0 0 0 0
Net income attributable to MPT common stockholders $ 0.22 $ 0.11 $ 0.47 $ 0.28
Weighted average shares outstanding - diluted 239,008 208,640 238,413 206,127
Dividends declared per common share $ 0.23 $ 0.22 $ 0.45 $ 0.44
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Net income $ 53,924 $ 22,489 $ 112,149 $ 58,465
Other comprehensive income:        
Unrealized gain on interest rate swap 825 730 1,640 1,315
Foreign currency translation gain (loss) (14,683) 20,307 5,904 (39,286)
Total comprehensive income 40,066 43,526 119,693 20,494
Comprehensive income attributable to non-controlling interests (200) (82) (498) (161)
Comprehensive income attributable to MPT common stockholders 39,866 43,444 119,195 20,333
MPT Operating Partnership, L.P. [Member]        
Net income 53,924 22,489 112,149 58,465
Other comprehensive income:        
Unrealized gain on interest rate swap 825 730 1,640 1,315
Foreign currency translation gain (loss) (14,683) 20,307 5,904 (39,286)
Total comprehensive income 40,066 43,526 119,693 20,494
Comprehensive income attributable to non-controlling interests (200) (82) (498) (161)
Comprehensive income attributable to MPT common stockholders $ 39,866 $ 43,444 $ 119,195 $ 20,333
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Operating activities    
Net income $ 112,149 $ 58,465
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 45,170 30,564
Straight-line rent revenue (17,268) (9,980)
Straight-line rent and other write-off 3,063  
Impairment charges 7,375  
Direct financing lease interest accretion (4,766) (3,279)
Share / (Unit)-based compensation expense 4,152 5,645
Gain from sale of real estate and other asset dispositions, net (16,678)  
Amortization and write-off of deferred financing costs and debt discount 3,897 2,770
Other adjustments (6,605) (2,383)
Changes in:    
Interest and rent receivable (2,743) (15,685)
Accounts payable and accrued expenses 9,544 21,327
Net cash provided by operating activities 137,290 87,444
Investing activities    
Cash paid for acquisitions and other related investments (109,991) (562,633)
Net proceeds from sale of real estate 89,165  
Principal received on loans receivable 705,501 354,952
Investment in loans receivable (96,504) (347,768)
Construction in progress and other (108,065) (86,053)
Investment in unsecured senior note (50,000)  
Proceeds from sale of unsecured senior notes 50,000  
Net cash provided by (used for) investing activities 480,106 (641,502)
Financing activities    
Revolving credit facilities, net (1,075,000) 80,586
Proceeds from debt 500,000  
Payments of term debt (147) (140)
Distributions paid (104,788) (84,487)
Proceeds from sale of common shares / units, net of offering costs 44,306 479,902
Lease deposits and other obligations to tenants 9,593 (14,453)
Debt issuance costs paid and other financing activities (8,465) (662)
Net cash (used for) provided by financing activities (634,501) 460,746
Increase (decrease) in cash and cash equivalents for period (17,105) (93,312)
Effect of exchange rate changes 3,125 (5,325)
Cash and cash equivalents at beginning of period 195,541 144,541
Cash and cash equivalents at end of period 181,561 45,904
Interest paid 57,118 52,130
Supplemental schedule of non-cash financing activities:    
Distributions declared, unpaid 55,272 46,026
MPT Operating Partnership, L.P. [Member]    
Operating activities    
Net income 112,149 58,465
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 45,170 30,564
Straight-line rent revenue (17,268) (9,980)
Straight-line rent and other write-off 3,063  
Impairment charges 7,375  
Direct financing lease interest accretion (4,766) (3,279)
Share / (Unit)-based compensation expense 4,152 5,645
Gain from sale of real estate and other asset dispositions, net (16,678)  
Amortization and write-off of deferred financing costs and debt discount 3,897 2,770
Other adjustments (6,605) (2,383)
Changes in:    
Interest and rent receivable (2,743) (15,685)
Accounts payable and accrued expenses 9,544 21,327
Net cash provided by operating activities 137,290 87,444
Investing activities    
Cash paid for acquisitions and other related investments (109,991) (562,633)
Net proceeds from sale of real estate 89,165  
Principal received on loans receivable 705,501 354,952
Investment in loans receivable (96,504) (347,768)
Construction in progress and other (108,065) (86,053)
Investment in unsecured senior note (50,000)  
Proceeds from sale of unsecured senior notes 50,000  
Net cash provided by (used for) investing activities 480,106 (641,502)
Financing activities    
Revolving credit facilities, net (1,075,000) 80,586
Proceeds from debt 500,000  
Payments of term debt (147) (140)
Distributions paid (104,788) (84,487)
Proceeds from sale of common shares / units, net of offering costs 44,306 479,902
Lease deposits and other obligations to tenants 9,593 (14,453)
Debt issuance costs paid and other financing activities (8,465) (662)
Net cash (used for) provided by financing activities (634,501) 460,746
Increase (decrease) in cash and cash equivalents for period (17,105) (93,312)
Effect of exchange rate changes 3,125 (5,325)
Cash and cash equivalents at beginning of period 195,541 144,541
Cash and cash equivalents at end of period 181,561 45,904
Interest paid 57,118 52,130
Supplemental schedule of non-cash financing activities:    
Distributions declared, unpaid $ 55,272 $ 46,026
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Organization
6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Organization

1. Organization

Medical Properties Trust, Inc., a Maryland corporation, was formed on August 27, 2003, under the Maryland General Corporation Law for the purpose of engaging in the business of investing in, owning, and leasing commercial real estate. Our operating partnership subsidiary, MPT Operating Partnership, L.P., (the “Operating Partnership”) through which we conduct all of our operations, was formed in September 2003. Through another wholly-owned subsidiary, Medical Properties Trust, LLC, we are the sole general partner of the Operating Partnership. At present, we directly own substantially all of the limited partnership interests in the Operating Partnership and have elected to report our required disclosures and that of the Operating Partnership on a combined basis except where material differences exist.

We have operated as a real estate investment trust (“REIT”) since April 6, 2004, and accordingly, elected REIT status upon the filing in September 2005 of the calendar year 2004 federal income tax return. Accordingly, we will generally not be subject to federal income tax in the United States (“U.S.”), provided that we continue to qualify as a REIT and our distributions to our stockholders equal or exceed our taxable income. Certain activities we undertake must be conducted by entities which we elected to be treated as taxable REIT subsidiaries (“TRSs”). Our TRSs are subject to both U.S. federal and state income taxes. For our properties located outside the U.S., we are subject to local taxes; however, we do not expect to incur additional taxes in the U.S. as such income will flow through our REIT.

Our primary business strategy is to acquire and develop real estate and improvements, primarily for long-term lease to providers of healthcare services such as operators of general acute care hospitals, inpatient physical rehabilitation hospitals, long-term acute care hospitals, surgery centers, centers for treatment of specific conditions such as cardiac, pulmonary, cancer, and neurological hospitals, and other healthcare-oriented facilities. We also make mortgage and other loans to operators of similar facilities. In addition, we may obtain profits or equity interests in our tenants, from time to time, in order to enhance our overall return. We manage our business as a single business segment. All of our properties are located in the U.S. and Europe.

XML 21 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Unaudited Interim Condensed Consolidated Financial Statements: The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information, including rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles (“GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June 30, 2016, are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements.

For information about significant accounting policies, refer to the consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015. During the six months ended June 30, 2016, there were no material changes to these policies.

Recent Accounting Developments:

Revenue from Contracts with Customers

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. Entities may use a full retrospective approach or report the cumulative effect as of the date of adoption. On April 1, 2015, the FASB proposed deferring the effective date of this standard by one year to December 15, 2017, for annual reporting periods beginning after that date. The FASB also proposed permitting early adoption of the standard, but not before the original effective date of December 15, 2016. We are continuing to evaluate this standard; however, we do not expect it to have a significant impact on our financial results, as a substantial portion of our revenue consists of rental income from leasing arrangements, which are specifically excluded from ASU No. 2014-09.

Leases

In February 2016, the FASB issued ASU 2016-02 - Leases, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The ASU is not effective for us until January 1, 2019 with early adoption permitted. We are continuing to evaluate this standard and the impact to us from both a lessor and a lessee perspective.

Measurement of Credit Losses on Financial Instruments

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments, which is intended to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets not recorded at fair value based on historical experience, current conditions, and reasonable and supportable forecasts. The ASU will be required to be implemented through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the amendments are effective. The ASU is not effective for us until January 1, 2019. We do not expect the adoption of the ASU to have a significant impact on our consolidated financial statements.

 

Variable Interest Entities

At June 30, 2016, we had loans to and/or equity investments in certain variable interest entities (“VIEs”), which are also tenants of our facilities, including Ernest Health, Inc. (“Ernest”). We have determined that we are not the primary beneficiary of these VIEs. The carrying value and classification of the related assets and maximum exposure to loss as a result of our involvement with these VIEs are presented below at June 30, 2016 (in thousands):

 

VIE Type

   Maximum Loss
Exposure(1)
     Asset Type
Classification
   Carrying
    Amount(2)    
 

Loans, net

   $ 295,822       Mortgage and other loans    $ 226,101   

Equity investments

   $ 37,309       Other assets    $ 328   

 

(1) Our maximum loss exposure related to loans with VIEs represents our current aggregate gross carrying value of the loan plus accrued interest and any other related assets (such as rent receivables), less any liabilities. Our maximum loss exposure related to our equity investment in VIEs represents the current carrying values of such investment plus any other related assets (such as rent receivables) less any liabilities.
(2) Carrying amount reflects the net book value of our loan or equity interest only in the VIE.

For the VIE types above, we do not consolidate the VIE because we do not have the ability to control the activities (such as the day-to-day healthcare operations of our borrower or investees) that most significantly impact the VIE’s economic performance. As of June 30, 2016, we were not required to provide any material financial support through a liquidity arrangement or otherwise to our unconsolidated VIEs, including circumstances in which it could be exposed to further losses (e.g., cash short falls).

Typically, our loans are collateralized by assets of the borrower (some assets of which are on the premises of facilities owned by us) and further supported by limited guarantees made by certain principals of the borrower.

See Note 3 and 7 for additional description of the nature, purpose and activities of our more significant VIEs and interests therein.

XML 22 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities
6 Months Ended
Jun. 30, 2016
Text Block [Abstract]  
Real Estate and Lending Activities

3. Real Estate and Lending Activities

Acquisitions

We acquired the following assets (in thousands):

 

     Six Months
Ended June 30,
 
     2016      2015  

Assets Acquired

     

Land and land improvements

   $ 9,398       $ 62,434   

Building

     37,593         390,320   

Intangible lease assets — subject to amortization (weighted average useful life 25.8 years)

     —           42,262   

Mortgage loans

     —           40,000   

Net investments in direct financing leases

     63,000         10,700   

Other loans

     —           16,917   
  

 

 

    

 

 

 

Total assets acquired

   $ 109,991       $ 562,633   

Loans repaid (1)

     —           (183,826
  

 

 

    

 

 

 

Total net assets acquired

   $ 109,991       $ 378,807   
  

 

 

    

 

 

 

 

  (1) Loans advanced to MEDIAN in 2014 and repaid in 2015 as a part of the MEDIAN transaction.

The purchase price allocations attributable to the 2016 and certain 2015 acquisitions are preliminary. When all relevant information is obtained, resulting changes, if any, to our provisional purchase price allocation will be retrospectively adjusted to reflect new information obtained about the facts and circumstances that existed as of the respective acquisition dates that, if known, would have affected the measurement of the amounts recognized as of those dates.

2016 Activity

On May 2, 2016, we acquired an acute hospital in Newark, New Jersey for an aggregate purchase price of $63 million leased to Prime Healthcare Services, Inc. (“Prime”) pursuant to a fifth master lease, which has a 15-year term with three five-year extension options, plus consumer price-indexed increases, limited to a 2% floor. Furthermore, we committed to advance an additional $30 million to Prime over a three-year period to be used solely for capital additions to the real estate; any such additions will be added to the basis upon which the lessee will pay us rents.

 

On June 22, 2016, we closed on the final Median Kliniken S.à r.l., (“MEDIAN”) property for a purchase price of €41.6 million. See “2015 Activity” for a description of the initial MEDIAN Transaction.

From the respective acquisition dates, the properties acquired in 2016 contributed $1.1 million of revenue and income (excluding related acquisition expenses), for the three and six months ended June 30, 2016. In addition, we incurred $2.4 million of acquisition-related costs on the 2016 acquisitions for both the three and six months ended June 30, 2016.

2015 Activity

MEDIAN Transaction

On April 29, 2015, we entered into a series of definitive agreements with MEDIAN, a German provider of post-acute and acute rehabilitation services, to acquire the real estate assets of 32 hospitals owned by MEDIAN for an aggregate purchase price of approximately €688 million. Upon acquisition, each property became subject to a master lease between us and MEDIAN providing for the leaseback of the property to MEDIAN. The master lease had an initial term of 27 years and provided for an initial GAAP lease rate of 9.3%, with annual escalators at the greater of one percent or 70% of the German consumer price index.

MEDIAN is owned by an affiliate of Waterland Private Equity Fund V C.V. (“Waterland”), which acquired 94.9% of the outstanding equity interests in MEDIAN, and by a subsidiary of our operating partnership, which acquired the remaining 5.1% of the outstanding equity interests in MEDIAN, each in December 2014. In December 2014, we provided interim acquisition loans to affiliates of Waterland and MEDIAN in connection with Waterland’s acquisition of its stake in MEDIAN in an aggregate amount of approximately €425 million. In addition, we made further loans to MEDIAN during the first half of 2015 in an aggregate amount of approximately €240 million, which were used by MEDIAN to repay existing debt on properties we acquired.

Closing of the sale-leaseback transactions began in the second quarter of 2015. At each closing, the purchase price for each facility was reduced and offset against the interim loans made to affiliates of Waterland and MEDIAN as described above and against the amount of any debt assumed or repaid by us in connection with the closing. As of June 30, 2015, we had closed on 17 properties for an aggregate amount of €317 million.

Other Acquisitions

On June 16, 2015, we acquired the real estate of two facilities in Lubbock, Texas, a 60-bed inpatient rehabilitation hospital and a 37-bed long-term acute care hospital, for an aggregate purchase price of $31.5 million. We entered into a 20-year lease with Ernest for the rehabilitation hospital, which provides for three five-year extension options, and separately entered into a lease with Ernest for the long-term acute care hospital that has a final term ending December 31, 2034. In connection with the transaction, we funded an acquisition loan to Ernest of approximately $12.0 million. Ernest is operating the rehabilitation hospital in a joint venture with Covenant Health System, while the long-term acute care hospital continues to be operated by Fundamental Health under a new sublease with Ernest.

On February 27, 2015, we acquired an inpatient rehabilitation hospital in Weslaco, Texas for $10.7 million leased to Ernest pursuant to the 2012 master lease which had an original 20-year fixed term and three five-year extension options. This lease provides for consumer-priced-indexed annual rent increases, subject to a floor and a cap. In addition, we funded an acquisition loan in the amount of $5 million.

On February 13, 2015, we acquired two general acute care hospitals in the Kansas City area for $110 million. Affiliates of Prime is the tenant and operator pursuant to a new master lease that has similar terms and security enhancements as the other master lease agreements entered into in 2013. This master lease has a 10-year initial fixed term with two extension options of five years each. The lease provides for consumer-price-indexed annual rent increases, subject to a specified floor. In addition, we funded a mortgage loan in the amount of $40 million, which has a 10-year term.

From the respective acquisition dates, the properties and other assets acquired in 2015 contributed $4.2 million and $3.5 million of revenue and income (excluding related acquisition expenses), respectively, for the three months ended June 30, 2015. From the respective acquisition dates, the properties and other assets acquired in 2015 contributed $6.2 million and $4.9 million of revenue and income (excluding related acquisition expenses), respectively, for the six months ended June 30, 2015. In addition, we incurred $22.6 million and $26.7 million of acquisition-related costs on the 2015 acquisitions for the three and six months ended June 30, 2015, respectively.

 

Pro Forma Information

The following unaudited supplemental pro forma operating data is presented for the three and six months ended June 30, 2015, as if each acquisition (including completed development projects) was completed on January 1, 2015. Supplemental pro forma earnings were adjusted to exclude acquisition-related costs on consummated deals incurred. The unaudited supplemental pro forma operating data is not necessarily indicative of what the actual results of operations would have been assuming the transactions had been completed as set forth above, nor do they purport to represent our results of operations for future periods (in thousands, except per share/unit amounts).

 

     For the Three
Months Ended
June 30, 2015
     For the Six
Months Ended
June 30, 2015
 

Total revenues

   $ 109       $ 219   

Net income

   $ 50       $ 100   

Net income per share/unit — diluted

   $ 0.21       $ 0.42   

Development Activities

During the first six months of 2016, we completed construction and began recording rental income on the following facilities:

 

    Adeptus Health, Inc. (“Adeptus Health”) – We completed seven acute care facilities for this tenant during 2016. These facilities are leased pursuant to the master leases entered into in both 2014 and 2015 and are cross-defaulted with each other and with the original master lease executed in 2013.

 

    Ernest Toledo – This inpatient rehabilitation facility located in Toledo, Ohio opened on April 1, 2016 and is being leased to Ernest pursuant to the original 2012 master lease.

See table below for a status update on our current domestic development projects (in thousands):

 

Property

  

Commitment

    

Costs

Incurred

as of

06/30/16

    

Estimated

Completion

Date

 

Adeptus Health

   $ 62,154       $ 43,763         3Q 2016   

Adeptus Health

     53,836         15,343         4Q 2016   

Adeptus Health

     5,730         206         1Q 2017   

Adeptus Health

     61,997         16,311         2Q 2017   

Adeptus Health

     71,331         —           Various   
  

 

 

    

 

 

    
   $ 255,048       $ 75,623      
  

 

 

    

 

 

    

On September 9, 2015, we acquired the real estate of a general acute care hospital under development located in Spain, for an aggregate purchase and development price to us of approximately €21.4 million. The acquisition was effected through a joint venture between us and clients of AXA Real Estate, in which we will own a 50% interest. Upon completion, the facility will be leased to a Spanish operator of acute care hospitals, pursuant to a long-term lease. We expect construction to complete on this facility in the second quarter of 2017.

Disposals

Capella Transaction

On March 21, 2016, we entered into definitive agreements with RegionalCare Hospital Partners, Inc. (“RegionalCare”), an affiliate of certain funds managed by affiliates of Apollo Global Management, LLC (together with its consolidated subsidiaries, “Apollo”), under which our investment in the operations of Capella Healthcare, Inc. (“Capella”) would be merged with RegionalCare, forming RCCH Healthcare Partners (“RCCH”).

 

On April 29, 2016, this transaction closed and funded, effective April 30, 2016. As part of the transaction, we received net proceeds of approximately $550 million including approximately $492 million for our equity investment and loans made as part of the Capella transaction that closed on August 31, 2015. In addition, we received $210 million in prepayment of two mortgage loans for hospitals in Russellville, Arkansas, and Lawton, Oklahoma, that we made to subsidiaries of Capella in connection with the Capella transaction on August 31, 2015. We made a new $93.3 million loan for a hospital property in Olympia, Washington. Additionally, we and an Apollo affiliate invested $50 million each in unsecured senior notes issued by RegionalCare, which we sold to a large institution on June 20, 2016 at par. The proceeds from this transaction represented the recoverability of our investment in full, except for transaction costs incurred of $6.3 million.

We maintained our ownership of five Capella hospitals in Hot Springs, Arkansas; Camden, South Carolina; Hartsville, South Carolina; Muskogee, Oklahoma; and McMinnville, Oregon. Pursuant to the transaction described above, the underlying leases, one of which is a master lease covering all but one property, was amended to shorten the initial fixed lease term, increase the security deposit, and eliminate the lessees’ purchase option provisions. Due to this lease amendment, we reclassified the lease of the properties under the master lease from a direct finance lease (“DFL”) to an operating lease. This reclassification resulted in a write-off of $2.6 million in unbilled DFL rent in the 2016 second quarter.

On July 22, 2016, we acquired the Olympia, Washington property in exchange for the $93.3 million loan and an additional $7 million, which was contemplated in the original Capella transaction. The terms of the Olympia lease will be similar to the other leases with this tenant.

Post Acute Transaction

On May 23, 2016, we sold five properties (three of which were in Texas and two in Louisiana) that were leased and operated by Post Acute Medical (“Post Acute”). As part of this transaction, our outstanding loans of $4 million were paid in full, and we recovered our investment in the operations. Total proceeds from this transaction were $71 million resulting in a net gain of approximately $15 million.

Corinth Transaction

On June 17, 2016, we sold the Atrium Medical Center real estate located in Corinth, Texas, which was leased and operated by Corinth Investor Holdings. Total proceeds from the transaction were $28 million resulting in a gain on real estate of approximately $8 million. This gain on real estate was offset by approximately $9 million of non-cash charges that included the write-off of our investment in the operations of the facility, straight-line rent receivables, and a lease intangible.

HealthSouth Transaction

On May 20, 2016, we reached a firm commitment to sell three inpatient rehabilitation hospitals located in Texas and operated by HealthSouth Corporation (“HealthSouth”) for $111.5 million. At June 30, 2016, these facilities and related net assets were designated as held for sale and included the following (in thousands):

 

Real estate held for sale

   $  63,074   

Straight-line rent receivables

     2,441  

Other, net

     (625
  

 

 

 
   $  64,890   
  

 

 

 

On July 20, 2016, we completed this sale resulting in a net gain of approximately $45 million.

Summary of Operations for Disposed Assets

The properties which sold during the quarter and the assets held for sale at June 30, 2016, do not meet the definition of discontinued operations. However, the following represents the operating results (excluding gain on sale, transaction costs, and impairment or other non-cash charges) from these properties (excluding loans repaid in the Capella Transaction) for the periods presented (in thousands):

 

     For the Three Months      For the Six Months  
     Ended June 30,      Ended June 30,  
     2016      2015      2016      2015  

Revenues

   $ 3,092      $ 4,525      $ 7,607      $ 9,075  

Real estate depreciation and amortization

     (805      (949      (1,754      (1,897

Property-related expenses

     (72      (12      (113      (72

Other income (expense)

     (9      228        (68      557   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income from real estate dispositions, net

   $ 2,206      $ 3,792      $ 5,672      $ 7,663  
  

 

 

    

 

 

    

 

 

    

 

 

 

Leasing Operations

All of our leases are currently accounted for as operating leases except for the master lease of 15 Ernest facilities and six Prime facilities which are accounted for as DFLs. The components of our net investment in DFLs (which includes the Capella properties for 2015 only) consisted of the following (in thousands):

 

     As of June 30,
2016
     As of December 31,
2015
 

Minimum lease payments receivable

   $ 1,875,751       $ 2,587,912   

Estimated residual values

     292,646         393,097   

Less: Unearned income

     (1,639,650      (2,354,013
  

 

 

    

 

 

 

Net investment in direct financing leases

   $ 528,747       $ 626,996   
  

 

 

    

 

 

 

Twelve Oaks Facility

In the third quarter of 2015, we sent notice of termination of the lease to the tenant at our Twelve Oaks facility. This former tenant continues to occupy the facility. We called their letter of credit for approximately $0.5 million in the 2016 first quarter. At June 30, 2016, all past due receivables are fully reserved. Although no assurances can be made that we will not have any impairment charges in the future, we believe our real estate investment in Twelve Oaks at June 30, 2016 is fully recoverable.

Subsequent to June 30, 2016, we received approximately $2.5 million representing substantially all of amounts owed to us and agreed to general terms of a new lease, which we expect to execute during the 2016 third quarter.

 

Loans

The following is a summary of our loans (in thousands):

 

     As of
June 30, 2016
     As of
December 31, 2015
 

Mortgage loans

   $ 549,337       $ 757,581   

Acquisition loans

     216,100         610,469   

Working capital and other loans

     43,229         54,353   
  

 

 

    

 

 

 
   $ 808,666       $ 1,422,403   
  

 

 

    

 

 

 

The decrease in our mortgage and acquisition loans are related to the Capella Transaction as discussed previously.

Our non-mortgage loans typically consist of loans to our tenants for acquisitions and working capital purposes. At June 30, 2016, acquisition loans includes our original $93.2 million loan to Ernest and the $93.3 million loan to RCCH, which was repaid in July as discussed above.

On March 1, 2012, pursuant to our convertible note agreement, we converted $1.7 million of our $5.0 million convertible note into a 9.9% equity interest in the operator of our Hoboken University Medical Center facility. At June 30, 2016, $3.3 million remains outstanding on the convertible note, and we retain the option, subject to regulatory approvals, to convert this remainder into 15.1% of equity interest in the operator.

Concentrations of Credit Risk

Our revenue concentration for the six months ended June 30, 2016 as compared to the prior year is as follows (dollars in thousands):

 

Revenue by Operator

 

     For the Six Months Ended
June 30, 2016
    For the Six Months Ended
June 30, 2015
 

Operators

   Total
Revenue
     Percentage of
Total Revenue
    Total
Revenue
     Percentage of
Total Revenue
 

Prime

   $ 58,859         22.5   $ 49,869         25.5

MEDIAN

     47,745         18.3     32,212         16.5

Ernest

     33,322         12.8     29,695         15.2

RCCH

     32,909         12.6     —           —     

Adeptus Health

     16,205         6.2     7,425         3.8

Revenue by U.S. State and Country

 

     For the Six Months Ended
June 30, 2016
    For the Six Months Ended
June 30, 2015
 

U.S. States and Other Countries

   Total
Revenue
     Percentage of
Total Revenue
    Total
Revenue
     Percentage of
Total Revenue
 

Texas

   $ 48,256         18.5   $ 42,689         21.8

California

     33,187         12.7     33,065         16.9

All other states

     129,896         49.7     85,620         43.7
  

 

 

    

 

 

   

 

 

    

 

 

 

Total U.S.

   $ 211,339         80.9   $ 161,374         82.4

Germany

   $ 47,745         18.3   $ 32,212         16.5

United Kingdom, Italy, and Spain

     2,215         0.8     2,176         1.1
  

 

 

    

 

 

   

 

 

    

 

 

 

Total International

   $ 49,960         19.1   $ 34,388         17.6
  

 

 

    

 

 

   

 

 

    

 

 

 

Grand Total

   $ 261,299         100.0   $ 195,762         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

From an asset basis, our concentration as of June 30, 2016 as compared to December 31, 2015 is as follows (dollars in thousands):

Gross Assets by Operator

 

     As of June 30, 2016     As of December 31, 2015  

Operators

   Total
Gross Assets
     Percentage of
Total Gross Assets
    Total
Gross Assets
     Percentage of
Total Gross Assets
 
     (A)      (B)     (A)      (B)  

Prime

   $ 1,126,654         20.8   $ 1,032,353         17.1

MEDIAN

     1,054,368         19.4     1,031,039         17.1

Ernest

     584,411         10.8     579,182         9.6

Adeptus Health

     500,000         9.2     500,000         8.3

RCCH

     458,659         8.5     1,059,989         17.6

 

Gross Assets by U.S. State and Country

 

     As of June 30, 2016     As of December 31, 2015  
U.S. States and Other Countries    Total
Gross Assets
     Percentage of
Total Gross Assets
    Total
Gross Assets
     Percentage of
Total Gross Assets
 
     (A)      (B)     (A)      (B)  

Texas

   $ 920,959         17.0   $ 1,060,990         17.6

California

     547,079         10.1     547,085         9.1

All other states

     2,530,018         46.6     3,047,204         50.5

Other domestic assets

     189,358         3.5     177,317         2.9
  

 

 

    

 

 

   

 

 

    

 

 

 

Total U.S.

   $ 4,187,414         77.2   $ 4,832,596         80.1

Germany

   $ 1,054,368         19.4   $ 1,031,039         17.1

United Kingdom, Italy, and Spain

     156,630         3.0     161,317         2.7

Other international assets

     23,983         0.4     10,970         0.1
  

 

 

    

 

 

   

 

 

    

 

 

 

Total International

   $ 1,234,981         22.8   $ 1,203,326         19.9
  

 

 

    

 

 

   

 

 

    

 

 

 

Grand Total

   $ 5,422,395         100.0   $ 6,035,922         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

 

(A) Gross Assets represents total assets plus accumulated depreciation/amortization assuming all real estate commitments as of the period end are fully funded.
(B) Includes both leased and loaned assets.

On an individual property basis, we had no investment of any single property greater than 2.3% of our total assets as of June 30, 2016.

XML 23 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt
6 Months Ended
Jun. 30, 2016
Debt Disclosure [Abstract]  
Debt

4. Debt

The following is a summary of our debt (dollar amounts in thousands):

 

     As of June 30, 2016     As of December 31, 2015  
     Balance      Interest Rate     Balance      Interest Rate  

Revolving credit facility

   $ 25,000         Variable      $ 1,100,000         Variable   

2006 Senior Unsecured Notes

     125,000         Various        125,000         Various   

2011 Senior Unsecured Notes

     450,000         6.875     450,000         6.875

2012 Senior Unsecured Notes:

          

Principal amount

     350,000         6.375     350,000         6.375

Unamortized premium

     1,991           2,168      
  

 

 

      

 

 

    
     351,991           352,168      

2013 Senior Unsecured Notes (A)

     222,120         5.750     217,240         5.750

2014 Senior Unsecured Notes

     300,000         5.500     300,000         5.500

2015 Senior Unsecured Notes (A)

     555,300         4.000     543,100         4.000

2016 Senior Unsecured Notes

     500,000         6.375     —          —    

Term loans

     263,253         Various        263,400         Various   
  

 

 

      

 

 

    
   $ 2,792,664         $ 3,350,908      

Debt issue costs, net

     (34,029        (28,367   
  

 

 

      

 

 

    
   $ 2,758,635         $ 3,322,541      
  

 

 

      

 

 

    

 

(A) These notes are Euro-denominated and reflect the exchange rate at June 30, 2016 and December 31, 2015, respectively.

 

As of June 30, 2016, principal payments due on our debt (which exclude the effects of any discounts, premiums, or debt issue costs recorded) are as follows (in thousands):

 

2016

   $ 125,152 (A) 

2017

     320   

2018

     37,781   

2019

     250,000   

2020

     222,120   

Thereafter

     2,155,300   
  

 

 

 

Total

   $ 2,790,673   
  

 

 

 

 

(A) $65 million of our 2006 Senior Unsecured Notes were paid in full in July 2016, while the remaining $60 million will mature in October 2016.

On February 22, 2016, we completed a $500 million senior unsecured notes offering (“2016 Senior Unsecured Notes”), proceeds of which were used to repay borrowings under our revolving credit facility. Interest on the notes will be payable on March 1 and September 1 of each year, commencing on September 1, 2016. Interest on the notes will be paid in cash at a rate of 6.375% per year. The notes mature on March 1, 2024. We may redeem some or all of the notes at any time prior to March 1, 2019 at a “make whole” redemption price. On or after March 1, 2019, we may redeem some or all of the notes at a premium that will decrease over time. In addition, at any time prior to March 1, 2019, we may redeem up to 35% of the notes at a redemption price equal to 106.375% of the aggregate principal amount thereof, plus accrued and unpaid interest thereon, using proceeds from one or more equity offerings. In the event of a change in control, each holder of the notes may require us to repurchase some or all of the notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest to the date of purchase.

During the second quarter 2010, we entered into an interest rate swap to manage our exposure to variable interest rates by fixing $65 million of our 2006 Senior Unsecured Notes, which started July 31, 2011 (date on which the interest rate turned variable) through maturity date (or July 2016), at a rate of 5.507%. We also entered into an interest rate swap to fix $60 million of our 2006 Senior Unsecured Notes which started October 31, 2011 (date on which the related interest rate turned variable) through the maturity date (or October 2016) at a rate of 5.675%. The fair value of the interest rate swaps was $1.3 million and $2.9 million as of June 30, 2016 and December 31, 2015, respectively, which is reflected in accounts payable and accrued expenses on the consolidated balance sheets.

We account for our interest rate swaps as cash flow hedges. Accordingly, the effective portion of changes in the fair value of our swaps is recorded as a component of accumulated other comprehensive income/loss on the balance sheet and reclassified into earnings in the same period, or periods, during which the hedged transactions effect earnings, while any ineffective portion is recorded through earnings immediately. We did not have any hedge ineffectiveness from inception of our interest rate swaps through June 30, 2016 and therefore, there was no income statement effect recorded during the three and six month periods ended June 30, 2016 or 2015. We do expect current losses included in accumulated other comprehensive loss to be reclassified into earnings through October 2016. At June 30, 2016 and December 31, 2015, we have posted $0.8 million and $1.7 million of collateral related to our interest rate swaps, respectively, which is reflected in other assets on our consolidated balance sheets.

Covenants

Our debt facilities impose certain restrictions on us, including restrictions on our ability to: incur debts; create or incur liens; provide guarantees in respect of obligations of any other entity; make redemptions and repurchases of our capital stock; prepay, redeem or repurchase debt; engage in mergers or consolidations; enter into affiliated transactions; dispose of real estate or other assets; and change our business. In addition, the credit agreements governing our revolving credit facility and term loan limit the amount of dividends we can pay as a percentage of normalized adjusted funds from operations (“FFO”), as defined in the agreements, on a rolling four quarter basis. At June 30, 2016, the dividend restriction was 95% of normalized adjusted FFO. The indentures governing our senior unsecured notes also limit the amount of dividends we can pay based on the sum of 95% of funds from operations, proceeds of equity issuances and certain other net cash proceeds. Finally, our senior unsecured notes require us to maintain total unencumbered assets (as defined in the related indenture) of not less than 150% of our unsecured indebtedness.

In addition to these restrictions, the revolving credit facility and term loan contain customary financial and operating covenants, including covenants relating to our total leverage ratio, fixed charge coverage ratio, secured leverage ratio, consolidated adjusted net worth, unsecured leverage ratio, and unsecured interest coverage ratio. This facility also contains customary events of default, including among others, nonpayment of principal or interest, material inaccuracy of representations and failure to comply with our covenants. If an event of default occurs and is continuing under the facility, the entire outstanding balance may become immediately due and payable. At June 30, 2016, we were in compliance with all such financial and operating covenants.

 

At June 30, 2016, the unsecured leverage ratio covenant was 77.5%. In September 2016, the unsecured leverage ratio will reset to 65%. We are currently in compliance with the reset leverage covenant.

XML 24 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Common Stock/Partners' Capital
6 Months Ended
Jun. 30, 2016
Equity [Abstract]  
Common Stock/Partners' Capital

5. Common Stock/Partners’ Capital

Medical Properties Trust, Inc.

On March 1, 2016, we updated our at-the-market equity offering program, which gives us the ability to sell up to $227 million of stock with a commission rate of 1.25%. During the six months ended June 30, 2016, we sold approximately 3 million shares of our common stock under this program, resulting in net proceeds of approximately $45 million, after deducting approximately $0.6 million of commissions.

On January 14, 2015, we completed an underwritten public offering of 34.5 million shares (including the exercise of the underwriters’ 30-day option to purchase an additional 4.5 million shares) of our common stock, resulting in net proceeds of approximately $480 million, after deducting estimated offering expenses.

MPT Operating Partnership, L.P.

At June 30, 2016, the Company has a 99.83% ownership interest in the Operating Partnership with the remainder owned by three other partners, two of whom are employees and one of whom is a director. During the six months ended June 30, 2016 and 2015, the Operating Partnership issued 3 million units and 34.5 million units, respectively, in direct response to the common stock offerings by Medical Properties Trust, Inc.

XML 25 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock Awards
6 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Awards

6. Stock Awards

We adopted the 2013 Equity Incentive Plan (the “Equity Incentive Plan”) during the second quarter of 2013, which authorizes the issuance of common stock options, restricted stock, restricted stock units, deferred stock units, stock appreciation rights, performance units and awards of interests in our Operating Partnership. The Equity Incentive Plan is administered by the Compensation Committee of the Board of Directors. We have reserved 8,196,770 shares of common stock for awards under the Equity Incentive Plan for which 5,615,497 shares remain available for future stock awards as of June 30, 2016. We awarded the following stock awards during 2016 and 2015:

Time-based awards —We granted 45,528 shares to independent directors in 2016 and 217,177 shares to management, independent directors and certain employees in time-based restricted stock. These awards vest quarterly based on service, over three years, in equal amounts.

Performance-based awards —Our management team and certain employees were awarded 176,046 shares of performance based awards in 2015. No such awards have been granted in 2016. These awards vest ratably over a three-year period based on the achievement of certain total shareholder return measures, with a carry-back and carry-forward provision through December 31, 2017. Dividends on these awards are paid only upon achievement of the performance measures.

Multi-year Performance-based awards —We awarded 505,050 shares in 2015 of multi-year performance-based awards to management. No such awards have been granted in 2016. These shares are subject to three-year cumulative performance hurdles based on measures of total shareholder return. At the end of the three-year performance period, any earned shares will be subject to an additional two years of ratable time-based vesting on an annual basis. Dividends are paid on these shares only upon achievement of the performance measures.

XML 26 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments
6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments

7. Fair Value of Financial Instruments

We have various assets and liabilities that are considered financial instruments. We estimate that the carrying value of cash and cash equivalents, and accounts payable and accrued expenses approximate their fair values. Included in our accounts payable and accrued expenses are our interest rate swaps, which are recorded at fair value based on Level 2 observable market assumptions using standardized derivative pricing models. We estimate the fair value of our interest and rent receivables using Level 2 inputs such as discounting the estimated future cash flows using the current rates at which similar receivables would be made to others with similar credit ratings and for the same remaining maturities. The fair value of our mortgage loans and working capital loans are estimated by using Level 2 inputs such as discounting the estimated future cash flows using the current rates which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities. We determine the fair value of our senior unsecured notes (excluding our 2006 Senior Unsecured Notes) using Level 2 inputs such as quotes from securities dealers and market makers. We estimate the fair value of our 2006 Senior Unsecured Notes, our revolving credit facility, and term loans using Level 2 inputs based on the present value of future payments, discounted at a rate which we consider appropriate for such debt.

 

Fair value estimates are made at a specific point in time, are subjective in nature, and involve uncertainties and matters of significant judgment. Settlement of such fair value amounts may not be possible and may not be a prudent management decision. The following table summarizes fair value estimates for our financial instruments (in thousands):

 

     June 30, 2016      December 31, 2015  

Asset (Liability)

   Book
Value
     Fair
Value
     Book
Value
     Fair
Value
 

Interest and rent receivables

   $ 47,699       $ 47,653       $ 46,939       $ 46,858   

Loans (1)

     590,037         623,399         508,851         543,859   

Debt, net

     (2,758,635      (2,863,382      (3,322,541      (3,372,773

 

(1) Excludes loans related to Ernest and Capella (2015 only) since they are recorded at fair value and discussed below.

Items Measured at Fair Value on a Recurring Basis

Our equity interest in Ernest and related loans, which were acquired in 2012, are being measured at fair value on a recurring basis as we elected to account for these investments using the fair value option method. We have elected to account for these investments at fair value due to the size of the investments and because we believe this method is more reflective of current values. We have not made a similar election for other equity interests or loans made in or prior to 2016, except for our investments in Capella that were disposed of in the 2016 second quarter.

At June 30, 2016, these amounts were as follows (in thousands):

 

Asset Type

   Fair
Value
     Cost      Asset Type
Classification
 

Mortgage loans

   $ 101,762       $ 101,762         Mortgage loans   

Acquisition and other loans

     116,867         116,867         Other loans   

Equity investments

     3,300         3,300         Other assets   
  

 

 

    

 

 

    
   $ 221,929       $ 221,929      
  

 

 

    

 

 

    

Our mortgage loans with Ernest are recorded at fair value based on Level 2 inputs by discounting the estimated cash flows using the market rates which similar loans would be made to borrowers with similar credit ratings and the same remaining maturities. Our acquisition loans and equity investments in Ernest are recorded at fair value based on Level 3 inputs, by using a discounted cash flow model, which requires significant estimates of our investee such as projected revenue and expenses and appropriate consideration of the underlying risk profile of the forecast assumptions associated with the investee. We classify these loans and equity investments as Level 3, as we use certain unobservable inputs to the valuation methodology that are significant to the fair value measurement, and the valuation requires management judgment due to the absence of quoted market prices. For these cash flow models, our observable inputs include use of a capitalization rate, discount rate (which is based on a weighted-average cost of capital), and market interest rates, and our unobservable input includes an adjustment for a marketability discount (“DLOM”) on our equity investment of 40% at June 30, 2016.

In regards to the underlying projection of revenues and expenses used in the discounted cash flow model, such projections are provided by Ernest. However, we will modify such projections (including underlying assumptions used) as needed based on our review and analysis of Ernest’s historical results, meetings with key members of management, and our understanding of trends and developments within the healthcare industry.

In arriving at the DLOM, we started with a DLOM range based on the results of studies supporting valuation discounts for other transactions or structures without a public market. To select the appropriate DLOM within the range, we then considered many qualitative factors including the percent of control, the nature of the underlying investee’s business along with our rights as an investor pursuant to the operating agreement, the size of investment, expected holding period, number of shareholders, access to capital marketplace, etc. To illustrate the effect of movements in the DLOM, we performed a sensitivity analysis below by using basis point variations (dollars in thousands):

 

Basis Point Change in Marketability Discount

   Estimated Increase (Decrease)
In Fair Value
 

+100 basis points

   $ (54

- 100 basis points

     54   

Because the fair value of Ernest investments noted above approximate their original cost, we did not recognize any unrealized gains/losses during the first half of 2016 or 2015.

XML 27 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share/Common Unit
6 Months Ended
Jun. 30, 2016
Earnings Per Share [Abstract]  
Earnings Per Share/Common Unit

8. Earnings Per Share/Common Unit

Medical Properties Trust, Inc.

Our earnings per share were calculated based on the following (in thousands):

 

     For the Three Months
Ended June 30,
 
     2016      2015  

Numerator:

     

Income from continuing operations

   $ 53,924       $ 22,489   

Non-controlling interests’ share in continuing operations

     (200      (82

Participating securities’ share in earnings

     (132      (250
  

 

 

    

 

 

 

Income from continuing operations, less participating securities’ share in earnings

     53,592         22,157   

Income from discontinued operations attributable to MPT common stockholders

     —          —    
  

 

 

    

 

 

 

Net income, less participating securities’ share in earnings

   $ 53,592       $ 22,157   
  

 

 

    

 

 

 

Denominator:

     

Basic weighted-average common shares

     238,082         208,071   

Dilutive potential common shares

     926         569   
  

 

 

    

 

 

 

Dilutive weighted-average common shares

     239,008         208,640   
  

 

 

    

 

 

 

 

     For the Six Months
Ended June 30,
 
     2016      2015  

Numerator:

     

Income from continuing operations

   $ 112,150       $ 58,465   

Non-controlling interests’ share in continuing operations

     (498      (161

Participating securities’ share in earnings

     (276      (516
  

 

 

    

 

 

 

Income from continuing operations, less participating securities’ share in earnings

     111,376         57,788   

Loss from discontinued operations attributable to MPT common stockholders

     (1      —    
  

 

 

    

 

 

 

Net income, less participating securities’ share in earnings

   $ 111,375       $ 57,788   
  

 

 

    

 

 

 

Denominator:

     

Basic weighted-average common shares

     237,796         205,515   

Dilutive potential common shares

     617         612   
  

 

 

    

 

 

 

Dilutive weighted-average common shares

     238,413         206,127   
  

 

 

    

 

 

 

 

MPT Operating Partnership, L.P.

Our earnings per common unit were calculated based on the following (in thousands):

 

     For the Three Months
Ended June 30,
 
     2016      2015  

Numerator:

     

Income from continuing operations

   $ 53,924       $ 22,489   

Non-controlling interests’ share in continuing operations

     (200      (82

Participating securities’ share in earnings

     (132      (250
  

 

 

    

 

 

 

Income from continuing operations, less participating securities’ share in earnings

     53,592         22,157   

Income from discontinued operations attributable to MPT Operating Partnership partners

     —           —    
  

 

 

    

 

 

 

Net income, less participating securities’ share in earnings

   $ 53,592       $ 22,157   
  

 

 

    

 

 

 

Denominator:

     

Basic weighted-average units

     238,082         208,071   

Dilutive potential units

     926         569   
  

 

 

    

 

 

 

Dilutive weighted-average units

     239,008         208,640   
  

 

 

    

 

 

 

 

     For the Six Months
Ended June 30,
 
     2016      2015  

Numerator:

     

Income from continuing operations

   $ 112,150       $ 58,465   

Non-controlling interests’ share in continuing operations

     (498      (161

Participating securities’ share in earnings

     (276      (516
  

 

 

    

 

 

 

Income from continuing operations, less participating securities’ share in earnings

     111,376         57,788   

Loss from discontinued operations attributable to MPT Operating Partnership partners

     (1      —    
  

 

 

    

 

 

 

Net income, less participating securities’ share in earnings

   $ 111,375       $ 57,788   
  

 

 

    

 

 

 

Denominator:

     

Basic weighted-average units

     237,796         205,515   

Dilutive potential units

     617         612   
  

 

 

    

 

 

 

Dilutive weighted-average units

     238,413         206,127   
  

 

 

    

 

 

 

XML 28 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

9. Commitments and Contingencies

Contingencies

We are a party to various legal proceedings incidental to our business. In the opinion of management, after consultation with legal counsel, the ultimate liability, if any, with respect to those proceedings is not presently expected to materially affect our financial position, results of operations or cash flows.

XML 29 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Subsequent Events
6 Months Ended
Jun. 30, 2016
Subsequent Events [Abstract]  
Subsequent Events

10. Subsequent Events

Stock Issuance

During the month of July, we sold 2.7 million shares of common stock under our at-the-market program generating net proceeds of $41.1 million.

Bond Issuance

On July 22, 2016, we completed a $500 million senior unsecured notes offering. Interest on the notes will be payable on February 1 and August 1 of each year, commencing on February 1, 2017. Interest on the notes will be paid in cash at a rate of 5.25% per year. The notes mature on August 1, 2026. We may redeem some or all of the notes at any time prior to August 1, 2021 at a “make whole” redemption price. On or after August 1, 2021, we may redeem some or all of the notes at a premium that will decrease over time. In addition, at any time prior to August 1, 2019, we may redeem up to 35% of the notes at a redemption price equal to 105.25% of the aggregate principal amount thereof, plus accrued and unpaid interest thereon, using proceeds from one or more equity offerings. In the event of a change in control, each holder of the notes may require us to repurchase some or all of the notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest to the date of purchase.

We used the net proceeds from this offering to redeem our $450 million 2011 bonds, which will be completed on August 12, 2016. We expect to incur a one-time charge related to the redemption of approximately $23 million.

XML 30 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Financial Statements: The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information, including rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles (“GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June 30, 2016, are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements.

For information about significant accounting policies, refer to the consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015. During the six months ended June 30, 2016, there were no material changes to these policies.

Recent Accounting Developments

Recent Accounting Developments:

Revenue from Contracts with Customers

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. Entities may use a full retrospective approach or report the cumulative effect as of the date of adoption. On April 1, 2015, the FASB proposed deferring the effective date of this standard by one year to December 15, 2017, for annual reporting periods beginning after that date. The FASB also proposed permitting early adoption of the standard, but not before the original effective date of December 15, 2016. We are continuing to evaluate this standard; however, we do not expect it to have a significant impact on our financial results, as a substantial portion of our revenue consists of rental income from leasing arrangements, which are specifically excluded from ASU No. 2014-09.

Leases

In February 2016, the FASB issued ASU 2016-02 - Leases, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The ASU is not effective for us until January 1, 2019 with early adoption permitted. We are continuing to evaluate this standard and the impact to us from both a lessor and a lessee perspective.

Measurement of Credit Losses on Financial Instruments

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments, which is intended to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets not recorded at fair value based on historical experience, current conditions, and reasonable and supportable forecasts. The ASU will be required to be implemented through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the amendments are effective. The ASU is not effective for us until January 1, 2019. We do not expect the adoption of the ASU to have a significant impact on our consolidated financial statements.

Variable Interest Entities

Variable Interest Entities

At June 30, 2016, we had loans to and/or equity investments in certain variable interest entities (“VIEs”), which are also tenants of our facilities, including Ernest Health, Inc. (“Ernest”). We have determined that we are not the primary beneficiary of these VIEs. The carrying value and classification of the related assets and maximum exposure to loss as a result of our involvement with these VIEs are presented below at June 30, 2016 (in thousands):

 

VIE Type

   Maximum Loss
Exposure(1)
     Asset Type
Classification
   Carrying
    Amount(2)    
 

Loans, net

   $ 295,822       Mortgage and other loans    $ 226,101   

Equity investments

   $ 37,309       Other assets    $ 328   

 

(1) Our maximum loss exposure related to loans with VIEs represents our current aggregate gross carrying value of the loan plus accrued interest and any other related assets (such as rent receivables), less any liabilities. Our maximum loss exposure related to our equity investment in VIEs represents the current carrying values of such investment plus any other related assets (such as rent receivables) less any liabilities.
(2) Carrying amount reflects the net book value of our loan or equity interest only in the VIE.

For the VIE types above, we do not consolidate the VIE because we do not have the ability to control the activities (such as the day-to-day healthcare operations of our borrower or investees) that most significantly impact the VIE’s economic performance. As of June 30, 2016, we were not required to provide any material financial support through a liquidity arrangement or otherwise to our unconsolidated VIEs, including circumstances in which it could be exposed to further losses (e.g., cash short falls).

Typically, our loans are collateralized by assets of the borrower (some assets of which are on the premises of facilities owned by us) and further supported by limited guarantees made by certain principals of the borrower.

See Note 3 and 7 for additional description of the nature, purpose and activities of our more significant VIEs and interests therein.

XML 31 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Carrying Value and Classification of Related Assets and Maximum Exposure to Loss
The carrying value and classification of the related assets and maximum exposure to loss as a result of our involvement with these VIEs are presented below at June 30, 2016 (in thousands):

 

VIE Type

   Maximum Loss
Exposure(1)
     Asset Type
Classification
   Carrying
    Amount(2)    
 

Loans, net

   $ 295,822       Mortgage and other loans    $ 226,101   

Equity investments

   $ 37,309       Other assets    $ 328   

 

(1) Our maximum loss exposure related to loans with VIEs represents our current aggregate gross carrying value of the loan plus accrued interest and any other related assets (such as rent receivables), less any liabilities. Our maximum loss exposure related to our equity investment in VIEs represents the current carrying values of such investment plus any other related assets (such as rent receivables) less any liabilities.
(2) Carrying amount reflects the net book value of our loan or equity interest only in the VIE.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities (Tables)
6 Months Ended
Jun. 30, 2016
Text Block [Abstract]  
Assets Acquired

We acquired the following assets (in thousands):

 

     Six Months
Ended June 30,
 
     2016      2015  

Assets Acquired

     

Land and land improvements

   $ 9,398       $ 62,434   

Building

     37,593         390,320   

Intangible lease assets — subject to amortization (weighted average useful life 25.8 years)

     —           42,262   

Mortgage loans

     —           40,000   

Net investments in direct financing leases

     63,000         10,700   

Other loans

     —           16,917   
  

 

 

    

 

 

 

Total assets acquired

   $ 109,991       $ 562,633   

Loans repaid (1)

     —           (183,826
  

 

 

    

 

 

 

Total net assets acquired

   $ 109,991       $ 378,807   
  

 

 

    

 

 

 

 

  (1) Loans advanced to MEDIAN in 2014 and repaid in 2015 as a part of the MEDIAN transaction.
Schedule of Unaudited Supplemental Pro Forma Operating Data

The following unaudited supplemental pro forma operating data is presented for the three and six months ended June 30, 2015, as if each acquisition (including completed development projects) was completed on January 1, 2015. Supplemental pro forma earnings were adjusted to exclude acquisition-related costs on consummated deals incurred. The unaudited supplemental pro forma operating data is not necessarily indicative of what the actual results of operations would have been assuming the transactions had been completed as set forth above, nor do they purport to represent our results of operations for future periods (in thousands, except per share/unit amounts).

 

     For the Three
Months Ended
June 30, 2015
     For the Six
Months Ended
June 30, 2015
 

Total revenues

   $ 109       $ 219   

Net income

   $ 50       $ 100   

Net income per share/unit — diluted

   $ 0.21       $ 0.42   

Summary of Status Update on Current Development Projects

See table below for a status update on our current domestic development projects (in thousands):

 


Property

  

Commitment

    

Costs

Incurred

as of

06/30/16

    

Estimated

Completion

Date

 

Adeptus Health

   $ 62,154       $ 43,763         3Q 2016   

Adeptus Health

     53,836         15,343         4Q 2016   

Adeptus Health

     5,730         206         1Q 2017   

Adeptus Health

     61,997         16,311         2Q 2017   

Adeptus Health

     71,331         —           Various   
  

 

 

    

 

 

    
   $ 255,048       $ 75,623      
  

 

 

    

 

 

    
Summary of Facilities and Related Net Assets Designated as Held for Sale

On May 20, 2016, we reached a firm commitment to sell three inpatient rehabilitation hospitals located in Texas and operated by HealthSouth for $111.5 million. At June 30, 2016, these facilities and related net assets were designated as held for sale and included the following (in thousands):

 

Real estate held for sale

   $  63,074   

Straight-line rent receivables

     2,441  

Other, net

     (625
  

 

 

 
   $  64,890   
  

 

 

 
Summary of Operations for Disposed Assets

The properties which sold during the quarter and the assets held for sale at June 30, 2016, do not meet the definition of discontinued operations. However, the following represents the operating results (excluding gain on sale, transaction costs, and impairment or other non-cash charges) from these properties for the periods presented (in thousands):

 

     For the Three Months      For the Six Months  
     Ended June 30,      Ended June 30,  
     2016      2015      2016      2015  

Revenues

   $ 3,092      $ 4,525      $ 7,607      $ 9,075  

Real estate depreciation and amortization

     (805      (949      (1,754      (1,897

Property-related expenses

     (72      (12      (113      (72

Other income (expense)

     (9      228        (68      557   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income from real estate dispositions, net

   $ 2,206      $ 3,792      $ 5,672      $ 7,663  
  

 

 

    

 

 

    

 

 

    

 

 

Components of Net Investment in Direct Financing Leases

The components of our net investment in DFLs (which includes the Capella properties for 2015 only) consisted of the following (in thousands):

 

     As of June 30,
2016
     As of December 31,
2015
 

Minimum lease payments receivable

   $ 1,875,751       $ 2,587,912   

Estimated residual values

     292,646         393,097   

Less: Unearned income

     (1,639,650      (2,354,013
  

 

 

    

 

 

 

Net investment in direct financing leases

   $ 528,747       $ 626,996   
  

 

 

    

 

 

 

Summary of Loans

The following is a summary of our loans (in thousands):

 

     As of
June 30, 2016
     As of
December 31, 2015
 

Mortgage loans

   $ 549,337       $ 757,581   

Acquisition loans

     216,100         610,469   

Working capital and other loans

     43,229         54,353   
  

 

 

    

 

 

 
   $ 808,666       $ 1,422,403   
  

 

 

    

 

 

 

Schedule of Revenue by Operator

Revenue by Operator

 

     For the Six Months Ended
June 30, 2016
    For the Six Months Ended
June 30, 2015
 

Operators

   Total
Revenue
     Percentage of
Total Revenue
    Total
Revenue
     Percentage of
Total Revenue
 

Prime

   $ 58,859         22.5   $ 49,869         25.5

MEDIAN

     47,745         18.3     32,212         16.5

Ernest

     33,322         12.8     29,695         15.2

RCCH

     32,909         12.6     —           —     

Adeptus Health

     16,205         6.2     7,425         3.8

Schedule of Revenue from External Customers by Geographic Areas

Revenue by U.S. State and Country

 

     For the Six Months Ended
June 30, 2016
    For the Six Months Ended
June 30, 2015
 

U.S. States and Other Countries

   Total
Revenue
     Percentage of
Total Revenue
    Total
Revenue
     Percentage of
Total Revenue
 

Texas

   $ 48,256         18.5   $ 42,689         21.8

California

     33,187         12.7     33,065         16.9

All other states

     129,896         49.7     85,620         43.7
  

 

 

    

 

 

   

 

 

    

 

 

 

Total U.S.

   $ 211,339         80.9   $ 161,374         82.4

Germany

   $ 47,745         18.3   $ 32,212         16.5

United Kingdom, Italy, and Spain

     2,215         0.8     2,176         1.1
  

 

 

    

 

 

   

 

 

    

 

 

 

Total International

   $ 49,960         19.1   $ 34,388         17.6
  

 

 

    

 

 

   

 

 

    

 

 

 

Grand Total

   $ 261,299         100.0   $ 195,762         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 
Schedule of Gross Assets by Operator

Gross Assets by Operator

 

     As of June 30, 2016     As of December 31, 2015  

Operators

   Total
Gross Assets
     Percentage of
Total Gross Assets
    Total
Gross Assets
     Percentage of
Total Gross Assets
 
     (A)      (B)     (A)      (B)  

Prime

   $ 1,126,654         20.8   $ 1,032,353         17.1

MEDIAN

     1,054,368         19.4     1,031,039         17.1

Ernest

     584,411         10.8     579,182         9.6

Adeptus Health

     500,000         9.2     500,000         8.3

RCCH

     458,659         8.5     1,059,989         17.6
Schedule of Gross Assets by Geographic Areas

Gross Assets by U.S. State and Country

 

     As of June 30, 2016     As of December 31, 2015  
U.S. States and Other Countries    Total
Gross Assets
     Percentage of
Total Gross Assets
    Total
Gross Assets
     Percentage of
Total Gross Assets
 
     (A)      (B)     (A)      (B)  

Texas

   $ 920,959         17.0   $ 1,060,990         17.6

California

     547,079         10.1     547,085         9.1

All other states

     2,530,018         46.6     3,047,204         50.5

Other domestic assets

     189,358         3.5     177,317         2.9
  

 

 

    

 

 

   

 

 

    

 

 

 

Total U.S.

   $ 4,187,414         77.2   $ 4,832,596         80.1

Germany

   $ 1,054,368         19.4   $ 1,031,039         17.1

United Kingdom, Italy, and Spain

     156,630         3.0     161,317         2.7

Other international assets

     23,983         0.4     10,970         0.1
  

 

 

    

 

 

   

 

 

    

 

 

 

Total International

   $ 1,234,981         22.8   $ 1,203,326         19.9
  

 

 

    

 

 

   

 

 

    

 

 

 

Grand Total

   $ 5,422,395         100.0   $ 6,035,922         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

 

(A) Gross Assets represents total assets plus accumulated depreciation/amortization assuming all real estate commitments as of the period end are fully funded.
(B) Includes both leased and loaned assets.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt (Tables)
6 Months Ended
Jun. 30, 2016
Debt Disclosure [Abstract]  
Summary of Debt

The following is a summary of our debt (dollar amounts in thousands):

 

     As of June 30, 2016     As of December 31, 2015  
     Balance      Interest Rate     Balance      Interest Rate  

Revolving credit facility

   $ 25,000         Variable      $ 1,100,000         Variable   

2006 Senior Unsecured Notes

     125,000         Various        125,000         Various   

2011 Senior Unsecured Notes

     450,000         6.875     450,000         6.875

2012 Senior Unsecured Notes:

          

Principal amount

     350,000         6.375     350,000         6.375

Unamortized premium

     1,991           2,168      
  

 

 

      

 

 

    
     351,991           352,168      

2013 Senior Unsecured Notes (A)

     222,120         5.750     217,240         5.750

2014 Senior Unsecured Notes

     300,000         5.500     300,000         5.500

2015 Senior Unsecured Notes (A)

     555,300         4.000     543,100         4.000

2016 Senior Unsecured Notes

     500,000         6.375     —          —    

Term loans

     263,253         Various        263,400         Various   
  

 

 

      

 

 

    
   $ 2,792,664         $ 3,350,908      

Debt issue costs, net

     (34,029        (28,367   
  

 

 

      

 

 

    
   $ 2,758,635         $ 3,322,541      
  

 

 

      

 

 

    

 

(A) These notes are Euro-denominated and reflect the exchange rate at June 30, 2016 and December 31, 2015, respectively.
Principal Payments Due on Debt

As of June 30, 2016, principal payments due on our debt (which exclude the effects of any discounts, premiums, or debt issue costs recorded) are as follows (in thousands):

 

2016

   $ 125,152 (A) 

2017

     320   

2018

     37,781   

2019

     250,000   

2020

     222,120   

Thereafter

     2,155,300   
  

 

 

 

Total

   $ 2,790,673   
  

 

 

 

 

(A) $65 million of our 2006 Senior Unsecured Notes were paid in full on in July 2016, while the remaining $60 million will mature in and October 2016.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments (Tables)
6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Summary of Fair Value Information of Financial Instruments

The following table summarizes fair value estimates for our financial instruments (in thousands):

 

     June 30, 2016      December 31, 2015  

Asset (Liability)

   Book
Value
     Fair
Value
     Book
Value
     Fair
Value
 

Interest and rent receivables

   $ 47,699       $ 47,653       $ 46,939       $ 46,858   

Loans (1)

     590,037         623,399         508,851         543,859   

Debt, net

     (2,758,635      (2,863,382      (3,322,541      (3,372,773

 

(1) Excludes loans related to Ernest and Capella (2015 only) since they are recorded at fair value and discussed below.
Equity Interest in Related Party and Related Loans Measured at Fair Value on Recurring Basis

At June 30, 2016, these amounts were as follows (in thousands):

 


Asset Type

   Fair
Value
     Cost      Asset Type
Classification
 

Mortgage loans

   $ 101,762       $ 101,762         Mortgage loans   

Acquisition and other loans

     116,867         116,867         Other loans   

Equity investments

     3,300         3,300         Other assets   
  

 

 

    

 

 

    
   $ 221,929       $ 221,929      
  

 

 

    

 

 

    
Summary Showing Sensitivity Analysis by Using Basis Point Variations

To illustrate the effect of movements in the DLOM, we performed a sensitivity analysis below by using basis point variations (dollars in thousands):

 

Basis Point Change in Marketability Discount

   Estimated Increase (Decrease)
In Fair Value
 

+100 basis points

   $ (54

- 100 basis points

     54   

XML 35 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share/Common Unit (Tables)
6 Months Ended
Jun. 30, 2016
Earnings Per Share [Abstract]  
Calculation of Earnings Per Share

Medical Properties Trust, Inc.

Our earnings per share were calculated based on the following (in thousands):

 

     For the Three Months
Ended June 30,
 
     2016      2015  

Numerator:

     

Income from continuing operations

   $ 53,924       $ 22,489   

Non-controlling interests’ share in continuing operations

     (200      (82

Participating securities’ share in earnings

     (132      (250
  

 

 

    

 

 

 

Income from continuing operations, less participating securities’ share in earnings

     53,592         22,157   

Income from discontinued operations attributable to MPT common stockholders

     —          —    
  

 

 

    

 

 

 

Net income, less participating securities’ share in earnings

   $ 53,592       $ 22,157   
  

 

 

    

 

 

 

Denominator:

     

Basic weighted-average common shares

     238,082         208,071   

Dilutive potential common shares

     926         569   
  

 

 

    

 

 

 

Dilutive weighted-average common shares

     239,008         208,640   
  

 

 

    

 

 

 

 

     For the Six Months
Ended June 30,
 
     2016      2015  

Numerator:

     

Income from continuing operations

   $ 112,150       $ 58,465   

Non-controlling interests’ share in continuing operations

     (498      (161

Participating securities’ share in earnings

     (276      (516
  

 

 

    

 

 

 

Income from continuing operations, less participating securities’ share in earnings

     111,376         57,788   

Loss from discontinued operations attributable to MPT common stockholders

     (1      —    
  

 

 

    

 

 

 

Net income, less participating securities’ share in earnings

   $ 111,375       $ 57,788   
  

 

 

    

 

 

 

Denominator:

     

Basic weighted-average common shares

     237,796         205,515   

Dilutive potential common shares

     617         612   
  

 

 

    

 

 

 

Dilutive weighted-average common shares

     238,413         206,127   
  

 

 

    

 

 

 

 

MPT Operating Partnership, L.P.

Our earnings per common unit were calculated based on the following (in thousands):

 

     For the Three Months
Ended June 30,
 
     2016      2015  

Numerator:

     

Income from continuing operations

   $ 53,924       $ 22,489   

Non-controlling interests’ share in continuing operations

     (200      (82

Participating securities’ share in earnings

     (132      (250
  

 

 

    

 

 

 

Income from continuing operations, less participating securities’ share in earnings

     53,592         22,157   

Income from discontinued operations attributable to MPT Operating Partnership partners

     —           —    
  

 

 

    

 

 

 

Net income, less participating securities’ share in earnings

   $ 53,592       $ 22,157   
  

 

 

    

 

 

 

Denominator:

     

Basic weighted-average units

     238,082         208,071   

Dilutive potential units

     926         569   
  

 

 

    

 

 

 

Dilutive weighted-average units

     239,008         208,640   
  

 

 

    

 

 

 

 

     For the Six Months
Ended June 30,
 
     2016      2015  

Numerator:

     

Income from continuing operations

   $ 112,150       $ 58,465   

Non-controlling interests’ share in continuing operations

     (498      (161

Participating securities’ share in earnings

     (276      (516
  

 

 

    

 

 

 

Income from continuing operations, less participating securities’ share in earnings

     111,376         57,788   

Loss from discontinued operations attributable to MPT Operating Partnership partners

     (1      —    
  

 

 

    

 

 

 

Net income, less participating securities’ share in earnings

   $ 111,375       $ 57,788   
  

 

 

    

 

 

 

Denominator:

     

Basic weighted-average units

     237,796         205,515   

Dilutive potential units

     617         612   
  

 

 

    

 

 

 

Dilutive weighted-average units

     238,413         206,127   
  

 

 

    

 

 

 
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies - Carrying Value and Classification of Related Assets and Maximum Exposure to Loss (Detail)
Jun. 30, 2016
USD ($)
Mortgage and other loans [Member]  
Variable Interest Entity [Line Items]  
Carrying Amount $ 226,101,000
Loans, net [Member]  
Variable Interest Entity [Line Items]  
Maximum Loss Exposure 295,822,000
Other Assets [Member]  
Variable Interest Entity [Line Items]  
Carrying Amount 328,000
Equity investments [Member]  
Variable Interest Entity [Line Items]  
Maximum Loss Exposure $ 37,309,000
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Assets Acquired (Detail) - USD ($)
$ in Thousands
Jun. 30, 2016
Jun. 30, 2015
Business Acquisition [Line Items]    
Total assets acquired $ 109,991 $ 562,633
Loans repaid   (183,826)
Total net assets acquired 109,991 378,807
Land and Land Improvements [Member]    
Business Acquisition [Line Items]    
Total assets acquired 9,398 62,434
Building [Member]    
Business Acquisition [Line Items]    
Total assets acquired 37,593 390,320
Intangible Lease Assets - Subject to Amortization [Member]    
Business Acquisition [Line Items]    
Total assets acquired   42,262
Net Investments in Direct Financing Leases [Member]    
Business Acquisition [Line Items]    
Total assets acquired $ 63,000 10,700
Other Loans [Member]    
Business Acquisition [Line Items]    
Total assets acquired   16,917
Mortgage Loans [Member]    
Business Acquisition [Line Items]    
Total assets acquired   $ 40,000
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Assets Acquired (Parenthetical) (Detail)
6 Months Ended
Jun. 30, 2015
Intangible Lease Assets - Subject to Amortization [Member]  
Business Acquisition [Line Items]  
Weighted average useful life of acquired intangible lease assets (in years) 25 years 9 months 18 days
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - 2016 Activity - Additional Information (Detail)
$ in Thousands, € in Millions
3 Months Ended 6 Months Ended
May 02, 2016
USD ($)
RenewalOptions
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Jun. 22, 2016
EUR (€)
Business Acquisition [Line Items]            
Acquisition related costs   $ 4,767 $ 25,809 $ 3,702 $ 32,048  
Median [Member]            
Business Acquisition [Line Items]            
Value of properties closed | €           € 41.6
Acute Care Hospital [Member] | New Jersey [Member]            
Business Acquisition [Line Items]            
Term of lease, years 15 years          
Number of lease extension options | RenewalOptions 3          
Increase in consumer price-index, floor rate 2.00%          
Commitment to advance an additional amount for capital additions $ 30,000          
Commitment period to advance an additional amount for capital additions 3 years          
Acquisition costs $ 63,000          
Business Acquisitions [Member] | 2016 [Member]            
Business Acquisition [Line Items]            
Revenue contributed by the acquired entity   1,100   1,100    
Acquisition related costs   $ 2,400   $ 2,400    
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - 2015 Activity - Additional Information (Detail)
$ in Thousands, € in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2015
EUR (€)
Property
Jun. 16, 2015
USD ($)
RenewalOptions
Property
Bed
Apr. 29, 2015
EUR (€)
Hospital
Feb. 27, 2015
USD ($)
RenewalOptions
Feb. 13, 2015
USD ($)
Facility
RenewalOptions
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Jun. 22, 2016
EUR (€)
Dec. 31, 2014
EUR (€)
Business Acquisition [Line Items]                      
Income contributed by the acquired entity             $ 50   $ 100    
Acquisition related costs           $ 4,767 25,809 $ 3,702 32,048    
Median [Member]                      
Business Acquisition [Line Items]                      
Value of properties closed | €                   € 41.6  
2015 [Member] | Ernest [Member]                      
Business Acquisition [Line Items]                      
Acquisition costs   $ 31,500                  
Term of lease, years   20 years                  
Loans provided for acquisition   $ 12,000                  
Number of properties acquired | Property   2                  
Number of lease extension options | RenewalOptions   3                  
Term of lease extension, years   5 years                  
2015 [Member] | Inpatient Rehabilitation Hospital [Member] | Ernest [Member] | Weslaco Texas [Member]                      
Business Acquisition [Line Items]                      
Acquisition costs       $ 10,700              
Number of lease extension options | RenewalOptions       3              
Term of lease extension, years       5 years              
Payments to fund long-term loans to related parties       $ 5,000              
Lease original term       17 years              
2015 [Member] | Acute Care Hospital [Member] | Kansas [Member]                      
Business Acquisition [Line Items]                      
Term of lease, years         10 years            
Number of lease extension options | RenewalOptions         2            
Term of lease extension, years         5 years            
Number of facilities acquired | Facility         2            
Purchase price of acquisition         $ 110,000            
Mortgage financing         $ 40,000            
Mortgage financing term         10 years            
2015 [Member] | Acute Care Hospital [Member] | Ernest [Member]                      
Business Acquisition [Line Items]                      
Number of beds acquired | Bed   37                  
2015 [Member] | Rehabilitation Hospital with Covenant Health System [Member] | Ernest [Member]                      
Business Acquisition [Line Items]                      
Number of beds acquired | Bed   60                  
2015 [Member] | Median [Member]                      
Business Acquisition [Line Items]                      
Number of hospitals acquired | Hospital     32                
Acquisition costs | €     € 688.0                
Term of lease, years     27 years                
Lease rent increase percentage     70.00%                
Lease rate     9.30%                
Ownership percentage                     5.10%
Loans provided for acquisition | € € 240.0                   € 425.0
Number of properties closed | Property 17                    
Value of properties closed | € € 317.0                    
2015 [Member] | Waterland Private Equity Fund [Member] | Median [Member]                      
Business Acquisition [Line Items]                      
Ownership percentage                     94.90%
2015 [Member] | Business Acquisitions [Member]                      
Business Acquisition [Line Items]                      
Revenue contributed by the acquired entity             4,200   6,200    
Income contributed by the acquired entity             3,500   4,900    
Acquisition related costs             $ 22,600   $ 26,700    
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Schedule of Unaudited Supplemental Pro Forma Operating Data (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2015
Business Acquisition, Pro Forma Information [Abstract]    
Total revenues $ 109 $ 219
Net income $ 50 $ 100
Net income per share/unit - diluted $ 0.21 $ 0.42
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Development Activities - Additional Information (Detail)
€ in Millions
Sep. 09, 2015
EUR (€)
Jun. 30, 2016
Facility
2015 [Member] | AXA Real Estate [Member]    
Business Acquisition [Line Items]    
Ownership interest in joint venture under the equity method 50.00%  
Acute Care Facilities in Altoona [Member] | Development Activities [Member]    
Business Acquisition [Line Items]    
Number of facilities constructed | Facility   7
Acute Care Hospital [Member] | 2015 [Member] | Spain [Member] | AXA Real Estate [Member]    
Business Acquisition [Line Items]    
Estimated total development cost | € € 21.4  
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Summary of Status Update on Current Development Projects (Detail)
$ in Thousands
6 Months Ended
Jun. 30, 2016
USD ($)
Business Acquisition [Line Items]  
Commitment $ 255,048
Costs Incurred as of 06/30/16 75,623
Adeptus Health One [Member]  
Business Acquisition [Line Items]  
Commitment 62,154
Costs Incurred as of 06/30/16 $ 43,763
Estimated Completion Date 3Q 2016
Adeptus Health Two [Member]  
Business Acquisition [Line Items]  
Commitment $ 53,836
Costs Incurred as of 06/30/16 $ 15,343
Estimated Completion Date 4Q 2016
Adeptus Health Three [Member]  
Business Acquisition [Line Items]  
Commitment $ 5,730
Costs Incurred as of 06/30/16 $ 206
Estimated Completion Date 1Q 2017
Adeptus Health Four [Member]  
Business Acquisition [Line Items]  
Commitment $ 61,997
Costs Incurred as of 06/30/16 $ 16,311
Estimated Completion Date 2Q 2017
Adeptus Health Five [Member]  
Business Acquisition [Line Items]  
Commitment $ 71,331
Estimated Completion Date Various
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Disposals - Additional Information (Detail)
$ in Millions
3 Months Ended 6 Months Ended
Jul. 20, 2016
USD ($)
Jun. 17, 2016
USD ($)
May 23, 2016
USD ($)
Property
May 20, 2016
USD ($)
Hospital
Apr. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2016
Hospital
Jul. 22, 2016
USD ($)
Capella [Member]                
Debt Instrument [Line Items]                
Net proceeds from transaction         $ 550.0      
Net proceeds from equity investment and loans         492.0      
Proceeds from prepayment of mortgage loans         210.0      
New loan for hospital property         93.3      
Investment on unsecured senior notes         50.0      
Transaction costs incurred         $ 6.3      
Number of hospital owned | Hospital             5  
Write off of unbilled direct finance lease rent           $ 2.6    
Capella [Member] | Subsequent Event [Member]                
Debt Instrument [Line Items]                
Sale and leaseback arrangement               $ 93.3
Additional fund               $ 7.0
Post Acute [Member]                
Debt Instrument [Line Items]                
Number of properties sold | Property     5          
Outstanding loans paid in full     $ 4.0          
Proceeds from sale of facilities   $ 28.0 71.0          
Gain on real estate dispositions   8.0 $ 15.0          
Post Acute [Member] | Texas [Member]                
Debt Instrument [Line Items]                
Number of properties sold | Property     3          
Gain offset by non-cash charges   $ 9.0            
Post Acute [Member] | Louisiana [Member]                
Debt Instrument [Line Items]                
Number of properties sold | Property     2          
HealthSouth [Member]                
Debt Instrument [Line Items]                
Proceeds from sale of facilities       $ 111.5        
HealthSouth [Member] | Subsequent Event [Member]                
Debt Instrument [Line Items]                
Gain on real estate dispositions $ 45.0              
HealthSouth [Member] | Texas [Member]                
Debt Instrument [Line Items]                
Number of hospitals sold | Hospital       3        
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Summary of Facilities and Related Net Assets Designated as Held for Sale (Detail) - Texas [Member] - HealthSouth [Member]
$ in Thousands
Jun. 30, 2016
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Real estate held for sale $ 63,074
Straight-line rent receivables 2,441
Other, net (625)
Assets held for sale, Net $ 64,890
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Summary of Operations for Disposed Assets (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]        
Revenues $ 3,092 $ 4,525 $ 7,607 $ 9,075
Real estate depreciation and amortization (805) (949) (1,754) (1,897)
Property-related expenses (72) (12) (113) (72)
Other income (expense) (9) 228 (68) 557
Income from real estate dispositions, net $ 2,206 $ 3,792 $ 5,672 $ 7,663
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Leasing Operations - Additional Information (Detail) - Leasing Operations [Member]
6 Months Ended
Jun. 30, 2016
Leases
Ernest [Member]  
Business Acquisition [Line Items]  
Number of direct financing leases 15
Prime Facilities [Member]  
Business Acquisition [Line Items]  
Number of direct financing leases 6
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Components of Net Investment in Direct Financing Leases (Detail) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Business Combinations [Abstract]    
Minimum lease payments receivable $ 1,875,751 $ 2,587,912
Estimated residual values 292,646 393,097
Less: Unearned income (1,639,650) (2,354,013)
Net investment in direct financing leases $ 528,747 $ 626,996
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Twelve Oaks Facility - Additional Information (Detail) - Twelve Oaks Facility [Member] - USD ($)
$ in Millions
Aug. 08, 2016
Mar. 31, 2016
Business Acquisition [Line Items]    
Letter of credit outstanding   $ 0.5
Subsequent Event [Member]    
Business Acquisition [Line Items]    
Outstanding amount receivable from tenant past due including interest $ 2.5  
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Summary of Loans (Detail) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Loans [Line Items]    
Loans, Balance $ 808,666 $ 1,422,403
Mortgage Loans [Member]    
Loans [Line Items]    
Loans, Balance 549,337 757,581
Acquisition Loans [Member]    
Loans [Line Items]    
Loans, Balance 216,100 610,469
Working Capital and Other Loans [Member]    
Loans [Line Items]    
Loans, Balance $ 43,229 $ 54,353
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Loans Receivable - Loans - Additional Information (Detail) - USD ($)
$ in Millions
6 Months Ended
Mar. 01, 2012
Jun. 30, 2016
Business Acquisition [Line Items]    
Amount of convertible note converted into equity interest $ 1.7  
Convertible note $ 5.0  
Percentage of equity shares from convertible debt 9.90% 15.10%
Remaining convertible debt after conversion of part of debt   $ 3.3
Ernest Transaction and Other Acquisitions [Member]    
Business Acquisition [Line Items]    
Existing mortgage loans   93.2
RCCH [Member]    
Business Acquisition [Line Items]    
Existing mortgage loans   $ 93.3
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Schedule of Revenue by Operator (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Investment And Revenue From External Customers [Line Items]        
Total Revenue $ 126,300 $ 99,801 $ 261,299 $ 195,762
Revenue [Member] | Credit Concentration Risk [Member]        
Investment And Revenue From External Customers [Line Items]        
Total Revenue     $ 261,299 $ 195,762
Percentage of Total Revenue     100.00% 100.00%
Revenue [Member] | Credit Concentration Risk [Member] | Prime [Member]        
Investment And Revenue From External Customers [Line Items]        
Total Revenue     $ 58,859 $ 49,869
Percentage of Total Revenue     22.50% 25.50%
Revenue [Member] | Credit Concentration Risk [Member] | Median [Member]        
Investment And Revenue From External Customers [Line Items]        
Total Revenue     $ 47,745 $ 32,212
Percentage of Total Revenue     18.30% 16.50%
Revenue [Member] | Credit Concentration Risk [Member] | Ernest [Member]        
Investment And Revenue From External Customers [Line Items]        
Total Revenue     $ 33,322 $ 29,695
Percentage of Total Revenue     12.80% 15.20%
Revenue [Member] | Credit Concentration Risk [Member] | RCCH [Member]        
Investment And Revenue From External Customers [Line Items]        
Total Revenue     $ 32,909  
Percentage of Total Revenue     12.60%  
Revenue [Member] | Credit Concentration Risk [Member] | Adeptus Health [Member]        
Investment And Revenue From External Customers [Line Items]        
Total Revenue     $ 16,205 $ 7,425
Percentage of Total Revenue     6.20% 3.80%
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Schedule of Revenue from External Customers by Geographic Areas (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Investment And Revenue From External Customers By Geographic Area [Line Items]        
Total Revenue $ 126,300 $ 99,801 $ 261,299 $ 195,762
Revenue [Member] | Credit Concentration Risk [Member]        
Investment And Revenue From External Customers By Geographic Area [Line Items]        
Total Revenue     $ 261,299 $ 195,762
Percentage of Total Revenue     100.00% 100.00%
Revenue [Member] | Texas [Member] | Credit Concentration Risk [Member]        
Investment And Revenue From External Customers By Geographic Area [Line Items]        
Total Revenue     $ 48,256 $ 42,689
Percentage of Total Revenue     18.50% 21.80%
Revenue [Member] | California [Member] | Credit Concentration Risk [Member]        
Investment And Revenue From External Customers By Geographic Area [Line Items]        
Total Revenue     $ 33,187 $ 33,065
Percentage of Total Revenue     12.70% 16.90%
Revenue [Member] | All Other States [Member] | Credit Concentration Risk [Member]        
Investment And Revenue From External Customers By Geographic Area [Line Items]        
Total Revenue     $ 129,896 $ 85,620
Percentage of Total Revenue     49.70% 43.70%
Revenue [Member] | United States [Member] | Credit Concentration Risk [Member]        
Investment And Revenue From External Customers By Geographic Area [Line Items]        
Total Revenue     $ 211,339 $ 161,374
Percentage of Total Revenue     80.90% 82.40%
Revenue [Member] | Germany [Member] | Credit Concentration Risk [Member]        
Investment And Revenue From External Customers By Geographic Area [Line Items]        
Total Revenue     $ 47,745 $ 32,212
Percentage of Total Revenue     18.30% 16.50%
Revenue [Member] | United Kingdom, Italy, and Spain [Member] | Credit Concentration Risk [Member]        
Investment And Revenue From External Customers By Geographic Area [Line Items]        
Total Revenue     $ 2,215 $ 2,176
Percentage of Total Revenue     0.80% 1.10%
Revenue [Member] | International [Member] | Credit Concentration Risk [Member]        
Investment And Revenue From External Customers By Geographic Area [Line Items]        
Total Revenue     $ 49,960 $ 34,388
Percentage of Total Revenue     19.10% 17.60%
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Schedule of Gross Assets by Operator (Detail) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2016
Dec. 31, 2015
Investment And Revenue From External Customers [Line Items]    
Total Gross Assets $ 5,117,933 $ 5,609,351
Assets, Total [Member] | Credit Concentration Risk [Member]    
Investment And Revenue From External Customers [Line Items]    
Total Gross Assets $ 5,422,395 $ 6,035,922
Percentage of Total Gross Assets 100.00% 100.00%
Assets, Total [Member] | Credit Concentration Risk [Member] | Prime [Member]    
Investment And Revenue From External Customers [Line Items]    
Total Gross Assets $ 1,126,654 $ 1,032,353
Percentage of Total Gross Assets 20.80% 17.10%
Assets, Total [Member] | Credit Concentration Risk [Member] | Median [Member]    
Investment And Revenue From External Customers [Line Items]    
Total Gross Assets $ 1,054,368 $ 1,031,039
Percentage of Total Gross Assets 19.40% 17.10%
Assets, Total [Member] | Credit Concentration Risk [Member] | Ernest [Member]    
Investment And Revenue From External Customers [Line Items]    
Total Gross Assets $ 584,411 $ 579,182
Percentage of Total Gross Assets 10.80% 9.60%
Assets, Total [Member] | Credit Concentration Risk [Member] | Adeptus Health [Member]    
Investment And Revenue From External Customers [Line Items]    
Total Gross Assets $ 500,000 $ 500,000
Percentage of Total Gross Assets 9.20% 8.30%
Assets, Total [Member] | Credit Concentration Risk [Member] | RCCH [Member]    
Investment And Revenue From External Customers [Line Items]    
Total Gross Assets $ 458,659 $ 1,059,989
Percentage of Total Gross Assets 8.50% 17.60%
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Schedule of Gross Assets by Geographic Areas (Detail) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2016
Dec. 31, 2015
Investment And Revenue From External Customers By Geographic Area [Line Items]    
Total Gross Assets $ 5,117,933 $ 5,609,351
Assets, Total [Member] | Credit Concentration Risk [Member]    
Investment And Revenue From External Customers By Geographic Area [Line Items]    
Total Gross Assets $ 5,422,395 $ 6,035,922
Percentage of Total Gross Assets 100.00% 100.00%
Assets, Total [Member] | Texas [Member] | Credit Concentration Risk [Member]    
Investment And Revenue From External Customers By Geographic Area [Line Items]    
Total Gross Assets $ 920,959 $ 1,060,990
Percentage of Total Gross Assets 17.00% 17.60%
Assets, Total [Member] | California [Member] | Credit Concentration Risk [Member]    
Investment And Revenue From External Customers By Geographic Area [Line Items]    
Total Gross Assets $ 547,079 $ 547,085
Percentage of Total Gross Assets 10.10% 9.10%
Assets, Total [Member] | All Other States [Member] | Credit Concentration Risk [Member]    
Investment And Revenue From External Customers By Geographic Area [Line Items]    
Total Gross Assets $ 2,530,018 $ 3,047,204
Percentage of Total Gross Assets 46.60% 50.50%
Assets, Total [Member] | Other Domestic Assets [Member] | Credit Concentration Risk [Member]    
Investment And Revenue From External Customers By Geographic Area [Line Items]    
Total Gross Assets $ 189,358 $ 177,317
Percentage of Total Gross Assets 3.50% 2.90%
Assets, Total [Member] | United States [Member] | Credit Concentration Risk [Member]    
Investment And Revenue From External Customers By Geographic Area [Line Items]    
Total Gross Assets $ 4,187,414 $ 4,832,596
Percentage of Total Gross Assets 77.20% 80.10%
Assets, Total [Member] | Germany [Member] | Credit Concentration Risk [Member]    
Investment And Revenue From External Customers By Geographic Area [Line Items]    
Total Gross Assets $ 1,054,368 $ 1,031,039
Percentage of Total Gross Assets 19.40% 17.10%
Assets, Total [Member] | United Kingdom, Italy, and Spain [Member] | Credit Concentration Risk [Member]    
Investment And Revenue From External Customers By Geographic Area [Line Items]    
Total Gross Assets $ 156,630 $ 161,317
Percentage of Total Gross Assets 3.00% 2.70%
Assets, Total [Member] | Other International Assets [Member] | Credit Concentration Risk [Member]    
Investment And Revenue From External Customers By Geographic Area [Line Items]    
Total Gross Assets $ 23,983 $ 10,970
Percentage of Total Gross Assets 0.40% 0.10%
Assets, Total [Member] | International [Member] | Credit Concentration Risk [Member]    
Investment And Revenue From External Customers By Geographic Area [Line Items]    
Total Gross Assets $ 1,234,981 $ 1,203,326
Percentage of Total Gross Assets 22.80% 19.90%
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
Real Estate and Lending Activities - Concentrations of Credit Risk - Additional Information (Detail) - Assets, Total [Member] - Customer Concentration Risk [Member]
Jun. 30, 2016
Investment
Business Acquisition [Line Items]  
Number of investment in property 0
Maximum percentage of entity's total assets invested on single property 2.30%
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt - Summary of Debt (Detail) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2016
Dec. 31, 2015
Feb. 22, 2016
Debt Instrument [Line Items]      
Principal amount $ 2,790,673    
Debt issue costs, net (34,029) $ (28,367)  
Debt $ 2,758,635 $ 3,322,541  
Revolving Credit Facility [Member]      
Debt Instrument [Line Items]      
Interest rate Variable Variable  
Debt $ 25,000 $ 1,100,000  
2006 Senior Unsecured Notes [Member]      
Debt Instrument [Line Items]      
Interest rate Various Various  
Debt $ 125,000 $ 125,000  
2011 Senior Unsecured Notes [Member]      
Debt Instrument [Line Items]      
Senior unsecured notes, interest rate 6.875% 6.875%  
Debt $ 450,000 $ 450,000  
2012 Senior Unsecured Notes [Member]      
Debt Instrument [Line Items]      
Principal amount $ 350,000 $ 350,000  
Senior unsecured notes, interest rate 6.375% 6.375%  
Unamortized premium $ 1,991 $ 2,168  
Debt $ 351,991 $ 352,168  
2013 Senior Unsecured Notes [Member]      
Debt Instrument [Line Items]      
Senior unsecured notes, interest rate 5.75% 5.75%  
Debt $ 222,120 $ 217,240  
2014 Senior Unsecured Notes [Member]      
Debt Instrument [Line Items]      
Senior unsecured notes, interest rate 5.50% 5.50%  
Debt $ 300,000 $ 300,000  
2015 Senior Unsecured Notes [Member]      
Debt Instrument [Line Items]      
Senior unsecured notes, interest rate 4.00% 4.00%  
Debt $ 555,300 $ 543,100  
2016 Senior Unsecured Notes [Member]      
Debt Instrument [Line Items]      
Senior unsecured notes, interest rate 6.375%    
Debt $ 500,000    
2016 Senior Unsecured Notes [Member] | Revolving Credit Facility [Member]      
Debt Instrument [Line Items]      
Senior unsecured notes, interest rate     6.375%
Term Loans [Member]      
Debt Instrument [Line Items]      
Interest rate Various Various  
Debt $ 263,253 $ 263,400  
Senior Unsecured Debt [Member]      
Debt Instrument [Line Items]      
Debt $ 2,792,664 $ 3,350,908  
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt - Principal Payments Due for Debt (Detail)
$ in Thousands
Jun. 30, 2016
USD ($)
Debt Disclosure [Abstract]  
2016 $ 125,152
2017 320
2018 37,781
2019 250,000
2020 222,120
Thereafter 2,155,300
Total $ 2,790,673
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt - Principal Payments Due for Debt (Parenthetical) (Detail) - 2006 Senior Unsecured Notes [Member] - USD ($)
$ in Millions
Oct. 31, 2016
Jul. 31, 2016
Subsequent Event [Member]    
Debt Instrument [Line Items]    
Unsecured debt, current   $ 65
Scenario, Forecast [Member]    
Debt Instrument [Line Items]    
Unsecured debt, current $ 60  
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt - Additional Information (Detail) - USD ($)
1 Months Ended 6 Months Ended
Feb. 22, 2016
Oct. 31, 2011
Jun. 30, 2016
Dec. 31, 2015
Jun. 30, 2010
2016 Senior Unsecured Notes [Member]          
Debt Instrument [Line Items]          
Senior unsecured notes, interest rate     6.375%    
2006 Senior Unsecured Notes [Member] | Interest Rate Swap [Member]          
Debt Instrument [Line Items]          
Portion of debt instrument face amount         $ 65,000,000
2006 Senior Unsecured Notes [Member] | Interest Rate Contract [Member]          
Debt Instrument [Line Items]          
Fair value of the interest rate swaps     $ 1,300,000 $ 2,900,000  
2006 Senior Unsecured Notes [Member] | Interest Rate Contract One [Member]          
Debt Instrument [Line Items]          
Interest rate of interest rate derivative instrument         5.507%
Maturity date of interest rate swap     2016-07    
2006 Senior Unsecured Notes [Member] | Interest Rate Contract Two [Member]          
Debt Instrument [Line Items]          
Maturity date of interest rate swap     2016-10    
Interest rate swap, amount fixed   $ 60,000,000      
Interest rate of derivative instrument   5.675%      
Revolving Credit Facility [Member] | 2016 Senior Unsecured Notes [Member]          
Debt Instrument [Line Items]          
Portion of debt instrument face amount $ 500,000,000        
Senior unsecured notes, maturity date Mar. 01, 2024        
Senior unsecured notes, interest rate 6.375%        
Debt instrument, redemption price percentage 106.375%        
Senior notes, repurchased price percentage on principal amount plus accrued and unpaid interest 101.00%        
Senior unsecured notes, payable term Interest on the notes will be payable on March 1 and September 1 of each year        
Senior unsecured notes commencing date of payment Sep. 01, 2016        
Senior notes, earliest redemption date Mar. 01, 2019        
Senior unsecured notes, redemption description We may redeem some or all of the notes at any time prior to March 1, 2019 at a “make whole” redemption price. On or after March 1, 2019, we may redeem some or all of the notes at a premium that will decrease over time. In addition, at any time prior to March 1, 2019, we may redeem up to 35% of the notes at a redemption price equal to 106.375% of the aggregate principal amount thereof, plus accrued and unpaid interest thereon, using proceeds from one or more equity offerings. In the event of a change in control, each holder of the notes may require us to repurchase some or all of the notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest to the date of purchase.        
Revolving Credit Facility [Member] | 2016 Senior Unsecured Notes [Member] | Maximum [Member]          
Debt Instrument [Line Items]          
Senior unsecured notes, redemption percentage on principal amount 35.00%        
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt - Interest Rate Swap - Additional Information (Detail) - Interest Rate Swap [Member] - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Debt Instrument [Line Items]          
Hedge ineffectiveness and income statement effect in period $ 0 $ 0 $ 0 $ 0  
Other assets, collateral $ 800,000   $ 800,000   $ 1,700,000
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt - Covenants - Additional Information (Detail)
6 Months Ended
Jun. 30, 2016
Sep. 30, 2016
Debt Instrument [Line Items]    
Percentage of dividends which could be paid from adjusted operating funds 95.00%  
Percentage of dividends which could be paid from operation funds 95.00%  
Maximum percentage of total unencumbered assets 150.00%  
Revolving Credit Facility [Member]    
Debt Instrument [Line Items]    
Unsecured leverage ratio 77.50%  
Scenario, Forecast [Member] | Revolving Credit Facility [Member]    
Debt Instrument [Line Items]    
Unsecured leverage ratio   65.00%
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.5.0.2
Common Stock/Partners' Capital - Additional Information (Detail)
shares in Thousands, $ in Thousands
6 Months Ended
Mar. 01, 2016
USD ($)
Jan. 14, 2015
USD ($)
shares
Jun. 30, 2016
USD ($)
Partner
Director
Employee
shares
Jun. 30, 2015
USD ($)
shares
Dec. 31, 2015
shares
Class of Stock [Line Items]          
Common stock, shares issued | shares     240,341   236,744
Proceeds from sale of common shares / units, net of offering costs     $ 44,306 $ 479,902  
MPT Operating Partnership, L.P. [Member]          
Class of Stock [Line Items]          
Proceeds from sale of common shares / units, net of offering costs     $ 44,306 $ 479,902  
Ownership interest in equity     99.83%    
Number of other partners | Partner     3    
Number of units sold | shares     3,000 34,500  
Employee [Member]          
Class of Stock [Line Items]          
Number of partners shared remaining ownership percentage | Employee     2    
Director [Member]          
Class of Stock [Line Items]          
Number of partners shared remaining ownership percentage | Director     1    
Market Equity Offering Program [Member]          
Class of Stock [Line Items]          
Sales commission percentage 1.25%        
Common stock, shares issued | shares     3,000    
Proceeds from sale of common shares / units, net of offering costs     $ 45,000    
Sales commissions, amount     $ 600    
Market Equity Offering Program [Member] | Maximum [Member]          
Class of Stock [Line Items]          
Value of stock $ 227,000        
Public Offering [Member]          
Class of Stock [Line Items]          
Common stock, shares issued | shares   34,500      
Proceeds from sale of common shares / units, net of offering costs   $ 480,000      
Additional shares purchased by underwriters | shares   4,500      
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock Awards - Additional Information (Detail) - shares
6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Time-Based Awards [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation, multi-year performance-based awards 45,528 217,177
Stock awards vesting period in years 3 years  
Performance Shares [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation, multi-year performance-based awards 0 176,046
Stock awards vesting period in years 3 years  
Multi-year performance-based awards [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation, multi-year performance-based awards 0 505,050
Stock awards vesting period in years 3 years  
Equity Incentive Plan [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Reserved shares of common stock for awards under the Equity Incentive Plan 8,196,770  
Common stock remaining for future stock awards transferred to the equity incentive plan 5,615,497  
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments - Summary of Fair Value Information of Financial Instruments (Detail) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Fair Value Disclosures [Abstract]    
Interest and rent receivables, Book value $ 47,699 $ 46,939
Loans, Book value 590,037 508,851
Debt, net Book value (2,758,635) (3,322,541)
Interest and rent receivables, Fair value 47,653 46,858
Loans, Fair value 623,399 543,859
Debt, net Fair value $ (2,863,382) $ (3,372,773)
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments - Equity Interest in Related Party and Related Loans Measured at Fair Value on Recurring Basis (Detail)
$ in Thousands
Jun. 30, 2016
USD ($)
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]  
Fair Value $ 221,929
Cost 221,929
Fair Value Measurements, Recurring [Member] | Equity investments [Member] | Other Assets [Member]  
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]  
Fair Value 3,300
Cost 3,300
Fair Value Measurements, Recurring [Member] | Acquisition and Other Loans [Member] | Other Loans [Member]  
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]  
Fair Value 116,867
Cost 116,867
Fair Value Measurements, Recurring [Member] | Mortgage Loans [Member] | Mortgage Loans [Member]  
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]  
Fair Value 101,762
Cost $ 101,762
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments - Additional information (Detail)
6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Adjustment for marketability discount 40.00%
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments - Summary Showing Sensitivity Analysis by Using Basis Point Variations (Detail)
$ in Thousands
6 Months Ended
Jun. 30, 2016
USD ($)
+100 basis points [Member]  
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]  
Estimated Increase (Decrease) In Fair Value of Financial Instruments $ (54)
- 100 basis points [Member]  
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]  
Estimated Increase (Decrease) In Fair Value of Financial Instruments $ 54
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share/Common Unit - Calculation of Earnings Per Share (Detail) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
Income from continuing operations $ 53,924 $ 22,489 $ 112,150 $ 58,465
Non-controlling interests' share in continuing operations (200) (82) (498) (161)
Participating securities' share in earnings (132) (250) (276) (516)
Income from continuing operations, less participating securities' share in earnings 53,592 22,157 111,376 57,788
Income (loss) from discontinued operations attributable to MPT Operating Partnership partners     (1)  
Net income, less participating securities' share in earnings $ 53,592 $ 22,157 $ 111,375 $ 57,788
Basic weighted-average common shares 238,082 208,071 237,796 205,515
Dilutive potential common shares 926 569 617 612
Dilutive weighted-average common shares 239,008 208,640 238,413 206,127
MPT Operating Partnership, L.P. [Member]        
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
Income from continuing operations $ 53,924 $ 22,489 $ 112,150 $ 58,465
Non-controlling interests' share in continuing operations (200) (82) (498) (161)
Participating securities' share in earnings (132) (250) (276) (516)
Income from continuing operations, less participating securities' share in earnings 53,592 22,157 111,376 57,788
Income (loss) from discontinued operations attributable to MPT Operating Partnership partners     (1)  
Net income, less participating securities' share in earnings $ 53,592 $ 22,157 $ 111,375 $ 57,788
Basic weighted-average common shares 238,082 208,071 237,796 205,515
Dilutive potential common shares 926 569 617 612
Dilutive weighted-average common shares 239,008 208,640 238,413 206,127
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.5.0.2
Subsequent Events - Additional Information (Detail) - USD ($)
shares in Thousands, $ in Thousands
1 Months Ended 6 Months Ended
Jul. 22, 2016
Jul. 31, 2016
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Subsequent Event [Line Items]          
Common stock, shares issued     240,341   236,744
Proceeds from sale of common shares / units, net of offering costs     $ 44,306 $ 479,902  
2016 Senior Unsecured Notes [Member]          
Subsequent Event [Line Items]          
Senior unsecured notes, interest rate     6.375%    
2016 Senior Unsecured Notes [Member] | Subsequent Event [Member]          
Subsequent Event [Line Items]          
Senior unsecured notes face amount $ 500,000        
Senior unsecured notes, maturity date Aug. 01, 2026        
Senior unsecured notes, interest rate 5.25%        
Debt instrument, redemption price percentage 105.25%        
Senior notes, repurchased price percentage on principal amount plus accrued and unpaid interest 101.00%        
2016 Senior Unsecured Notes [Member] | Subsequent Event [Member] | Maximum [Member]          
Subsequent Event [Line Items]          
Senior unsecured notes, redemption percentage on principal amount 35.00%        
2011 Bonds [Member] | Subsequent Event [Member]          
Subsequent Event [Line Items]          
Senior unsecured notes face amount $ 450,000        
2026 Senior Unsecured Notes [Member] | Subsequent Event [Member]          
Subsequent Event [Line Items]          
Redemption period, end date Aug. 12, 2016        
Debt redemption value $ 23,000        
Senior unsecured notes, payable term Interest on the notes will be payable on February 1 and August 1 of each year        
Senior unsecured notes commencing date of payment Feb. 01, 2017        
Senior notes, earliest redemption date Aug. 01, 2021        
Senior unsecured notes, redemption description We may redeem some or all of the notes at a premium that will decrease over time. In addition, at any time prior to August 1, 2019, we may redeem up to 35% of the notes at a redemption price equal to 105.25% of the aggregate principal amount thereof, plus accrued and unpaid interest thereon, using proceeds from one or more equity offerings. In the event of a change in control, each holder of the notes may require us to repurchase some or all of the notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest to the date of purchase.        
Market Equity Offering Program [Member]          
Subsequent Event [Line Items]          
Common stock, shares issued     3,000    
Proceeds from sale of common shares / units, net of offering costs     $ 45,000    
Market Equity Offering Program [Member] | Subsequent Event [Member]          
Subsequent Event [Line Items]          
Common stock, shares issued   2,700      
Proceeds from sale of common shares / units, net of offering costs   $ 41,100      
EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

D>_E\=@N[M MD00A'OJ,H"'QA$":L@05R ;&%"BC*Z30G3Z1 @^-;! GJ$B?0"NO"T&+PD3& MJ@I\+1ZT+$PZ)5XZN38R83XZ,2O]+*&++6_I9 .I^:Z\P 0M#A.IU$%K249+PZ13YJ63:U.3W$>G?%GPLB0A!)?)PO&<9"N) ;1* MC)0@]E#)!O$45>D3B*^0<=4;L.H-7_E' K0ZC"H!^*@$KCT-U$.E$31F/^X^ MJ$HNG$W)U3I XJ.2!>+X'Y,-RM;(N*H-6-4F6VD\P-4X@%?G *X=#3Z] RR; M@H1E*P*=]L$$9X#+9GI)/9*)%CUZ+]M2?752PE]>F M/RHM9N?ST0/T/?X'?+NY%"?QLVA/9:."%ZG-2:%OZX]2:F%8Q%^,TF=S@IMO M*G'4W9";<3N<:88;+2_3$6T^)V[_ 5!+ P04 " #$A0E)PF23/P\$ #- M% &0 'AL+W=O3?K?W1W_QY?-VP MGH,IS*'MN\B[CP^S-T71]]2-_._4Z>>8?6/VMOCG>FPO M'5NVB8[FE-^+]KM]_&&F.:B^PX,MFN%_=+@WK2WG)INHS'^.G]=J^'R,WV1L M:D8W$%,#\6SP'(=N %,#^&R0##,=F0WS^BUO\]VVMH^H'L6XY;WF_ 6ZE3M$ MS?"P'I>KFUG3/?W8R0RV\4??T801 ^9MB>$48H]Z29(G)NX8/&D(BL8TA%AT M(,@A$"*C1P!J!!@G"DN*4M$=2*H#.78@T1Q33#(=IS%BJ@&C.$\U (7;(US" M-"A.$U(>0@H1IY)*6"0$S M$$J[,J@O/8B0^(!!BW&03ACD>FE\?B.0WVA7XO5%" B*$."K:0B)$("C@9*0 MT.6T D+WYW!S\&4(",D0&)1*4J<5R&%9X/,;0'ZC7?/Q90@(RA#@JVH(R1"P MS 9<)0DP6B:$2[C3]<"7(2 D0R"08O3>M (Y]B;P^0VDJ N7T+X, 4$9 GPU M#2$9 E"& +W^43Z+I%$MZ=21QJ4O/\B0_(! BM$[TPKDV)FDSVLD1UVX?J+[ M\H,,R@_25\\R)#](E L$=/[,29560 8@'#N3])X]A"0(!%*,WIE6H'5AQXO3 MH]+4Y^%4K8D.]EX-AWB+I\^3NZ]B.'WZA.^VM_QL_LKK\[5JHG?;MK8<#IQ. MUK:F8\&^= YS,?GQ>5.84]M?IMUU/9ZVC3>MO&PO=V]R:W-H965T=]O"7%U!XJ[&].##CNML8K[D-HC<;T% MWJ0F)0FC])8H+C2NRE1[ME5I3EX*#<\6N9-2W/[=@S3##A?X4G@1Q\[' JE* M,O4U0H%VPFADH=WA^V*[7T=$ OP6,+A9C*+W@S&O,?G9[#"-%D!"[2,##\L9 M'D#*2!2$WT;._Y*Q<1Y?V)_2:8/[ W?P8.0?T?@NF*48-=#RD_0O9O@!XQ$V MD; VTJ4OJD_.&W5IP4CQ][P*G=8A[]S1L>UZ QL;V-3 TB1(%DHV'[GG56G- M@&P>;<_C#19;%@91(Y>*-I\^&'6A>JXV]*XDYT@T8EC"[)>8[Q.&!/Y)A%T3 M6641-B-@&WJ=8'6-8)T)5G,'!5VZO,TN,T8GS"<2ZR\DU@N)8BF1,?LEAGT0 M(;/)]_P(O[@]"NW0P?APB6GBK3$> A.]V6#4A:&PO=V]R:W-H M965T2^*K/[OQ>;5[7FE5O.+[Y?3N>U?A-M->(\[7 I;-I>J#&I[ M?%Y]54^O)NHA ^+OB[TUB_N@)_]653_ZAS\/SZNHYV!SNV_[)K+N\F%W-L_[ MEKJ>_YT:_>RS#US>SZW_/@RWH_^6-797Y?]<#NVY8QNM@H,]9N]Y^[VZ_6&G M,9B^P7V5-\-OL']OVJJ80U9!D?T#>#Q^ 4P!^ M!L1B@)X"]&? 0"D03BS0B98!%+@HY!BRWUF@1X:$1":B!7) M":)D).M0VD>EI7DH028!1RE))J.(RX"C#!5K#+-*L9=*4BDK4LL O$H4A+Q* M+A EP]K"3&;MH])ZD7UM(J=* HY2DHQ&$8< Q[('K$-,*D'DHQ)(%0WT0X)? M^B90.9>)*S$2CE)B'6*F!!X3YP%DV(GC!%$RDM< \1J(^?S@LFS3E)U>.X(" M%:\=="2W 1^W 4UD-[!"6W02^W0V< M($I&VJ*@SQX%EYL/8[KYX%")X#0JITJ2UR!Q"'1\CZ"T34&O?0I*%8VICTH4 MY%@!M;0-T3[;$+W<7QAA^FO)'C0M:LZ&E(M3XZ\2^/H!B^'8^3%V_O9\5<8CC,_X=O--3O9O[+Z="F;X*UJVZH8 M3C"/5=7:CDGTI9O 9YL=[@^Y/;;];=+=U^-Y[_C05M?Y^/I^AK[]'U!+ P04 M " #$A0E)D4:'!?8QE\4C**0]A+.>VC2#0]ID@\L0F/ZDG'.$52 M+?DY$A/'J#5)E$0PCK.(HF$,Z\K$7GE=L8LDPXA?>2 NE"+^]X@)FP\A"&^! MM^'<2QV(ZBI:\]J!XE$,; PX[@[A-[ _EEIA!+\'/ MG'NC:3XR]Z\7/]A#& MN@1,<".U U+#%3]C0K21 G\LGO^1.M&=W]Q?S&Y5]2"FN*,GSXD[?LP><;,LIO9R-*(W5SP_* M'X#R# MQEF>? %%SF&ZX+@3NIIKN;< M7BAV(=ETNQ[7.[K^!U!+ P04 " #$A0E)]Z*N![T! "T! &0 'AL M+W=OL1HDD,:1.,-Q&.:8$]H'5>EJS[(JQ4TSVL.S M1.K&.9%_3L#$> RBX%%XH==.VP*N2CSS&LJA5U3T2$)[##Y'AW-A$0[PD\*H M%G-DO5^$>+6+[\TQ"*T%8%!KJT#,<(,=AXF(W$6T92;R1>"*1AOBV0 M; DD7B!9""1YN"V0[CA(5Q&2=K%4*#$0J?3-[.7"'S@D&K M[;0P<^G_*K_08GC<$?-%5?T%4$L#!!0 ( ,2%"4EG&DZ.+ , H/ 9 M >&PO=V]R:W-H965T!B3V M&L36()YJP*T!GVH@K($8&81=L]I6[U*=KI>5N@=5-S^N:3,-R9,P'_,0U.U@ MU7U!T^S:C'ZL>!DH#>)@!'76BT^R@AN-!N"<( M!WV:XPZ$ITPQI6A=3 M:FW6*6<*SU M!N6ESX*!+!@VW_R(X\.* &8X1[D:B80CCH\L M#BCB6(^-@BD^ B/KI( M,J5:*'*L L3'%H%PH1AOK*'*!1'] 4L"H6>!P@2ESSP &PO=V]R:W-H965T0/&/Q,K,BQ-'EI][#2: Z[9^+@V!HP7B#Q[-\O#\?!(S1)#@':5=75 M8-K%P/B':#"6X).23JR#1LI^!:&H&DR1>&$][M23FG&*I%KR,Q0]Q^AD2)3 M. P7D**V"\K"Q-YX6;"+)&V'WS@0%TH1_[?!A WK( IN@??VW$@=@&4!)]ZI MI;@3+>L Q_4Z>(U6ATPC#.!WBP?AS('V?F3L0R]^GM9!J"U@@BNI%9 :KGB+ M"=%"*O'?4?.>4A/=^4W]8*I5[H](X"TC?]J3;)39, G7*,+D>]L^(''$HS# MBA%A_D%U$9+1&R4 %'W:L>W,.-@G>3C2_(1X),038H-IL MH:+7,LO# EZUT(B)#6;C8O+4!]FYD&A"0&5@^Q)L742>>3T\ M%-D_%CG,1')_)8FODL3N9^+PDT7H%TA] JD52&<'$LU-+NUV64QG,*$/L7V( MV#U$[/V(62'9-X5DLT)B;R&9DR(/]<_K]3G8P85%RSG.VH;.Y:"8GTT?$Z!B MET[J(W2B4ZM\C?7E^A+?1*MMY(GOHM7>=L*[?%GTZ(Q_(7YN.P&.3*HK;>Y? MS9C$RGCXHIPWJOE/"X)KJ:=+->>V']J%9/VMNT^?F/(_4$L#!!0 ( ,2% M"4DQ.BL_%@( *8& 9 >&PO=V]R:W-H965T(##(JUMHTUF78SF;W89#(7N]?4GE8S("[0.OOV"VBM3FBG-P+' M\_TL6HDT+T# M<89)&,XQIU4=Y)F+O)%(GSJG\MP$FVG40!9? >W4LM0W@/,,# M;E]QJ%4E:B3AL Z>H]4V(C;%9?RNH%6C.;+F=T)\V,7/_3H(K0=@4&A+0]*II@>/YA?W%E6OL[ZB"K6!_JKTNC=LP0'LXT!/3[Z)]A;Z& MQ!(6@BGW1,5):<$OD !Q^MF-5>W&MGN3SGJ8'T!Z !D @XX?$/> ^ IP"KAS MYNKZ037-,RE:)+O-:*C=\V@5FR]7(.6"LOMXG,TX M)QHRL&$?)(A/HH>3$9SX!+9D8F+FEXA]$G%713PBB.>AGV#F(YAU!+.)@V3J MLLO93'/F?I'DCD@R(4B](LDC(O,[(O,)P<(K,LU9^D72.R+IF"!*_02+.QNV M>&3#EG<<+,<.EJ&WS&G.C3_7'O6;*O;EB(+L+[2*'JDU,A[@"XNR/?% M;K\DQ5]T\*@M<)!'URX5*L2I=MUY%!U:\K/KR/B:GF<-/<(O*H]5K=!.:-.< M7":. DJX"QVFN[?KPTFM2O; MY26 ,^?,&=MS#(LKZ]_XB5(1?;1-QY?Q28CS?9+PW8FV%;]C9]K)?PZL;RLA M'_MCPL\]K?9#4-LD"( L::NZBU>+8>RY7RW8131U1Y_[B%_:MNK_K6G#KLL8 MQM/ 2WT\"360K!;)+6Y?M[3C->NBGAZ6\0.\WV*@( /B=TVOW+B/5/&OC+VI MAY_[90Q4#;2A.Z%25/+R3C>T:50FR?Q7)_WD5('F_91].\B5Y;]6G&Y8\Z?> MBY.L%L31GAZJ2R->V/4'U1I2E7#'&C[\1KL+%ZR=0N*HK3[&:]T-U^OX3P%T MF#L Z0!T"T P&(!U /X,R(,!1 >06T :+BG5 >EC[*BW)(GE7B30 BUC4E= MF(V-R5R81QN3NS!/-J9P8;8VIKQA$JGW)AJY1.-1-#(29 "X$V!7 C(FP%8" M:%>9C6I'3#=@$ &8.&%;"X:SG!!W.210#C'*@2FV>?*Q'&+P$()!YD(]6:B\ M+ %R5Y,&JDF-:I!'3198G6S.ZN2! O(9TY'/FHY\YG04@6H*2PZR>4;,HXW! M;I(R0%):"8AS0Y:&& ^%:L5>#O6G09(Z231(LP!C^0S4DXTBJ6^5H;-U3?5 MJY[,DR+4"."L3@!#K0#:O2!WSXKE<@]+R.&06"R%)X73EI/6=)96IS.G*FQK MEFZMF:$5>EA"]H6F?S/H*]3IN4EK,4MKR%'0LA2$+M^NOX \*XM"KD)@QEF" MO*ZRB4)V07!&6]0@W?%2/Y/351.3Y2KH84(&DW>)4,AZR+(>]!PUR.FKZ4V MS-DH*'3<(+[';O1 MH&\[/ IY$)7?;]D-,L\U4@#OU.*0#;%E0^ALXQL,OKCC"U%BO'N?JR/]5?7' MNN/1*Q/R-7YXYSXP)JC,!>[DCCC)+[[;0T,/0MWF\KX?OX'&!\'.TR?=[;MR M]1]02P,$% @ Q(4)2&ULC5;;CILP$/T5Q R$M M;L2;"Z$UXF)+KPYK*49GY517#G3=T*E1V=A9JFQO-$O)C5=E@]^HQ6YUC>B_ M ZY(M[>!/1K>RVO!I<')4F?R.YVSOB";A5_)]T//-002,*<5$S]6_F-<5*/+K95H\_^63;JV?5O M8G=P,SO P0%.#E,FZOJ&.,I22CJ+]H?1(GGF8.<)Y7*+ M*2/MY1*5,6&]9R&(4^-.\Q!QT#H]@<)%H)$LV">&:">$7T>(OHR4H&R0;1$TU. MURBXC@!1Z/JA.1/Y35A,1;[\4O(9:%%S8&S7,;236F5S6KF963 M6\/E$-"LTWW@%5Z;Z4_0=02P,$% @ Q(4)2>EV MR1LG @ A 8 !D !X;"]W;W)K&UL?97-CILP M%(5?!;'O #;&3D20&JJJ750:S:)=.\0): !3VPG3MZ^-209'#AO\PSGW?I=K MF7SDXEW6C*G@HVM[N0MKI89M%,FJ9AV5+WQ@O7YSXJ*C2B_%.9*#8/0XF;HV M G&<11UM^K#(I[U74>3\HMJF9Z\BD)>NH^+?GK5\W(5)>-MX:\ZU,AM1D4=W MW['I6"\;W@>"G7;AUV1;$J.8!+\;-LK%/##L!\[?S>+G<1?&!H&UK%(F M7# ME96L;4T@G?CO'/,SI3$NY[?HWZ=J-?V!2E;R]D]S5+6&C+;Y#6 V@+LA25<-<#; !T-D MR::ZOE%%BUSP,1"V%P,U+4^V4'^Y*I#3IK"?2UZUR #)HZL)-&O I-DO M-<"G*!W%9Y!( ]PI@(\"6@JP\" O@"I#0"=,C8N)+9E6$T_:5*<;;RJ MTE%E&[CQPZ0K,.D2!L9NFLS"I(LT:!/'$/MDI2.+"4%/O@U:P4$.3N+%08L\ M7P!&)(/("^0((00 I4^0LA6DS$$"7J3,;1>"7AY'E1'TY/#A%1CLP'C3[/$B M308@?#P\,\U2AE)(T)/30U9PB(.3>H\R<=JEFP4)\)YFXK8+ XSA U*TN# & M>F:_J#@WO0P.7.F[9[HH3IPKIL/%+[K]M?XEW!&ULC97?;ILP%,9?!?$ !1LP)")(2Z=JNYA4]6*[=A(G MH!I,;2=T;S\;&P82N-S$?SCG^QU_T;'SCO%W41(BO<^:-N+@EU*V^R 0YY+4 M6#RQEC3JRY7Q&DNUY+= M)S@2Y]4TP"&(0IJ7#5^D?=[K[S(V5W2JB&OW!/W MNL;\[Y%0UAU\X \;;]6ME'HC*/)@S+M4-6E$Q1J/D^O!_P;V1X!T2!_QNR*= MF,P]7?R)L7>]^'DY^*&N@5!REEH"J^%!G@FE6DF1/ZSH?Z9.G,X']9?^N*K\ M$Q;DF=$_U466JMK0]R[DBN]4OK'N![%G2+3@F5'1_WKGNY"L'E)\K\:?9JR: M?NS,ERRT:L\;KQML?X+P1XJ(\Z>Z#>Y.;TJ M5*C=1X&B) \>6LC&P#[F.(V!,1AC J4_0N 2)#(0.(.@98%H22 V M%,()U7 MF9HJ34QCJH1@!W?+G-C!B6><;,Y!AA-OY"0.3C+CK @@AZ-HBZ.IHX+4Y:@] M:3HY:12%X3(E+/35X&V_RUM4N(-GB;3(]< A2 M!%=0BXTUH)#+6WO5V" '*IC"W[Y7QB11:N&3*KQ4 M[^:XH.0J]315$K.0K!T>QO%U+OX!4$L#!!0 ( ,2%"4EM<(0!I $ M +$# 9 >&PO=V]R:W-H965TL#U\/S.><3FA>;,] M@"/O2FI[S'KGA@.EMNY!<7N' VC_IT6CN/-'TU$[&.!-)"E)69X_4,6%SJHR MQEY,5>+HI-#P8H@=E>+F[PDD3L=LEUT#KZ+K70C0JJ0+KQ$*M!6HB8'VF#WM M#J5J'C.J4_C_E,VR:PF< 60O*AR2BF^94[7I4&)V+2U0X\='!W8/XB:F)C MT*3J?:+61R_50\%*>@E",X9%S&F-V2T(ZM47"[9E,=/9BLZVZ?LM^CYEN%^[ M?_F/?[$E4"2!XJ;$_6V)"7.ZQ12?3.CJ3A68+HZ.)36..@[J*KI,YQ.+/?F M5^7 ._C)32>T)6=TOK.Q#2VB Y]$?G>?D=Z_G^4@H75A^^CW)HU4.C@:75/U!+ P04 " #$A0E)(?]52M(! #:! &0 'AL+W=OGH-6Z/V*LRA8840^B M!VYV:B$9T68I&ZQZ":1R($9Q%(8I9J3C09&[V+,LZ+RD%IP6Z0 #'RYL>.NW'T.UDXP;8!T02( M9D#DA?M"3N87HDF12S$BZ8^V)_8/[HZ1.8@2*1>4WKT1JDST6J1QDN.K)9IR M(I=S7N;LY@QLV.<2T5:)"1XMX%'\'X+]%D'L->Y7&M-M@GB+8.\)XA7!89L@ MN:,@61%DZU,Z>)L^A[N<3TF\722]4R1=%?F\37"X8_/P$9O9'079!VQF"YO_ MN,2+R\= -J['%"K%P%U'+Z)S&S]&[O*^IQ=Y3QKX0633<84N0IL6U%D*# MT1 ^F+-NS4,S+RC4VDX/9BY][_F%%OWM)9F?L^(O4$L#!!0 ( ,2%"4EL M#)=_!@0 +$3 9 >&PO=V]R:W-H965T:E3@'%7 *9*5]^\W!R?*@&;^W^[.JBO:#OJJZ_^6HFZKH^MOF MY+?71A6'<5)5^B((8K\J+O5BO1K'OC;KE;YUY:567QNOO555T?S>J%+?7Q:P M> Q\NYS.W3#@KU?^<][A4JFZO>C::]3Q9?$1ECL1#I)1\=]%W5OKVAN*?]7Z MQW#SY?"R"(8:5*GVW1"BZ+_>5*[*_M9VNGI,67A5\6OZOM3C M]WWZ)0W,-'J",!/$<\(S#STA-!/"]PF1S79N^UXV S+4C?N[8??5O',ECY;T,@HQ&C9F-KTHB2 M;&T)/!5^7\"S"D%583((:[J@$N2V(I5D#7\,LF."H#)#JLQP:E:(FL7XC*@ MT10@LML4Q+C(9.K%I*E'C0PS$5&JW%8)$:49I=K:*@ !\P6>9#N4,HUBIC72 MX4RBULS:'T_.I)7FG_Z%18ER)$K)0%NDB;*4$NV0"&)FM6*'IQAY"DE/,

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end XML 72 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 258 291 1 false 95 0 false 15 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.medicalpropertiestrust.com/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Net Income (Unaudited) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/StatementCondensedConsolidatedStatementsOfNetIncomeUnaudited Condensed Consolidated Statements of Net Income (Unaudited) Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 107 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 108 - Disclosure - Organization Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Organization Notes 7 false false R8.htm 109 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies Notes 8 false false R9.htm 110 - Disclosure - Real Estate and Lending Activities Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsRealEstateAndLoansReceivablesTextBlock Real Estate and Lending Activities Notes 9 false false R10.htm 111 - Disclosure - Debt Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock Debt Notes 10 false false R11.htm 112 - Disclosure - Common Stock/Partners' Capital Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsPartnersCapitalNotesDisclosureTextBlock Common Stock/Partners' Capital Notes 11 false false R12.htm 113 - Disclosure - Stock Awards Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock Awards Notes 12 false false R13.htm 114 - Disclosure - Fair Value of Financial Instruments Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value of Financial Instruments Notes 13 false false R14.htm 115 - Disclosure - Earnings Per Share/Common Unit Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Earnings Per Share/Common Unit Notes 14 false false R15.htm 116 - Disclosure - Commitments and Contingencies Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 15 false false R16.htm 117 - Disclosure - Subsequent Events Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events Notes 16 false false R17.htm 118 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 17 false false R18.htm 119 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Summary of Significant Accounting Policies (Tables) Tables http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 18 false false R19.htm 120 - Disclosure - Real Estate and Lending Activities (Tables) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsRealEstateAndLoansReceivablesTextBlockTables Real Estate and Lending Activities (Tables) Tables http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsRealEstateAndLoansReceivablesTextBlock 19 false false R20.htm 121 - Disclosure - Debt (Tables) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlockTables Debt (Tables) Tables http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock 20 false false R21.htm 122 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value of Financial Instruments (Tables) Tables http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock 21 false false R22.htm 123 - Disclosure - Earnings Per Share/Common Unit (Tables) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Earnings Per Share/Common Unit (Tables) Tables http://www.medicalpropertiestrust.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 22 false false R23.htm 124 - Disclosure - Summary of Significant Accounting Policies - Carrying Value and Classification of Related Assets and Maximum Exposure to Loss (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesCarryingValueAndClassificationOfRelatedAssetsAndMaximumExposureToLoss Summary of Significant Accounting Policies - Carrying Value and Classification of Related Assets and Maximum Exposure to Loss (Detail) Details 23 false false R24.htm 125 - Disclosure - Real Estate and Lending Activities - Assets Acquired (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesAssetsAcquired Real Estate and Lending Activities - Assets Acquired (Detail) Details 24 false false R25.htm 126 - Disclosure - Real Estate and Lending Activities - Assets Acquired (Parenthetical) (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesAssetsAcquiredParenthetical Real Estate and Lending Activities - Assets Acquired (Parenthetical) (Detail) Details 25 false false R26.htm 127 - Disclosure - Real Estate and Lending Activities - 2016 Activity - Additional Information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivities2016ActivityAdditionalInformation Real Estate and Lending Activities - 2016 Activity - Additional Information (Detail) Details 26 false false R27.htm 128 - Disclosure - Real Estate and Lending Activities - 2015 Activity - Additional Information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivities2015ActivityAdditionalInformation Real Estate and Lending Activities - 2015 Activity - Additional Information (Detail) Details 27 false false R28.htm 129 - Disclosure - Real Estate and Lending Activities - Schedule of Unaudited Supplemental Pro Forma Operating Data (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesScheduleOfUnauditedSupplementalProFormaOperatingData Real Estate and Lending Activities - Schedule of Unaudited Supplemental Pro Forma Operating Data (Detail) Details 28 false false R29.htm 130 - Disclosure - Real Estate and Lending Activities - Development Activities - Additional Information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesDevelopmentActivitiesAdditionalInformation Real Estate and Lending Activities - Development Activities - Additional Information (Detail) Details 29 false false R30.htm 131 - Disclosure - Real Estate and Lending Activities - Summary of Status Update on Current Development Projects (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesSummaryOfStatusUpdateOnCurrentDevelopmentProjects Real Estate and Lending Activities - Summary of Status Update on Current Development Projects (Detail) Details 30 false false R31.htm 132 - Disclosure - Real Estate and Lending Activities - Disposals - Additional Information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesDisposalsAdditionalInformation Real Estate and Lending Activities - Disposals - Additional Information (Detail) Details 31 false false R32.htm 133 - Disclosure - Real Estate and Lending Activities - Summary of Facilities and Related Net Assets Designated as Held for Sale (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesSummaryOfFacilitiesAndRelatedNetAssetsDesignatedAsHeldForSale Real Estate and Lending Activities - Summary of Facilities and Related Net Assets Designated as Held for Sale (Detail) Details 32 false false R33.htm 134 - Disclosure - Real Estate and Lending Activities - Summary of Operations for Disposed Assets (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesSummaryOfOperationsForDisposedAssets Real Estate and Lending Activities - Summary of Operations for Disposed Assets (Detail) Details 33 false false R34.htm 135 - Disclosure - Real Estate and Lending Activities - Leasing Operations - Additional Information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesLeasingOperationsAdditionalInformation Real Estate and Lending Activities - Leasing Operations - Additional Information (Detail) Details 34 false false R35.htm 136 - Disclosure - Real Estate and Lending Activities - Components of Net Investment in Direct Financing Leases (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesComponentsOfNetInvestmentInDirectFinancingLeases Real Estate and Lending Activities - Components of Net Investment in Direct Financing Leases (Detail) Details 35 false false R36.htm 137 - Disclosure - Real Estate and Lending Activities - Twelve Oaks Facility - Additional Information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesTwelveOaksFacilityAdditionalInformation Real Estate and Lending Activities - Twelve Oaks Facility - Additional Information (Detail) Details 36 false false R37.htm 138 - Disclosure - Real Estate and Lending Activities - Summary of Loans (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesSummaryOfLoans Real Estate and Lending Activities - Summary of Loans (Detail) Details 37 false false R38.htm 139 - Disclosure - Real Estate and Loans Receivable - Loans - Additional Information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLoansReceivableLoansAdditionalInformation Real Estate and Loans Receivable - Loans - Additional Information (Detail) Details 38 false false R39.htm 140 - Disclosure - Real Estate and Lending Activities - Schedule of Revenue by Operator (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesScheduleOfRevenueByOperator Real Estate and Lending Activities - Schedule of Revenue by Operator (Detail) Details 39 false false R40.htm 141 - Disclosure - Real Estate and Lending Activities - Schedule of Revenue from External Customers by Geographic Areas (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesScheduleOfRevenueFromExternalCustomersByGeographicAreas Real Estate and Lending Activities - Schedule of Revenue from External Customers by Geographic Areas (Detail) Details 40 false false R41.htm 142 - Disclosure - Real Estate and Lending Activities - Schedule of Gross Assets by Operator (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesScheduleOfGrossAssetsByOperator Real Estate and Lending Activities - Schedule of Gross Assets by Operator (Detail) Details 41 false false R42.htm 143 - Disclosure - Real Estate and Lending Activities - Schedule of Gross Assets by Geographic Areas (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesScheduleOfGrossAssetsByGeographicAreas Real Estate and Lending Activities - Schedule of Gross Assets by Geographic Areas (Detail) Details 42 false false R43.htm 144 - Disclosure - Real Estate and Lending Activities - Concentrations of Credit Risk - Additional Information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureRealEstateAndLendingActivitiesConcentrationsOfCreditRiskAdditionalInformation Real Estate and Lending Activities - Concentrations of Credit Risk - Additional Information (Detail) Details 43 false false R44.htm 145 - Disclosure - Debt - Summary of Debt (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureDebtSummaryOfDebt Debt - Summary of Debt (Detail) Details 44 false false R45.htm 146 - Disclosure - Debt - Principal Payments Due for Debt (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureDebtPrincipalPaymentsDueForDebt Debt - Principal Payments Due for Debt (Detail) Details 45 false false R46.htm 147 - Disclosure - Debt - Principal Payments Due for Debt (Parenthetical) (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureDebtPrincipalPaymentsDueForDebtParenthetical Debt - Principal Payments Due for Debt (Parenthetical) (Detail) Details 46 false false R47.htm 148 - Disclosure - Debt - Additional Information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureDebtAdditionalInformation Debt - Additional Information (Detail) Details 47 false false R48.htm 149 - Disclosure - Debt - Interest Rate Swap - Additional Information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureDebtInterestRateSwapAdditionalInformation Debt - Interest Rate Swap - Additional Information (Detail) Details 48 false false R49.htm 150 - Disclosure - Debt - Covenants - Additional Information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureDebtCovenantsAdditionalInformation Debt - Covenants - Additional Information (Detail) Details 49 false false R50.htm 151 - Disclosure - Common Stock/Partners' Capital - Additional Information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureCommonStockPartnersCapitalAdditionalInformation Common Stock/Partners' Capital - Additional Information (Detail) Details 50 false false R51.htm 152 - Disclosure - Stock Awards - Additional Information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureStockAwardsAdditionalInformation Stock Awards - Additional Information (Detail) Details 51 false false R52.htm 153 - Disclosure - Fair Value of Financial Instruments - Summary of Fair Value Information of Financial Instruments (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueInformationOfFinancialInstruments Fair Value of Financial Instruments - Summary of Fair Value Information of Financial Instruments (Detail) Details 52 false false R53.htm 154 - Disclosure - Fair Value of Financial Instruments - Equity Interest in Related Party and Related Loans Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsEquityInterestInRelatedPartyAndRelatedLoansMeasuredAtFairValueOnRecurringBasis Fair Value of Financial Instruments - Equity Interest in Related Party and Related Loans Measured at Fair Value on Recurring Basis (Detail) Details 53 false false R54.htm 155 - Disclosure - Fair Value of Financial Instruments - Additional information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation Fair Value of Financial Instruments - Additional information (Detail) Details 54 false false R55.htm 156 - Disclosure - Fair Value of Financial Instruments - Summary Showing Sensitivity Analysis by Using Basis Point Variations (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryShowingSensitivityAnalysisByUsingBasisPointVariations Fair Value of Financial Instruments - Summary Showing Sensitivity Analysis by Using Basis Point Variations (Detail) Details 55 false false R56.htm 157 - Disclosure - Earnings Per Share/Common Unit - Calculation of Earnings Per Share (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureEarningsPerShareCommonUnitCalculationOfEarningsPerShare Earnings Per Share/Common Unit - Calculation of Earnings Per Share (Detail) Details 56 false false R57.htm 158 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.medicalpropertiestrust.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation Subsequent Events - Additional Information (Detail) Details 57 false false All Reports Book All Reports mpw-20160630.xml mpw-20160630.xsd mpw-20160630_cal.xml mpw-20160630_def.xml mpw-20160630_lab.xml mpw-20160630_pre.xml true true ZIP 77 0001193125-16-676855-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-16-676855-xbrl.zip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�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end